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   Histone deacetylases (HDACs) are a class of enzymes that play a crucial role in 
DNA expression by removing an acetyl group from the ɛ-N-acetyl lysine residue on 
histone proteins. Out of 18 isoforms of HDAC enzymes which are classified into 4 
classes, only 11 of them are metalloenzymes that require zinc for its catalytic activity. 
HDACs are considered promising target for drug development in cancer and other 
parasitic diseases due to their role in gene expression. Histone deacetylase inhibitors 
(HDACi) can cause cell cycle arrest, and induce differentiation or apotosis. While 
HDACi shows promising antitumor effects, their mechanism of action and selectivity 
against cancer cells have not been adequately defined yet. In addition, low oral 
bioavailability, short half-life time, bone marrow toxicity, and cardiotoxicity limit their 
use in clinic. Therefore, there is considerable interest in developing compounds with 
selectivity and specificity towards individual family members of HDACs. The 
prototypical pharmacophore for HDAC inhibitors consist of a metal-binding moiety that 
coordinates to the catalytic metal ion within the HDAC active site, a capping group that 
interacts with the residues at the entrance of the active site and a linker that appropriately 
positions the metal-binding moiety and capping group for interactions in the active site. It 
has been shown that modification of cap, cap linking moiety, linker or zinc binding group 
(ZBG) shows promises of superior potency and isoform selectivity. My thesis research 
involves manipulating different aspects of the pharmacophoric model to yield not only 
more potent, selective, and effective drugs but also to help understand the biology of zinc 






Pharmacophoric Model of HDACi 
 
   In the quest of effective chemotherapy, we modified the cap group to introduce 
an additional anticancer drug (warhead) in the HDACi design to combat cancer 
effectively. As many essential enzymes are overexpressed in cancer cells, multi-targeting 
therapy might be more beneficial, not only to eliminate cancer cells but also to combat 
the emergence of drug resistance. To explore the prospect in cancer therapy of a bivalent 
agent that combines two complimentary chemo-active groups within a single molecular 
architecture, we have synthesized bifunctional HDAC - topoisomerase II (topo II) and 
HDAC – topoisomerase I (topo I) inhibitors. We have identified single agents that 
simultaneously inhibit topoisomerase and HDAC activities for the first time. Moreover, 
they potently inhibit the proliferation of representative cancer cell lines.  
 In a class of these dual acting agents, the topoisomerase inhibiting moieties were 
connected to the HDACi pharmacophore through a cap linking moiety. One of the most 
commonly employed cap linking moiety in HDACi design is the amide group. We have 
introduced 1,2,3-triazole as an alternative cap group linking moiety. Simple 
hydroxamates containing triazole linking moiety have enhanced HDACi activities. This 
xxv 
 
development simplified our compound design and facilitated facile synthesis of numerous 
novel and structurally diverse HDACi.  
 Another important biological phenomenon thought to be regulated by HDACs is 
the pre-mRNA splicing catalyzed by the spliceosome. We have screened our triazole 
based HDACi library for their effect on splicing reaction in an in vitro system in 
collaboration with Prof. Reinhard Luhrmann of the Max Planck Institute, Germany. We 
have indentified molecular architecture of a novel class of zinc chelating agents with 
splicing inhibitory activities. Interestingly however there is no correlation between 
HDAC and spliceosome inhibiting activities of these compounds. This result suggests 
that these compounds may be inhibiting the functional role of Zn-ion in splicing since 
only a subset of them, with well defined structure, is active.  
 In concluding part of my thesis research, I undertook the challenge of identifying 
a non-hydroxamate ZBG in HDACi design. Even though hydroxamic acids are widely 
used as ZBG, they suffer from many drawbacks such as poor in vivo stability, low oral 
bioavailability, generation of harmful unwanted metabolites, low isoform selectivity among 
others. I have explored heterocyclic aromatic functional groups as potentially more stable, 
less-toxic, potent alternatives to hydroxamate ZBG. Using the tools of structure-based drug 
design, fragment-based drug discovery and in vitro biological screening, I have successfully 
identified 3-hydroxypyridin-2-ones as novel ZBG in HDAC inhibitor design. Additionally, 
structure activity relationship (SAR) studies through structural optimization of linker region 
and surface recognition cap group have yielded small molecules with HDAC8 selectivity 
relative to HDAC1. These isoform selective inhibitors could be ideal chemical tools to 
elucidate the individual functions of each HDAC isoform. Such selective inhibitors could be 
critical in deciphering the roles of HDAC isoforms in cancer etiology and possibly provide 
xxvi 
 
more effective chemotherapy compared to nonselective inhibitors. Molecular docking 
analysis revealed structural basis of selectivity and was attributed to the effective 
accommodation of the inhibitors at the shallow active site of HDAC8 enzyme in comparison 
to HDAC1. This prompted us to investigate other zinc-metalloenzymes with similar active 
site attributes, such as HDAC8-Leishmanolysin (gp63), a zinc metalloprotease found on cell 
surface of Leishmania species, with a shallow active site similar to HDAC8. It is well 
established that gp63 is essential for the degradation of host proteins and it is an attractive 
target for the development of anti-leishmanial chemotherapeutics. Leishmaniasis is a 
tropical/sub-tropical parasitic disease caused by protozoan parasites of the genus 
Leishmania. Although it affects about 2 million people per year, there is a dearth of 
effective treatment modalities for this fatal disease. Despite the attractiveness of gp63 as 
an anti-leishmanial target, there are currently no efficient, non-toxic inhibitors of gp63. 
Using a molecular docking analysis, I found that the 3-hydroxypyridin-2-one based 
HDAC8 inhibitors adopted docked poses on gp63 that were similar to those they adopted 
on HDAC8. Subsequent whole cell assay reveal that these compounds are potent 
inhibitors of the promastigote and amastigote forms of L. donovani with IC50 comparable 
to Miltefosine, the only clinically approved oral drug against visceral leishmaniasis. 
Ongoing efforts are on identifiying the intracellular target(s) that confers anti-leishmanial 
activity to these 3-hydroxypyridin-2-one based HDACi.   
 Overall, my thesis research aims at better understanding biology of zinc 
metalloenzymes by developing potent and selective small molecule inhibitors. This will 
aid in improvement of existing therapeutics for treatment of cancer, leishmania, malaria 








1.1 Histone Deacetylases (HDACs) 
 
   In eukaryotes, DNA is wrapped tightly around histone and non-histone proteins to 
form higher order structure called chromatin. Chromatin consists of basic repeating units 
called nucleosome which consists of approximately 146 bp of DNA tightly wrapped 
around histone octamers. There are two copies of each of the four core histones, H2A, 
H2B, and H3 and H4 in each nucleosome.1-4 Histones are small globular proteins with 
more flexible and charged NH2-terminus (histone tails) that protrudes from the 
nucleosome. Post-translational modifications of histones such as acetylation of lysines, 
methylation of lysines and arginines, phosphorylation of serines, and ubiquitination and 
sumoylation of lysines constitute a “histone code” that ultimately regulates gene 
expression by modulating the unwinding of DNA and recruitment of binding partners.1,2 
Transcriptionally active genes associate with hyperacetylated chromatin, whereas 
transcriptionally silent genes associate with hypoacetylated chromatin. Chromatin 
acetylation is controlled by the opposite effects of two families of enzymes, histone 
acetyltransferases (HATs) and histone deacetylases (HDACs). HATs catalyze the 
addition of acetyl groups on the ε-amino groups of lysine residues in the amino terminal 
tails of core histones. HDACs remove the acetyl group from the acetylated lysines in 
histones (Figure 1-1).3,4 Increased acetylation has been correlated with increased gene 
expression, and decreased acetylation has been correlated with transcriptional 
repression.4 A controlled equilibrium between HAT and HDAC activity is required for 
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normal cell growth.1 Aberrant HDAC function has been linked to cancer development 
and maintenance, which could be attributed to abnormal silencing of the expression of  
gene.4 HATs and HDACs also target non-histone protein substrates, in particular 
transcriptional factors such as p53, GATA-1, E2F, estrogen receptor (ER), and various 
cell-cycle regulatory proteins with variable functional consequences.5 
 
      
Transcriptional activation form                              Transcriptional repression form 
 
Figure 1-1. Acetylation switch16b 
  
 
1.2 HDAC Isoforms and Inhibition 
  
There are four subclasses of HDACs in humans. They are classified on the basis 
of on their size, cellular localization, number of catalytic active sites, and homology to 
yeast HDAC proteins. Class I includes HDAC1, HDAC2, HDAC3, HDAC8. Class II 
includes HDAC4, HDAC5, HDAC6, HDAC7, HDAC9, HDAC10. Class II has been 
further subdivided into IIa (HDAC4, HDAC5, HDAC7, HDAC9) and IIb (HDAC6, 
HDAC10) because of their single and double catalytic active sites respectively. HDAC11 
is the only member of class IV. Class I, II and IV operate by metal (Zn2+) ion dependent 
mechanism. In contrast, Class III (Sirtuins) operate by NAD+ dependent mechanism and 
are unrelated to other class of HDAC enzymes.6,10a Class I, II and IV HDACs have been 
intensively scrutinized in recent years because of their role in cancer pathogenesis, as 
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well as several other diseases.4,7 Classes I and IV HDACs are primarily found in the 
nucleus with the exception of HDAC3 which is also found in cytoplasm in addition to 
nuclear localization. Class I and IV HDACs are expressed in many cell types, while the 
expression of class II HDACs, which are able to shuttle in and out of the nucleus, are 
restricted to some tissues.8 HDAC6 in particular is a cytoplasmic and microtubule 
associated enzyme.8c Because of their crucial role in a plethora of biological events 
including gene expression, cell development, differentiation and apoptosis, various 
HDAC isoforms are associated with different basic cellular events and disease conditions. 
For example, HDAC 1, 6, and 8 are crucial for breast cancer; HDAC 1-3 are 
overexpressed in ovarian cancers; HDAC 1 and 3 are implicated in lung cancers, HDAC2 
associated with gastric cancers; and there is possible correlation between HDAC8 
overexpression and acute myeloid leukemia (AML).9 While different HDAC isoforms are 
linked to cancer formation, the exact cellular function of HDACs is still far from being 
completely elucidated. Particularly, the molecular mechanism connecting aberrant HDAC 
activity to cancer formation is not well understood. 
 
 (a) (b)     
Figure 1-2. (A) HDAC1 homology model and (B) HDAC8 crystal structure as viewed in 
PYMOL. Zinc ion is shown as white sphere. 
4 
 
          Structural information essential for rational design of isoform selective class I 
and II HDACs inhibitors is scarce. To date, only the crystal structure of HDAC-like 
protein (HDLP, bacterial homologue to human class I HDAC), HDAC2, HDAC7, and 
human HDAC8 are available (Figure 1-2).10 However, HDAC1 homology model built 
from human HDAC2 X-ray crystal structure with 3MAX coordinates has found useful 
applications in literature to understand HDAC1 enzyme structural attributes.11 Overall the 
architecture of HDAC1 and HDAC8 active site is conserved relative to other class I and 
II HDACs. In HDAC1, the active site is composed of a hydrophobic tunnel 
approximately 14 Å deep (Figure 1-3). The amino acid residues, Pro29, Phe150, Phe205, 
Leu271, His178, Tyr204, Gly149, and Tyr303, formed the wall of the tunnel. The Zn2+ 
ion at the base of the tunnel is coordinated with adjacent amino acid residues (Asp176, 
His140, and Asp264) and water molecules to hydrolyze the acetylated lysine of the N-
terminal tail of core histones.10a In HDAC8, the only architectural difference is the 
replacement of leucine with methionine among the amino acid residues that constructed 
the wall of the active site. In addition, the HDAC8 active site adopts a different shape and 
is only 12 Å deep, a distinction that can be exploited in the design of isoform structure 






(a)        
(b) (b) 
 
Figure 1-3. Mesh representation of the (A) HDAC1 homology and (B) HDAC8 tunnel-like active 
site viewed in PYMOL. Zinc ion is shown as white sphere. 
 
  HDACi generally conforms to a three-motif pharmacophoric model consisting of 
a zinc binding group (ZBG), a hydrophobic linker chain, and a surface recognition group 
(consisting of cap linking moiety and a cap group).13 The recognized mode of HDAC 
inhibition involves ZBG interaction with the catalytic zinc ion at the base of the active 
site while the linker efficiently positions the cap group to make interactions with amino 
acid residues on the surface of the enzyme.10a Most HDACi chelate the active site Zn2+ 


















Figure 1-4: Pharmacophoric Model of HDACi. Representation of  HDAC inhibitor   




    The mechanism of action of these zinc metalloenzyme involves the removal of 
the acetyl group of lysine residues via charge relay system consisting of two adjacent 
histidine residues, two aspartate residues, and one tyrosine residue. Mechanism involves 
coordination of the carbonyl group of the N-acetyl lysine residue to the Zn2+ ion. The 
Zn2+ ion polarizes the carbonyl group making the carbonyl carbon more electrophilic.10  
This coordination brings the acetylated lysine in close proximity with the water molecule 
which interacts with histidine and Zn2+ ions making it more nucleophilic. This leads to 
the hydrolysis of the carbonyl carbon to form a tetrahedral oxyanion intermediate. The 
intermediate is stabilized by two oxygen-zinc interactions and hydrogen bonding to the 
hydroxyl group of a tyrosine residue. During next step, the oxyanion restores its charges 
by forming a carbonyl group leading to the cleavage of the carbon nitrogen bond of the 
intermediate.10 The free nitrogen then accepts a proton from histidine yielding the free 
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lysine residue and the acetate group (Figure 1-5). Binding of HDACi often results in the 
displacement of the Zn2+ ion thereby making charge-relay system dysfunctional.10 
Understanding the overall structure and mechanism of the class I and II HDACs active 
site has led to the development of many HDACi with few in clinical trials. In fact, 
HDACi have drawn much interest and research efforts have culminated in the validation 
of HDAC inhibition as a clinically viable approach for cancer treatment with the approval 
of SAHA and Romidepsin (FK-228) for the treatment of cutaneous T-cell lymphoma.15 
 
 
Figure 1-5. The proposed mechanism for the deacetylation of acetylated lysine residue at HDAC  




1.3 HDAC Inhibitors 
Inhibition of HDAC activity has emerged as a promising approach for reversing 
the anomalous epigenetic states associated with cancer and other chronic diseases, 
because of their role in fundamental cellular processes.1-3,7 Majority of HDACi are 
relatively less toxic to normal cells while broad variety of transformed cells are more 
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sensitive to HDACi.4b HDACi show promising antitumor effects however their 
mechanism of action and selectivity against cancer cells have not yet been adequately 
defined. Most HDACi are global, non-selective inhibitors of various HDAC isoform.4 
Their low isoform selectivity does not differentiate the relevant HDACs that regulate 
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Figure 1-6: Representative Examples of HDACi a) Simple hydroxamates such as TSA & SAHA;  




              In addition, low oral bioavailability, short half-life time, bone marrow toxicity, 
and cardiotoxicity are limiting the clinical use of current HDACi.2b Therefore, there is 
considerable interest in developing compounds with selectivity towards individual family 
members of HDACs. 
 My thesis research work centers around addressing important drawbacks of 
current generation HDACi to generate more potent, selective drugs as well as design 
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novel molecules that will aid in our understanding of the biology of these important zinc 
metalloenzymes. Most of the current HDACi fits into pharmacophoric model depicted in 
Figure 1-4 which has been extensively used to design and SAR studies on existing 
HDACi with the goal of improving potency, selectivity, and pharmacokinetic 
profiles.13,14 
              To address some of the major drawbacks that have limited the progress of 
current HDACi, I have worked on the HDACi pharmacophoric model in this thesis. I 
have designed new surface recognition groups (chapter 4), new cap linking moiety 
(chapter 2), investigated SAR of the linker group and identified a new ZBG compatible 
with HDAC inhibition (chapter 5). Some of the important outcomes of the studies 
disclosed in this thesis are the identification of a new class of HDAC-topo inhibitors, the 
introduction of 1,2,3-triazole as a new cap linking moiety and 3-hydroxypyridin-2-one as 
a new HDACi ZBG. Several of the HDACi disclosed in this thesis have anticancer, anti-
malarial, and anti-leishmanial activity. I have also used several of these molecules as 
tools to probe the role of Zn-metalloenzyme in pre-mRNA splicing.  
 
1.4 Bifunctional Inhibitors  
         Currently a “one drug, one target” paradigm is the dominant approach to drug 
discovery in pharmaceutical industry. This approach has yielded many blockbuster drugs 
and will continue to dominate the future drug discovery efforts. Despite this, there are 
lots of disease conditions which are inadequately treated. Therefore developing agents 
that can modulate multiple targets simultaneously with combination of drugs or 
bifunctional agents which can enhance efficacy could be a useful approach. Many 
essential enzymes are overexpressed in cancer cells and are responsible for maintenance 
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of the transformed state of human tumors.18 Therefore multi-targeting therapy might be 
more beneficial, not only to eliminate cancer cells but also to combat the emergence of 
drug resistance.19 Despite promising clinical reports and low toxicity, HDACi have 
proven difficult as a sole agent to improve the cancer chemotherapy outcome, partly due 
to reversible cell cycle arrest by HDACi.20 Therefore, many HDACi including SAHA 
have been shown to increase the efficiency of several anticancer drugs that target 
DNA.21,22 However combination therapies are often scheduling dependent and often 
associated with dose dependant toxic side effects not seen with individual drugs.23 
Additionally, multiple drug therapy is often complicated by the inherent pharmacokinetic 
disadvantage of separate drugs, drug-drug interactions, and the possibility of additive 
toxicity. Therefore a single molecule containing a dual warhead of combination therapy 
could be useful. Such compounds may lead to agents that require only low doses to elicit 
antiproliferative activities, thereby minimizing dose dependent side effects of 
combination therapy. These dual acting inhibitors are expected to act across various 
stages of cancer cell cycle, thereby targeting larger population of cells, resulting in 
superior cytotoxicity.21,22 
 
1.4.1 Dual -acting topoisomerase-HDAC inhibitors  
DNA topoisomerases (Topo) are essential human enzymes that alter the 
supercoiling of DNA. They are classified as topo I and topo II depending on whether they 
induce a DNA single and double strand break respectively. DNA topoisomerases aids in 
the transcription and replication of DNA.23 
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  DNAs do not exist as naked structures; they are locked up in complexes with 
histone proteins. Agents, such as HDACi, that induce hyperacetylation of histone2b 
proteins complexed with DNA could unlock these complexes. The unlocking of the DNA 
histone complexes could increase the accessibility of cellular DNA within chromatin and 
thus potentiate the activities of DNA targeting, Topo II- and Topo I-inhibiting anticancer 
agents. 
 
1.4.2 Anthracyclines (Topoisomerase II inhibitor) –  
Anthracyclines (Figure 1-7) rank among the most effective anticancer drugs and 
are effective against more types of cancer than any other class of chemotherapy agents. 
They act primarily by stabilizing the intermediate of Topo II-DNA reaction, the cleavage 
complex, through the formation of a ternary complex. The tetracyclic ring of 
anthracyclines intercalates DNA while the sugar moiety functions as a DNA minor 
groove binder.25 
 The clinical use of anthracyclines is limited by the occurrence of both chronic 
and acute cardiotoxicity that can often lead to cardiomyopathy, myocardial infarction, 
and congestive heart failure.26 
 
Figure 1-7. Representative Structures of Anthracycline Antibiotics 
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  Several preclinical reports have shown that HDACi act synergistically with Topo 
II inhibitor such as anthracyclines to enhance apoptosis.27 The HDACi-induced structural 
changes of chromatin may render the DNA more accessible and HDACi may therefore be 
used to potentiate DNA damaging agents such as topo II inhibitors. However such 
combination therapies are often sequence and dose dependent, complicated by the 
inherent pharmacokinetic disadvantages of individual drugs. Therefore development of 
single molecule containing "combination therapy" potential will harness the positive 
attributes of multiple drug therapy while eliminating or minimizing its shortcomings.19 
We have designed novel single agents that simultaneously inhibit Topo II and histone 
deacetylase (HDAC) activities. We found that many of these conjugates potently inhibit 
HDAC and Topo II activities comparable to that of SAHA and daunorubicin, standard 
HDACi and Topo II inhibitors, respectively.  Additionally, these compounds exhibited 
potent whole cell antiproliferative activities against representative breast, lung and 
prostate cell lines. 
 
1.4.3 Camptothecins (Topoisomerase I inhibitor) –  
  Camptothecin is a naturally occurring Topo I inhibitor.  It acts by stabilizing the 
intermediate of the Topo I-DNA reaction, the cleavage complex, through the formation of 
ternary complex. Camptothecins penetrate vertebrate cells readily and target Topo I 
within minutes of exposure. Therefore camptothecins are efficacious due to their 
selectivity rather than potency. However camptothecins have some limitations such as 
prolonged exposure to maintain persistent cleavage complex and deleterious side effects 




                         
                                   CPT-11 (prodrug)                              Topotecan (water soluble) 
Figure 1-8. Representative topoisomerase I inhibitors.29 
 
  It has been shown that HDACi facilitate the cytotoxic effectiveness of the 
topoisomerase I inhibitor camptothecin in the killing of tumor cells.20a Effectiveness of 
such therapy is sequence, scheduling and dose dependent in much the same way as the 
effect of HDACi on topo II inhibitor potency.20a In our efforts to design multifunctional 
compounds, we have synthesized range of compounds containing a HDACi moiety 
coupled with camptothecin templates. We anticipate that the individual anticancer 
moieties within these dual acting compounds would synergistically inhibit tumor cell 
proliferation with fewer off-target effects than the individual parent compounds. We 
propose that the HDACi will characteristically relax DNA-histone interactions, thereby 
allowing the better access to the camptothecin analog hence markedly increasing the 
efficacy of the compound. Additionally, while coupling a camptothecin analog to another 
active moiety may decrease the efficacy of topoisomerase poisoning, a decrease in the 
14 
 
off-target effects inherent with treatment of camptothecin alone could be a balancing 
benefit. 
   Classical examples of HDACi such as SAHA and TSA include either a keto or 
amide group as a cap linking moiety. We incorporated an amide group as cap linking 
moiety in 1st generation conjugates. However synthesis of these conjugates suffered a low 
overall yield. In order to address this issue, we proposed 1,2,3-triazole as an alternative, 
more synthetically tractable cap linking moiety for HDACi. A successful implementation 
of this proposal also helped in simplifying SAR study of 1st generation bifunctional 
conjugates.   
 In a related study, we investigated the consequence of incorporation of 1,2,3-
triazole moiety into the pharmacophore of SAHA-based simple aliphatic hydroxamates.30 
Our study on simple HDACi showed that triazole incorporation enhanced HDACi 
activities by several fold compared to control compound SAHA in vitro. An additional 
SAR study on cap group and linker region revealed cap group dependent preference for 
either five- or six- methylene spacer groups. A subset of these compounds potently 
inhibited the proliferation of representative cancer lines.30  
 
1.5 Stalling Spliceosome Assembly with Zinc Chelators  
   Splicing is a major source of proteomic diversity in humans. The splicing 
reaction is a 2-step transesterifcation reaction which excises the introns and ligates the 
exons.31 This exceedingly complex process recruits spliceosomes, a large and dynamic 
ribonucleo-particle consisting of 5 small nuclear RNAs (snRNAs) and close to 150 
proteins. In the first step, the 2’-OH of adenosine from the branch site nucleophilically 
 
attacks the phosphodiester bond at the 5’
During the second step, the 3’
attack at the 3’splice site, releasing 
intricate interplays between RNA
ultimately determine the identity of the protein formed from a pre
Understanding the splicing mechanism is of prime importance as many human genetic 
conditions, such as β-thalessemia, inherited breast cancer and many types of neurological 
diseases, are associated with aberrant pre
Figure 1
     Spliceosome formation proceeds through coordinated assemblies of complexes 
– A, B, B* and C (Figure 1
small nuclear ribonucleoproteins (
spliceosome continues to be a subject of intense research. Remarkable advances have 
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the intron lariat. The process is tightly controlled by 
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-mRNA splicing.33  
-9: Steps involved in splicing mechanism36 
 
-9).  The detail of molecular interactions between the five 





been made in the characterization and structural elucidation of the various spliceosome 
complexes.34 These studies have furnished exquisite information about spliceosome 
assembly at the RNA level. With the increased number of known splicing factors, we are 
now gaining an appreciation that the dynamic nature of the spliceosome is much more 
complex than simple addition and release of individual snRNPs proteins. However, the 
order of recruitment, interaction between these splicing factors, and signals that trigger 
their addition and release from the spliceosome remained poorly understood.35 
Additionally, little is known about the mechanism of catalysis and the trigger for the 
global conformational changes which ensure the fidelity of splicing. The availability of 
agents which perturb splicing at specific stages will greatly enhance our understanding of 
the workings of the spliceosome.  
    HDACs have been shown to be closely associated with spliceosome 
complexes, although their precise functions in splicing process are not clear. In order to 
gain more knowledge about spliceosome assembly and its function, we screened library 
of aryltriazolylhydroxamates HDACi to check their effect on splicing.  
             In collaboration with Prof. Reinhard Luhrmann of the Max Planck Institute, 
we have elucidated the molecular architecture that confer splicing inhibition to zinc 
chelating agents with HDAC inhibition activities. Characterization of the splicing 
complexes that accumulated on native gels, demonstrated that these agents specifically 
stalled the spliceosome assembly at A-like complex. However, there was no correlation 
between HDAC and splicing inhibition activities of these compounds. Therefore we 
conclude that the primary target(s) of the splicing inhibition activities of these 
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aryltriazolyl hydroxamates are not HDACs. This study has aided our understanding of 
splicing mechanism by shedding light on the role of zinc metalloenzyme/s in splicing.  
 
1.6 Novel Zinc Binding Group for HDAC Inhibition – 
The classic pharmacophore for HDACi consists of a metal-binding moiety that 
coordinates to the catalytic metal ion within the HDAC active site and a capping group 
that interacts with the residues at the entrance of active site. A linker appropriately 
positions the metal-binding moiety and capping group for interactions in the active site.13      
                      
                    SAHA                                                          TSA 
Figure 1-10. Structure of SAHA and TSA 
 
   Though hydroxamic acids are frequently employed as ZBG, they are often 
associated with poor pharmacokinetics and severe toxicity. Susceptibility to in vivo 
hydrolysis and metabolic transformations are some of the drawbacks which necessitate 
the indentification of novel ZBG with better potency and less toxicity.31 In addition, 
hydroxamic acids do not discriminate well among the HDAC subtypes. However, non-
hydroxamates such as benzamide have shown subtype selectivity.38,39 Therefore 
identification of non-hydroxamate ZBG may lead to potent HDACi with low toxicity. 
Towards this end, we have established 3-hydroxypyridin-2-thione (3-HPT) as a novel 
ZBG for HDAC inhibition. Preliminary biological studies on these compounds reveal 
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isoform selectivity for HDAC8 relative to HDAC1. Extensive SAR study on linker 
region confirms that either aromatic phenyl or aliphatic methylene linker are compatible 
with HDAC inhibition activity of these 3-HPT HDACi. Five methylene space shows 
optimum activity however other linkers such as one and seven methylene linkers showed 
respectable biological activities as well. For phenyl linker compounds, hydrophobic 
substitution on the aromatic surface cap group shows enhanced activity. We however 
found that a similar substitution on the five methylene linked compounds, is not 
compatible with HDAC inhibition. Molecular docking analysis reveals the important 
disparity between HDAC1 and HDAC8 active site that confers HDAC8 selectivity. 
HDAC8 active site is apparently shallower and therefore more easily accessible to 3-HPT 
based compounds.   Based on this observation, we surveyed the possibility of interaction 
of 3-HPT based HDACi with gp63, another Zn-metalloenzyme which shared similar 
active site attributes with HDAC8.  
 
1.7 Antileishmanial Agents  
              Visceral leishmaniasis is parasitic disease that is caused by the bite of female 
sandfly. Out of four known clinical forms, visceral leishmaniasis is most deadly form if 
left untreated.40 It is caused by parasite Leishmania donovani and it shuttles between 
promastigote and amastigote forms during leishmania life cycle that includes transition 
from sandfly and mammalian host and vice versa.41,42 Leishmaniasis is contributing to 
significant morbidity and mortality worldwide. It has an estimated incidence of 500,000 
new cases and 60,000 deaths each year, a death toll that is highest among all the parasitic 
diseases except malaria.43 Human leishmaniasis is distributed worldwide, but mainly 
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concentrated in tropics and sub-tropics. The majority of deaths occur in developing 
countries such as Bangladesh, Brazil, Ethiopia, India, Nepal and Sudan.44 
 The major surface zinc-metalloenzyme leishmanolysin (gp63) is highly 
expressed on the surface of the promastigote form of Leishmania, where it is 
enzymatically active, prototypically cleaving several host defensive enzymes.45 Gp63 has 
been established as a virulence factor in leishmaniasis.46 With the aid of other major cell 
surface components such as the lipophosphoglycans (LPGs) and 
glycoinositolphospholipid (GIPL), gp63 enables promastigotes to reach and infect 
sufficient macrophages to establish an infection.45 Despite the attractiveness of gp63 as 
an anti-leishmanial target, there are currently no efficient, non-toxic inhibitors of gp63.  
Using a molecular docking analysis, I found that the 3-hydroxypyridin-2-one based 
HDAC8 inhibitors adopted docked poses on gp63 that were similar to those they adopted 
on HDAC8. Subsequent whole cell assay reveal that these compounds are potent 
inhibitors of the promastigote and amastigote forms of L. donovani with IC50 comparable 
to Miltefosine, the only clinically approved oral drug against visceral leishmaniasis. 
Ongoing efforts are on identifiying the intracellular target(s) that confers anti-leishmanial 
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Figure 2-1: Pharmacophoric Model of HDACi. 
 
  HDACi generally conforms to a pharmacophoric model consisting of a zinc 
binding group (ZBG), a hydrophobic linker chain and a surface recognition group (which 
comprises cap-linking moiety and a cap group) (Figure 2-1).1 ZBG interacts with a Zn2+ 
ion at the base of a tunnel-like active site. The linker region efficiently presents the ZBG 
in the vicinity of Zn2+ ion by filling the channel while the cap-group at the other end 
interacts with amino acid residues at the surface of the enzyme. 2-4 
  The most commonly used ZBG in HDACi is the hydroxamic acid. Attempts to 
incorporate non-hydroxamate based ZBG in HDACi have been modestly successful.1,2,5,6 
On the contrary, modulation of cap group have yielded many potent and more selective 
HDACi.7,8 For example, studies by Schreiber and coworkers have led to the identification 
of cap group-modified agents that display isoform selectivity for different HDACs.9,10 In 
order to connect these cap groups with rest of the pharmacophoric model of HDACi, 
either hydrogen bond accepting or donating groups such as keto- and amide- groups 
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(Figure 2-1) are used as the cap-linking moiety. We hypothesize that a 1,2,3-triazole ring 
could act as an HDACi cap-linking moiety. If successful, the proposed modification will 
simplify design and synthesis of complex HDACi due to the synthetic tractability and 
favorable pharmacokinetic profile of the triazole moiety.  
 
2.2 Design of SAHA-like Aryltriazolylhydroxamates 
To commence this study, we initially undertook the synthesis of SAHA-like 
aryltriazolylhydroxamates 4a-d (Figure 2-2), which linked the aromatic surface 
recognition cap group to the aliphatic zinc binding hydroxamate moiety via a 1,2,3-
triazole ring. In the first step, alkyne intermediate 1 was cyclized with azidomethylesters 
2a-d using Cu(I) catalyzed Huisgen cycloaddition reaction (click chemistry) to afford 
compounds 3a-d.11,12, 13-15 The utility of this chemistry was popularized by Sharpless and 
Meldal labs,12 and it has become a tool for synthesizing various complex macromolecules 
and rapid identification of small molecules that possess interesting biological activity. 12 
 
Figure 2-2. Synthesis of SAHA-like aryltriazolylhydraxamate 4a-d. 
 
 Treatment of the intermediate esters 3a-d with 50% aqueous hydroxylamine16 
furnished the desired hydroxamic acids 4a-d in good to excellent yields (Figure 2-2). 
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Similarly, the synthesis of analogs with other aromatic surface recognition cap groups is 
achieved starting from the corresponding aryl alkynes and azido esters (Figure 2-2).  
To further explore the SAR of this class of HDACi, we synthesized various 
analogs incorporating assorted surface recognition group using similar chemistry worked 
out for the synthesis of 4a-d. The requisite aryl alkynes, 5g, 5i, 5j, 5l, 5p, and 5q, that 
were not commercially available were synthesized from the corresponding aldehydes and 
carboxylic acids (through the intermediacy of aldehyde) using the Bestmann-Ohira 
Reagent.17-19 Coupling of these alkynes with appropriate azidomethylesters, following by 
treatment of the intermediate esters with 50% aqueous hydroxylamine gave the desired 
aryltriazolyhydroxamates 7a-y (Figure 2-3). 
 
Figure 2-3. Synthesis of aryltriazolyhydroxamates 7 for SAR studies. For R1 structures refer 
Table 1-2.  
 
2.3 SAR Studies of Triazole-linked Simple HDAC Inhibitors  
  Initially, we synthesized hydroxamates 4a-d to allow head to head comparison of 
their HDAC inhibition activity with SAHA. and conclude any advantage of triazole ring 
(or lack thereof) on potency. Analysis of the HDAC inhibition activity of 4a-d against 
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HeLa nuclear extract (mixture of HDAC1 and HDAC1), using the standard Fluor de lys 
assay20 revealed an interesting linker length dependency. Compound 4a, the analog with 
the shortest methylene linker didn’t show any detectable activity. However, 4b-d 
displayed linker-length dependence with five and six methylene linkers being the most 
potent (Table 2-1). This study is in good accord with the optimum linker for SAHA and 
TSA like compounds.1,21 More importantly, we observed that compounds  4c-d, the 
closest analogs to SAHA, are 4-fold more active than SAHA. This suggests that the 
replacement of HDACi amide cap linking moiety with triazole enhanced the anti-HDAC 
activities of the resulting aryltriazolyhydroxamates.   
 Further SAR study on cap group for five to six methylene spacer reveal that there 
is no clear trend in five- or six-methylene spacer regions. For example, for phenyl 
substituted compounds, the six-methylene linked compound 4d is slightly more active 
than the five-methylene compound 4c (Table 2-1). However, the introduction of N, N-
dimethylamino moiety to the para position of the phenyl group for five methylene linker, 
led to 25-fold more active analog than the corresponding six-methylene compound (Table 
2-1, compare 7a and 7b). Due to this cap group dependent potency for five- and six-
methylene spacer group, we prepared a series of aromatic and heteroaromatic derivatives 
consisting of either spacer group in order to flush out the SAR of these compounds. 
Relative to compounds 4c and 4d, nitrogen substitution into the phenyl ring (pyridine) 
did not improve the potency (Table 2-1, compounds 7c-f). However, the position of 
pyridine nitrogen affects the potency with the 2-pyridyl derivative 7e being more active 
than the corresponding 3-pyridyl and 4-pyridyl analogs 7c and 7d respectively. 
Additionally, pyridine based simple HDACi analogs 7e and 7f, which differ by a 
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methylene group, show a chain length dependency similar to that observed with 4c and 
4d. Similarly, among methyl-substituted compounds 7g-i ortho-substitution is more 
favorable. However, para-substitution is preferred for methoxy group substitution (Table 
2-1, compare compounds 7j-l with 7g-i). 
 
Table 2-1. In vitro inhibition data for arytriazolylhydroxamatesa 
 
Compounds    R1 n  IC50
b (nM)          Compounds R1 n IC50






























































Table 2-1 continued. 
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3 13.9  SAHA  65 
 
aPo-Chih Chen and Patience Green also contributed in synthesis of compound 7.  bData represent 
mean values of at least three-independent experiments in Fluor-de Lys assay; performed by 
William Guerrant. cNot determinable. *Compounds made by Patience Green +Compounds made 
by Po-Chih Chen, included here to clarify SAR studies. For details, refer to Chen et al, Bioorg. & 
Med. Chem., 2008, 16, 4839-4853. 
 
 There is a precedence that para-substitution has been preferred for methoxy-
substituted SAHA-like HDACi in which cap linking moiety was ketone instead of 
triazole.22 The enhanced steric bulkiness of the methoxy moiety relative to methyl group 
may be responsible for the observed para-position preference. To investigate this 
prospect, we synthesized the 2,6-dimethoxy substituted compound 7m. We observed a 
drop in activity for compound 7m compared to 7l. This result confirmed that steric 
repulsion at the ortho position influenced compound anti-HDAC activity. The 2-
quinoline analog 7w, in similar manner to the pyridine analogs 7c-e, is more active than 
the 7-quinoline analog 7x. We observed enhanced potency for the five-methylene linker 
compounds compared to six-methylene analogs. For example, 6-methoxynaphthalene 
capped compound 7u showed enhanced activity relative to a corresponding six-
methylene analog 7v. Furthermore, biphenyl compounds 7o-t showed preference for the 
meta-placement of the triazole ring and a five-methylene spacer (Table 2-1, compare 
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compounds 7o-r). Finally, to the importance of placement of triazole ring in compound 
design was confirmed by the disparity between the anti-HDAC activities of 4c and 7y, 
two analogs which have the same number of carbon atoms separating the cap group and 
the ZBG. Compound 4c contains triazole ring directly attached to the phenyl cap group 
and is several fold more potent than 7y whose triazole ring is separated from the cap 
group by a methylene group. This result supports the hypothesis that the triazole ring is 
indeed contributing to the interaction of this class of compound with the HDAC active 
site. 
 
2.4 Molecular Docking Analysis 
 In order to gain insight on structural basis for the observed disparity in the anti-
HDAC activities of these aryltriazolyhydroxamates HDACi, we performed molecular 
docking analyses using a validated molecular dock program (AutoDock)23-25 We chose to 
perform docking studies on histone deacetylase-like protein (HDLP)2 because it shared 
conserved active site residues with class I HDACs. Moreover, docking on HDAC1 
homology model built from the same HDLP structure also concurred with experimentally 
obtained data. Both approaches have been used in literature to validate the HDAC 
inhibition data.24 We used AutoDock 3.05 as described by Lu et al.25 Independent 
docking of SAHA, 4c, 7o, 7p, and 7u into HDLP revealed that these compounds bind to 
two different binding pockets at the protein surface (Figure. 2-4). It has been shown 
earlier that there are four pockets on HDLP surface where HDACi tend to bind.24 
Compounds 7o and 7u bind within the binding pocket designated as pocket 1 while 
SAHA, 4c and 7p bind within pocket 2. The 1,4-biphenyl ring of 7o adopts a co-planar 
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geometry to orient in pocket 1. This is due to the stacking interactions in pocket 1 that 
favor a co-planar orientation of the cap group, an inference that may be supported by the 
binding of 7u, an analog with a flat fused six-six ring, within pocket 1. To adopt the 
observed conformation, a sharp twist is introduced into the methylene linker portion of 
7o. The resulting twist in 7o pulls off the hydroxamate moiety thereby reducing Zn2+ 
binding of hydroxamate, compared to that of 7p and SAHA. This might cancel out any 
positive effects derived from the cap group interaction with pocket 1 and may explain the 
reduced potency of 7o compared to structurally similar 7p. Unlike 7o, the 1,3-biphenyl 
ring of 7p preferred a non-planar geometry with the biphenyl ring projecting deeper into 
the binding pocket 2 where it interacted hydrophobically further with the pocket residues. 
This extra interaction could explain the higher potency of 7p compared to 4c and SAHA. 
 
  
(a)                                                           (b) 
Figure 2-4. Molecular docking analysisa 7o (orange), 7p (green), 7u (magenta), and SAHA 
(cyan) to HDLP using Autodock 3.0519-21 and viewed in PYMOL. (a) Surface presentation of 
HDLP near the active site; (b) side view of the triazolylhydroxamics 7o, 7p, 7u, and SAHA 
coordinating to zinc with amino acid residues in and near the active sites.19-21  
aMolecular docking analysis performed by Po-Chih Chen. Presented here to explain SAR 
disparity. For details, refer to Chen et al, Bioorg. & Med. Chem., 2008, 16, 4839-4853. 
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2.5 Cell Growth Inhibition Studies of Triazole-linked Simple HDACi 
 To determine whole cell activity of these compounds against cancer cell line, we 
treated representative compounds with DU-145 cell line.26 We investigated compounds 
7s, 7u, 7v and 7w with SAHA as a control, using both the MTS test (a colorimetric 
method) and trypan blue exclusion.27,28  
 SAHA exhibited EC50 value of 2.12 µM which is in close agreement with the 
reported value in literature.29 Compounds 7s, 7u, 7v and 7w also inhibited the 
proliferation of DU-145 in a dose-dependent manner, with EC50 values ranging from 2.2 
to 8.0 µM (Table 2-2). These results validated the suitability of the triazole moiety as a 
linking moiety in the design of SAHA-like HDACi. 
 
 Table 2-2. Cell growth inhibitory data for lead compounds 




1.8 3.95 2.6 
 
15.3 7.76 3.99 
 










2.1 2.25 2.46 




SAHA was used as a control for these experiments. EC50 values were determined from 
atrypan blue exclusion data and bMTS assay (Progmega), in DU-145 prostate cancer cell 
line, performed by William Guerrant. cCompound made by Bob Chen. These are included 
to clarify the SAR. See Chen et al, Bioorg. & Med. Chem., 2008, 16, 4839-4853 for 
detailed synthetic protocol. 
 
 
2.6 Conclusions  
 
  We have demonstrated the suitability of 1,2,3-triazole ring as a cap group-linking 
moiety in SAHA-like HDAC inhibitors. This study showed that the anti-HDAC activities 
of the resulting triazole-linked hydroxamates followed a cap group dependent preference 
for five- and six- methylene linkers. We have identified compounds that are several folds 
more potent than SAHA. A subset of these compounds also inhibited the proliferation of 
DU-145 cells. These triazole based compounds are expected to simplify SAR study for 
more complex HDACi by facilitating easy synthetic access to connect linker and cap 
group.  
 
2.7 General Procedure and Experimental 
 
 
4-bromobutyric acid, 5-bromovaleric acid, 6-bromohexanoic acid, and 7-bromoheptane-
nitrile were purchased from Sigma Aldrich.  Anhydrous solvents and other reagents were 
purchased and used without further purification.  Analtech silica gel plates (60 F254) were 
used for analytical TLC, and Analtech preparative TLC plates (UV 254, 2000 µm) were 
used for purification.  UV light was used to examine the spots.  200-400 Mesh silica gel 
was used in column chromatography.  NMR spectra were recorded on a Varian-Gemini 
400 magnetic resonance spectrometer.  1H NMR spectra are recorded in parts per million 
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(ppm) relative to the peak of CDCl3, (7.24 ppm), CD3OD (3.31 ppm), or DMSO-d6 (2.49 
ppm).  13C spectra were recorded relative to the central peak of the CDCl3 triplet (77.0 
ppm), CD3OD (49.0 ppm), or the DMSO-d6 septet (39.7 ppm), and were recorded with 
complete hetero-decoupling.  Multiplicities are described using the abbreviation s, 
singlet; d, doublet, t, triplet; q, quartet; m, multiplet; and app, apparent.  High-resolution 
mass spectra were recorded at the Georgia Institute of Technology mass spectrometry 
facility in Atlanta.  Methyl bromoalkanoates 1a-d and azido alkylesters 2a-d were 
synthesized by adapting literature protocol.13-16,30 The Bestmann-Ohira reagent was 
prepared as described by Ghosh et al.18 Alkynes that we could not obtain from 
commercial sources were synthesized using the Bestmann-Ohira reagent as described 
before.29 
 
Representative procedure for Cu(I)-catalyzed cycloaddition reaction 
 
Methyl 7-(phenyl)triazolylheptanoate (3d). 
Methyl 4-azidobutanoate 2d (0.15 g, 0.81 mmol) and phenylacetylene (182 mg, 1.78 
mmol) were dissolved in anhydrous THF (10 mL) and stirred under argon at room 
temperature. Copper (I) iodide (0.011 g, 0.07 mmol) and Hunig’s base (0.1 mL) were 
then added to the reaction mixture, and stirring continued for 24 h.31 The reaction mixture 
was diluted with CH2Cl2 (20 mL) and washed with 1:4 NH4OH/saturated NH4Cl (3 x 30 
mL) and saturated NH4Cl (30 mL). The organic layer was dried over Na2SO4 and 
concentrated in vacuo. The crude product was purified by flash chromatography (silica, 
gradient 2:1; 3:2 Hexane/EtOAc) to give 151 mg (65%) of 3d as white solid.  1H NMR 
(CDCl3, 400 MHz) δ 1.35 (4H, p, J = 7.3, 3.5 Hz), 1.57-1.64 (2H, m), 1.89-1.96 (2H, m), 
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2.28 (2H, t, J = 7.3 Hz), 3.63 (3H, s), 4.36 (2H, t, J = 7.1 Hz), 7.30 (1H, t, J = 7.2 Hz), 
7.39 (2H, t, J = 7.3 Hz), 7.72 (1H, s), 7.80 (2H, d, J = 7.1 Hz); 13C NMR (CDCl3, 100 
MHz) δ 24.7, 26.2, 28.5, 30.2, 33.9, 50.2, 51.5, 119.2, 125.5, 127.9, 128.6, 130.5, 147.5, 
173.7; HRMS (FAB, thioglycerol) calcd for [C16H21N3O2 + H]
+ 288.1712, found 
288.1711. 
 
Methyl 7-(4-anilyl)triazolylheptanoate (6b). Reaction of methyl 7-azidoheptanoate 2d 
(0.15 g, 0.81 mmol) and 4-ethynyl-N,N-dimethylaniline 5a (127 mg, 0.87 mmol) within 
24 h as described for the synthesis of 3d, followed by flash chromatography (silica, 3:2 
Hexane/EtOAc) gave 165 mg (62%) of 6b as colorless oil. 1H NMR (CDCl3, 400 MHz) δ 
1.34-1.37 (4H, m), 1.58-1.64 (2H, m), 1.92 (2H, m), 2.28 (2H, t, J = 7.3 Hz), 2.97 (6H, 
s), 3.64 (3H, s), 4.34 (2H, t, J = 7.1 Hz), 6.75 (2H, d, J = 8.9 Hz), 7.58 (1H, s), 7.65-7.69 
(2H, m); 13C NMR (CDCl3, 100 MHz) δ 25.0, 26.5, 28.8, 30.5, 34.1, 40.8, 50.4, 51.7, 
112.6, 118.1, 119.1, 126.7, 148.2, 150.4, 174.0; HRMS (FAB, thioglycerol) calcd for 
[C18H26N4O2 + H]
+ 331.2134, found 331.2150. 
 
Methyl 6-(3-pyridyl)triazolylhexanoate (6c). Reaction of methyl 6-azidohexanoate 2c 
(0.2 g, 1.17 mmol) and 3-ethynylpyridine 5b (180 mg, 1.74 mmol) within 24 h as 
described for the synthesis of 3d, followed by flash chromatography (silica, 3:2 
Hexane/EtOAc) gave 294 mg (92%) of 6c as colorless oil. 1H NMR (CDCl3, 400 MHz) δ 
1.34-1.41 (2H, m), 1.67 (2H, m), 1.93-2.01 (2H, m), 2.30 (2H, t, J = 7.2 Hz), 3.63 (3H, 
s), 4.41 (2H, t, J = 7.1 Hz), 7.34 (1H, q, J = 7.9, 4.8 Hz), 7.85 (1H, s), 8.18 (1H, d, J = 7.9 
Hz), 8.54 (1H, d, J = 4.3 Hz), 8.97 (1H, d, J = 2.1 Hz); 13C NMR (CDCl3, 100 MHz) δ 
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24.1, 25.9, 30.0, 33.6, 50.2, 51.5, 119.7, 123.5, 126.6, 132.7, 144.4, 146.8, 148.9, 173.4; 
HRMS (FAB, thioglycerol) calcd for [C14H18N4O2 + H]
+ 275.1508, found 275.1491. 
 
Methyl 6-(4-pyridyl)triazolylhexanoate (6d). Reaction of methyl 6-azidohexanoate 2c 
(0.2 g, 1.17 mmol) and 4-ethynylpyridine 5c (180 mg, 1.74 mmol) within 24 h as 
described for the synthesis of 3d, followed by flash chromatography (silica, 3:2 
Hexane/EtOAc) gave 288 mg (90%) of 6d as colorless oil. 1H NMR (CDCl3, 400 MHz) δ 
1.30-1.38 (2H, m), 1.64 (2H, m), 1.90-1.99 (2H, m), 2.28 (2H, t, J = 7.2 Hz), 3.6 (3H, s), 
7.39 (2H, t, J = 7.1 Hz), 7.67 (2H, dd, J = 4.5, 1.5 Hz), 7.90 (1H, s), 8.6 (2H, dd, J = 4.5, 
1.5 Hz); 13C NMR (CDCl3, 100 MHz) δ 24.1, 25.8, 29.9, 33.5, 50.2, 51.5, 119.7, 120.9, 
137.7, 145.1, 150.1, 173.4; HRMS (FAB, thioglycerol) calcd for [C14H18N4O2 + H]
+ 
275.1508, found 275.1512. 
 
Methyl 6-(2-pyridyl)triazolylhexanoate (6e). Reaction of methyl 6-azidohexanoate 2c 
(0.2 g, 1.17 mmol) and 2-ethynylpyridine 5d (180 mg, 1.74 mmol) within 24 h as 
described for the synthesis of 3d, followed by flash chromatography (silica, 3:2 
Hexane/EtOAc) gave 269 mg (84%) of 6e as colorless oil. 1H NMR (CDCl3, 400 MHz) δ 
1.31-1.39 (2H, m), 1.65 (2H, m), 1.94 (2H, m), 2.27 (2H, t, J = 7.3 Hz), 3.62 (3H, s), 4.39 
(2H, t, J = 7.1 Hz), 7.17-7.20 (1H, m), 7.71 (1H, m), 8.09 (1H, s), 8.13 (1H, d, J = 7.9 
Hz), 8.52-8.54 (1H, m); 13C NMR (CDCl3, 100 MHz) δ 24.6, 26.3, 30.3, 34.0, 50.5, 51.8, 
120.3, 121.9, 122.9, 137.0, 148.4, 149.4, 150.4, 173.7; HRMS (FAB, thioglycerol) calcd 
for [C14H18N4O2 + H]




Methyl 7-(2-pyridyl)triazolylheptanoate (6f). Reaction of methyl 7-azidoheptanoate 2d 
(0.225 g, 1.21 mmol) and 2-ethynylpyridine 5d (134 mg, 1.30 mmol) within 24 h as 
described for the synthesis of 3d, followed by flash chromatography (silica, 3:2 
Hexane/EtOAc) gave 271 mg (78%) of 6f as colorless oil. 1H NMR (CDCl3, 400 MHz) δ 
1.35-1.39 (4H, m), 1.58-1.68 (2H, m), 1.92-1.99 (2H, m), 2.29 (2H, t, J = 7.4 Hz), 3.65 
(3H, s), 4.42 (2H, t, J = 7.1 Hz), 7.21-7.24 (1H, m), 7.75-7.79 (1H, m), 8.14 (1H, s), 8.17 
(1H, d, J = 7.9 Hz), 8.56-8.58 (1H, m); 13C NMR (CDCl3, 100 MHz) δ 24.5, 26.0, 28.3, 
29.9, 33.7, 50.2, 51.3, 119.8, 121.5, 122.5, 136.6, 147.9, 148.9, 149.9, 173.5; HRMS (EI) 
calcd for [C15H20N4O2 + H]
+ 289.1664, found 289.1665. 
 
Methyl 6-(4-tolyl)triazolylhexanoate (6g). Reaction of methyl 6-azidohexanoate 2c (0.2 
g, 1.17 mmol) and 4-ethynyltoluene 5m (204 mg, 1.76 mmol) within 24 h as described 
for the synthesis of 3d, followed by flash chromatography (silica, 3:2 Hexane/EtOAc) 
gave 287 mg (85%) of 6g as colorless oil. 1H NMR (CDCl3, 400 MHz) δ 1.18-1.26 (2H, 
m), 1.53 (2H, m), 1.79 (2H, m), 2.17 (2H, t, J = 7.3 Hz), 2.24 (3H, s), 3.52 (3H, s), 4.21 
(2H, t, J = 7.1 Hz), 7.09 (2H, t, J = 7.9 Hz), 7.60 (2H, t, J = 8.0 Hz), 7.67 (1H, s); 13C 
NMR (CDCl3, 100 MHz) δ 20.9, 23.9, 25.6, 29.6, 33.3, 49.6, 51.1, 118.9, 125.0, 127.4, 
128.9, 137.2, 147.0, 173.1; HRMS (EI) calcd for [C16H21N3O2 + H]
+ 288.1712, found 
288.1732. 
 
Methyl 6-(3-tolyl)triazolylhexanoate (6h). Reaction of methyl 6-azidohexanoate 2c (0.2 
g, 1.17 mmol) and 3-ethynyltoluene 5n (204 mg, 1.76 mmol) within 24 h as described for 
the synthesis of 3d, followed by flash chromatography (silica, 3:2 Hexane/EtOAc) gave 
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287 mg (84%) of 6h as colorless oil. 1H NMR (DMSO-d6, 400 MHz) δ 1.33-1.40 (2H, 
m), 1.63-1.70 (2H, m), 1.95 (2H, m), 2.30 (2H, t, J = 7.3 Hz), 2.38 (3H, s), 4.38 (2H, s, J 
= 7.1 Hz), 7.11-7.13 (1H, m), 7.28 (1H, t, J = 7.6 Hz), 7.55-7.59 (1H, m), 7.67 (1H, d, J = 
0.5 Hz), 7.72 (1H, s); 13C NMR (CDCl3, 100 MHz) δ 21.9, 24.5, 26.2, 30.3, 33.9, 50.3, 
51.8, 119.8, 122.8, 126.4, 128.8, 128.9, 130.6, 138.5, 147.8, 147.8; HRMS (EI) calcd for 
[C16H21N3O2 + H]
+ 288.1752, found 288.1744. 
 
Methyl 6-(2-tolyl)triazolylhexanoate (6i). Reaction of methyl 6-azidohexanoate 2c (0.2 
g, 1.17 mmol) and 2-ethynyltoluene 5o (204 mg, 1.76 mmol) within 24 h as described for 
the synthesis of 3d, followed by flash chromatography (silica, 3:2 Hexane/EtOAc) gave 
287 mg (60%) of 6i as colorless oil. 1H NMR (DMSO-d6, 400 MHz) δ 1.25-1.33 (2H, m), 
1.58 (2H, m), 1.87 (2H, m), 2.22 (2H, t, J = 7.3 Hz), 2.37 (3H, s), 3.56 (3H, s), 4.30 (2H, 
t, J = 7.1 Hz), 7.16 (2H, d, J = 3.1 Hz), 7.62 (1H, s), 7.66-7.70 (1H, s); 13C NMR 
(DMSO-d6, 100 MHz) δ 21.1, 23.9, 25.7, 29.7, 33.3, 49.6, 51.1, 121.4, 125.5, 127.5, 
128.2, 129.5, 130.3, 134.9, 146.3, 173.1; HRMS (EI) calcd for [C16H21N3O2 + H]
+ 
288.1712, found 288.1709. 
 
Methyl 6-(4-anisolyl)triazolylhexanoate (6j). Reaction of methyl 6-azidohexanoate 2c 
(0.2 g, 1.17 mmol) and 4-ethynylanisole 5r (0.232 mg, 1.75 mmol) within 24 h as 
described for the synthesis of 3d, followed by flash chromatography (silica, 3:2 
Hexane/EtOAc) gave 347 mg (98%) of 6j as colorless oil. 1H NMR (CDCl3, 400 MHz) δ 
1.29-1.37 (2H, m), 1.63 (2H, p, J = 15.0, 7.3 Hz), 1.91 (2H, p, J = 15.0, 7.3 Hz), 2.27 
(2H, t, J = 7.3 Hz), 3.61 (3H, s), 3.79 (3H, s), 4.33 (2H, t, J = 7.1 Hz), 6.88- 6.92 (2H, m), 
39 
 
7.64 (1H, s), 7.69-7.72 (2H, m); 13C NMR (CDCl3, 100 MHz) δ 24.2, 25.9, 30.1, 33.6, 
44.9, 51.5, 55.2, 114.0, 118.5, 123.2, 126.7, 147.3, 159.2, 173.4; HRMS (EI) calcd for 
[C16H21N3O3 + H]
+ 304.1661, found 304.1685. 
 
Methyl 6-(3-anisolyl)triazolylhexanoate (6k). Reaction of methyl 6-azidohexanoate 2c 
(0.2 g, 1.17 mmol) and 3-ethynylanisole 5s (0.232 g, 1.75 mmol) within 24 h as described 
for the synthesis of 3d, followed by flash chromatography (silica, 3:2 Hexane/EtOAc) 
gave 301 mg (85%) of 6k as colorless oil. 1H NMR (DMSO-d6, 400 MHz) δ 1.18-1.26 
(2H, m), 1.52 (2H, p, J = 14.9, 7.4 Hz), 1.84 (2H, p, J = 7.0, 14.3 Hz), 1.93 (2H, t, J = 7.2 
Hz), 3.79 (3H, s), 4.36 (2H, t, J = 6.9 Hz), 6.86-6.89 (1H, m), 7.33 (1H, app. t), 7.39-7.41 
(2H, m), 8.58 (1H, s), 8.67 (1H, s), 10.33 (1H, s); 13C NMR (DMSO- d6, 100 MHz) δ 
24.5, 25.4, 29.3, 32.0, 49.3, 55.0, 110.1, 113.3, 117.2, 121.2, 129.8, 131.9, 145.9, 159.3, 
168.6; HRMS (EI) calcd for [C16H20N3O3 + H]
+ 304.1661, found 304.1688. 
 
Methyl 6-(2-anisolyl)triazolylhexanoate (6l). Procedure: Reaction of methyl 6-
azidohexanoate 2c (0.2 g, 1.17 mmol) and 2-ethynylanisole 5t (0.232 mg, 1.75 mmol) 
within 24 h as described for the synthesis of 3d, followed by flash chromatography 
(silica, 3:2 Hexane/EtOAc) gave 336 mg (95%) of 6l as colorless oil. 1H NMR (CDCl3, 
400 MHz) δ 1.41-1.21 (2H, m), 1.47 (2H, p, J = 15.1, 7.4 Hz), 1.75 (2H, p, J = 14.8, 7.2 
Hz), 2.11 (2H, t, J = 7.42 Hz), 3.47 (3H, s), 3.73 (3H, s), 4.18 (2H, t, J = 7.1 Hz), 6.79 
(1H, d, J = 8.3 Hz), 6.89 (1H, t, J = 7.4 Hz), 7.09-7.13 (1H, m), 8.21 (1H, dd, J = 7.6, 1.5 
Hz); 13C NMR (CDCl3, 100 MHz) δ 23.8, 25.4, 29.5, 33.1, 49.3, 50.9, 54.8, 110.2, 118.8, 
40 
 
120.1, 122.4, 126.6, 128.1, 142.1, 154.8, 172.8; HRMS (FAB, thioglycerol) calcd for 
[C16H21N3O3 + H]
+ 304.1661, found 304.1676. 
 
Methyl 7-(3-biphenyl)triazolylheptanaoate (6q). Reaction of methyl 7-azidoheptanoate 
2d (0.184 g, 1.03 mmol) and 3-ethynylbiphenyl 5i (185 mg, 1.03 mmol). within 24 h as 
described for the synthesis of 3d, followed by flash chromatography (silica, 3:2 
Hexane/EtOAc) gave 201 mg (54%) of 6q as colorless oil. 1H NMR (CDCl3, 400 MHz) δ 
1.32-1.35 (4H, m), 1.59 (2H, p, J =14.72, 7.36), 1.91 (2H, m), 2.26 (2H, t, J = 7.4 Hz), 
3.62 (3H, s), 4.35 (2H, t, J = 7.1 Hz), 7.31-7.35 (1H, m), 7.39-7.44 (2H, m), 7.46 (1H, dd, 
J = 7.6, 0.4 Hz), 7.51-7.54 (1H, m), 7.60-7.63 (2H, m), 7.73-7.78 (1H, m), 7.79 (1H, s), 
8.05-8.06 (1H, m); 13C NMR (CDCl3, 100 MHz) δ 24.6, 26.1, 28.4, 30.1, 33.8, 50.2, 51.4, 
119.4, 124.2, 124.3, 126.9, 127.2, 128.5, 129.0, 129.3, 130.9, 140.5, 141.5, 147.3, 173.6; 
HRMS (EI) calcd for [C22H25N3O2 + H]
+ 364.2025, found 364.2045. 
 
Methyl 6-(4-pyridylphenyl)triazolylhexanoate (6s). Reaction of methyl 6-
azidohexanoate 2c (0.2 g, 1.17 mmol) and 4-(4-ethynylphenyl)-pyridine 5l (0.232 g, 1.76 
mmol) within 24 h as described for the synthesis of 3d, reaction followed by flash 
chromatography (silica,1:3 Hexane/EtOAc) gave 274 mg (67%) of 6s as colorless oil. 1H 
NMR (CDCl3, 400 MHz) δ 1.32-1.40 (2H, m), 1.62-1.70 (2H, m), 1.91-2.00 (2H, m), 
2.29 (2H, t, J = 7.42), 3.62 (3H, s), 4.38 (2H, t, J = 7.1 Hz), 7.49-7.50 (2H, m), 7.67 (2H, 
d, J = 8.3 Hz), 7.82 (1H, s), 7.91-7.93 (2H, m), 8.61-8.63 (2H, m); 13C NMR (CDCl3, 100 
MHz) δ 24.0, 25.7, 29.8, 33.4, 50.0, 51.4, 119.8, 121.2, 126.1, 127.2, 127.8, 128.5, 128.9, 
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131.3, 137.4, 146.8, 147.5, 150.1, 173.6. HRMS (FAB) calcd for [C20H22N4O2 + H]
+ 
351.1821, found 351.1844. 
 
Methyl 7-(4-pyridylphenyl)triazolylheptanoate (6t). Reaction of methyl 7-
azidoheptanoate 2d (0.17 g, 0.91 mmol) and 4-(4-ethynylphenyl)-pyridine 5l (163 mg, 
0.91 mmol) within 24 h as described for the synthesis of 3d, reaction followed by flash 
chromatography (silica, 3:2 Hexane/EtOAc) gave 231 mg (70%) of 6t as colorless oil. 1H 
NMR (CDCl3, 400 MHz) δ 1.28-1.32 (4H, m), 1.51- 1.58 (2H, m), 1.85-1.92 (2H, m), 
2.21 (2H, app. q), 3.58 (3H, s), 4.33 (2H, t, J = 7.2 Hz), 7.42-7.46 (2H, m), 7.62 (2H, d, J 
= 8.3 Hz), 7.78 (1H, s), 7.84-7.90 (2H, m), 8.58 (2H, d, J = 5.4 Hz); 13C NMR (CDCl3, 
100 MHz) δ 24.8, 26.4, 28.6, 30.3, 34.0, 50.5, 51.7, 119.9, 121.3, 126.3, 127.4, 131.5, 
137.4, 146.8, 147.5, 150.2, 173.8; HRMS (FAB, MNBA) calcd for [C21H24N4O2 + H]
+ 
365.1977, found 365.1982. 
 
Methyl 7-(6-methoxynapthalyl)triazolylheptanoate (6v). Reaction of methyl 7-
azidoheptanoate 2d (0.15 g, 0.81 mmol), and 2-ethynyl-6-methoxy-napthalene 5f (162 
mg, 0.89 mmol) within 24 h as described for the synthesis of 3d, followed by flash 
chromatography (silica, 6:1:1 Hexane/Acetone/Dichloromethane) gave 202 mg (68%) of 
6v as colorless oil. 1H NMR (CDCl3, 400 MHz) δ 1.45-1.49 (4H, m), 1.72 (2H, m), 2.02-
2.07 (2H, m), 2.39 (2H, t, J = 7.3 Hz), 3.75 (3H, s), 4.01 (3H, s), 4.42 (2H, t, J =7.1 Hz), 
7.20-7.27 (2H, m), 7.87 (2H, app. t), 4.48 (2H, t, J = 7.1 Hz), 7.23-7.26 (2H, m), 7.86 
(2H, dd, J = 8.5, 1.9 Hz), 7.90 (1H, s), 7.98 (1H, dd, J = 8.4, 1.5 Hz), 8.34 (1H, s); 13C 
NMR (CDCl3, 100 MHz) δ 24.6, 26.2, 28.5, 30.1, 33.8, 50.2, 51.5, 55.3, 105.6, 119.11, 
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119.17, 124.0, 124.2, 125.7, 127.1, 128.8, 129.4, 134.1, 147.7, 157.6, 173.7; HRMS 
(FAB, MNBA) calcd for [C21H25N3O3 + H]
+ 368.1974, found 368.1977. 
 
Methyl 6-(2-quinolyl)triazolylhexanoate (6w). Reaction of methyl 6-azidohexanoate 2c 
(0.13 g, 0.76 mmol) and 2-ethynylquinoline 5p (0.09 g, 0.58 mmol) within 24 h as 
described for the synthesis of 3d, followed by flash chromatography (silica, 3:2 
Hexane/EtOAc) gave 167 mg (68%) of 6w as colorless oil. 1H NMR (CDCl3, 400 MHz) 
δ 1.25-1.33 (2H, m), 1.58 (2H, p, J = 15.0, 7.3 Hz), 1.89 (2H, p, J = 14.9, 7.3 Hz), 2.22 
(2H, t, J = 7.3 Hz), 3.57 (3H, s), 4.34 (2H, t, J = 7.1 Hz), 7.39-7.43 (1H, m), 7.59-7.63 
(1H, m), 7.71 (1H, d, J = 8.0 Hz), 7.98 (1H, d, J = 8.4 Hz), 8.13 (1H, d, J = 8.6 Hz), 8.24-
8.28 (2H, m); 13C NMR (CDCl3, 100 MHz) δ 24.0, 25.7, 29.7, 33.4, 50.0, 51.3, 118.2, 
122.3, 125.9, 127.3, 127.4, 128.5, 129.3, 136.4, 147.5, 148.1, 150.1, 173.5; HRMS (FAB, 
thioglycerol) calcd for [C18H20N4O2 + H]
+ 325.1624, found 325.1621.  
 
Methyl 6-(7-quinolyl)triazolylhexanoate (6x). Reaction of methyl 6-azidohexanoate 2c 
(0.184 g, 1.07 mmol) and 7-ethynylquinoline 5q  (0.15 g, 0.98 mmol) within 24 h as 
described for the synthesis of 3d, followed by flash chromatography (silica, 1:4 
Hexane/EtOAc) gave 209 mg (60%) of 6x as colorless oil. 1H NMR (CDCl3, 400 MHz) δ 
1.20-1.28 (2H, m), 1.53 (2H, p, J = 15.0, 7.3 Hz), 1.79-1.88 (2H, m), 2.16 (2H, t, J = 7.2 
Hz), 3.49 (3H, s), 4.27 (2H, t, J = 7.0 Hz), 7.19-7.23 (1H, m), 7.70 (1H, d, J = 8.4 Hz), 
7.81 (1H, s), 7.97 (1H, d, J = 8.0 Hz), 8.02 (1H, d, J = 8.4 Hz), 8.26 (1H, s), 8.75 (1H, d, 
J = 4.1 Hz); 13C NMR (CDCl3, 100 MHz) δ 24.1, 25.8, 29.9, 33.5, 50.0, 51.4, 120.2, 
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120.8, 124.2, 125.1, 127.6, 128.1, 131.5, 135.5, 146.7, 148.0, 150.6, 173.3; HRMS (FAB, 
thioglycerol) calcd for [C18H20N4O2 + H]
+ 325.1704, found 325.1697.  
 
Methyl 5-(benzyl)triazolylpentanoate (6y). Reaction of methyl 5-azidopentanoate 2b 
(0.2 g, 1.27 mmol) and 3-phenyl-1-propyne 5k (221 mg, 1.91 mmol) within 24 h as 
described for the synthesis of 3d, followed by flash chromatography (silica, 3:2 
Hexane/EtOAc) gave 287 mg (87%) of 6y as colorless oil. 1H NMR (DMSO-d6, 400 
MHz) δ 1.56-1.63 (2H, m), 1.84-1.91 (2H, m), 2.30 (2H, t, J = 7.2 Hz), 3.62 (3H, s), 4.05 
(2H, s), 4.26 (2H, t, J = 7.1 Hz), 7.14 (1H, s), 7.17- 7.29 (5H, m); 13C NMR (DMSO-d6, 
100 MHz) δ 21.7, 29.5, 32.2, 33.1, 49.7, 51.5, 121.0, 126.2, 128.4, 138.8, 147.3, 172.9; 
HRMS (FAB, thioglycerol) calcd for [C15H19N3O2 + H]
+ 274.1555, found 274.1558. 
 
Representative Procedure for Conversion of Methyl Ester to Hydramic Acid.   
7-(phenyl)triazolylheptahydroxamic acid (4d).  
To a solution of methyl 7-(phenyl)triazolyl-heptanoate 3d (0.1 g, 0.35 mmol) in 1:1 THF 
(1.5 mL) and methanol (1.5 mL) was added aqueous hydroxylamine (0.23 mL, 3.74 
mmol) and KCN ( 0.004 g, 0.062 mmol), and the stirring continued for 24 h. The reaction 
was diluted with EtOAc (30 mL) and washed with saturated NaHCO3 (2 x 30 mL) and 
saturated brine (30 mL). The organic layer was dried over Na2SO4 and concentrated in 
vacuo to give 73 mg (73%) of 4d as white solid. 1H NMR (DMSO-d6, 400 MHz) δ 1.22-
1.27 (4H, m), 1.43-1.51 (2H, m), 1.84 (2H, m), 1.92 (2H, t, J = 7.2 Hz), 4.36 (2H, t, J = 
7.0 Hz), 7.31 (1H, t, J =  7.2 Hz), 7.43 (2H, t, J = 7.5 Hz), 7.82 (2H, d, J = 7.1 Hz), 8.56 
(1H, s), 8.63 (1H, s), 10.31 (1H, s); 13C NMR (DMSO-d6, 100 MHz) δ 24.9, 25.5, 27.9, 
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29.5, 32.1, 49.4, 120.9, 124.8, 127.5, 128.6, 130.6, 145.9, 168.6; HRMS (FAB, 
thioglycerol) calcd for [C15H20N4O2 + H]
+ 289.1664, found 289.1612. 
 
7-(4-anilyl)triazolylheptahydroxamic acid (7b). Reaction of methyl 7-(4-anilyl)-
triazolylheptanoate 6b (0.128 g, 0.38 mmol) and aqueous hydroxylamine (0.25 ml, 4.07 
mmol) within 32 h as described for the synthesis of 4d, gave 95 mg (76%) of 7b as white 
solid. 1H NMR (CD3OD, 400 MHz) δ 1.23-1.36 (4H, m), 1.52-1.59 (2H, m), 1.84-1.91 
(2H, m), 2.02 (2H, t, J =  7.2 Hz), 2.91 (6H, s) 4.33 (2H, t, J = 6.9 Hz), 6.75 (2H, d, J = 
8.5 Hz), 7.58 (2H, d, J = 8.5 Hz), 8.05 (1H, s); 13C NMR (CD3OD, 100 MHz) δ 26.5, 
27.1, 29.4, 31.1, 33.6, 40.7, 51.2, 113.6, 119.6, 120.4, 127.3, 149.2, 151.8, 172.5; HRMS 
(FAB, thioglycerol) calcd for [C17H25N5O2 + H]
+ 332.2086, found 332.2071. 
 
6-(3-pyridyl)triazolylhexahydoxamic acid (7c). Reaction of methyl 6-(3-pyridyl)-
triazolylhexanoate 6c (0.14 g, 0.51 mmol) and aqueous hydroxylamine (0.33 ml, 5.37 
mmol) within 32 h as described for the synthesis of 4d,  gave 103 mg (74%) of 7c as 
white solid. 1H NMR (CDCl3, 400 MHz) δ 1.19-1.30 (2H, m), 1.54 (2H, m), 1.85 (2H, 
m), 1.96 (2H, t, J = 7.2 Hz), 4.34 (2H, t, J = 7.0 Hz), 7.28 (1H, q, J = 7.6, 4.9 Hz), 8.13 
(1H, d, J = 7.9 Hz), 8.36-8.38 (2H, m), 8.86 (1H, s); 13C NMR (CDCl3, 100 MHz) δ 26.0, 
26.9, 30.8, 33.4, 51.3, 122.9, 125.4, 128.5, 134.7, 146.9, 149.2, 173.2; HRMS (FAB, 
thioglycerol) calcd for [C13H17N5O2 + H]
+ 276.1460, found 276.1478. 
 
6-(4-pyridyl)triazolylhexahydroxamic acid (7d). Reaction of methyl 6-(4-pyridyl)-
triazolylhexanoate 6d (0.14 g, 0.51 mmol) and aqueous hydroxylamine (0.33 ml, 5.37 
mmol) within 32 h as described for the synthesis of 4d, gave 96 mg (69%) of 7d as white 
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solid. 1H NMR (DMSO-d6, 400 MHz) δ 1.18-1.25 (2H, m), 1.51 (2H, m), 1.85 (2H, m), 
1.92 (2H, t, J = 7.2 Hz), 4.40 (2H, t, J = 6.9 Hz), 7.78 (2H, d, J = 5.6 Hz), 8.60 (2H, d, J 
= 5.5 Hz), 8.78 (1H, s), 10.35 (1H, s); 13C NMR (DMSO-d6, 100 MHz) δ 24.5, 25.4, 
29.3, 32.1, 49.6, 54.9, 119.3, 123.1, 137.8, 143.7, 150.1, 168.9, 184.0; HRMS (FAB, 
thioglycerol) calcd for [C13H17N5O2 + H]
+ 276.1460, found 276.1469. 
 
6-(2-pyridyl)triazolylhexahydroxamic acid (7e). Reaction of methyl 6-(2-pyridyl)-
triazolylhexanoate 6e (0.14 g, 0.51 mmol) and aqueous hydroxylamine (0.33 ml, 5.37 
mmol) within 32 h as described for the synthesis of 4d, gave 89 mg (64%) of 7e as white 
solid. 1H NMR (DMSO-d6, 400 MHz) δ 1.17-1.25 (2H, m), 1.51 (2H, m), 1.82-1.89 (2H, 
m), 1.92 (2H, t, J = 7.2 Hz), 4.40 (2H, t, J = 6.9 Hz), 7.30-7.34 (1H, m), 7.85-7.89 (1H, 
m), 7.99-8.02 (1H, m), 8.56-8.58 (1H, m), 8.60 (1H, s), 10.32 (1H, s); 13C NMR (DMSO-
d6, 100 MHz) δ 24.5, 25.4, 29.3, 32.0, 49.4, 119.1, 122.6, 122.9, 136.9, 146.9, 149.3, 
149.8, 168.5; HRMS (FAB, thioglycerol) calcd for [C13H17N5O2 + H]
+ 276.1460, found 
276.1457. 
 
7-(2-pyridyl)triazolylheptahydroxamic acid (7f). Reaction of methyl 7-(2-pyridyl)-
triazolylheptanoate 6f (0.1 g, 0.35 mmol)  and aqueous hydroxylamine (0.2 ml, 3.26 
mmol) within 32 h as described for the synthesis of 4d,  gave 57 mg (57%) of 7f as white 
solid. 1H NMR (CD3OD, 400 MHz) δ 1.36-1.40 (4H, m), 1.61 (2H, m), 1.96 (2H, m), 
2.07 (2H, t, J = 7.5 Hz), 4.47 (2H, t, J = 7.0 Hz), 7.34-7.37 (1H, m), 7.88-7.92 (1H, m), 
8.05 (1H, d, J = 7.9 Hz), 8.40 (1H, s), 8.56 (1H, d, J =4.4 Hz); 13C NMR (CD3OD, 100 
46 
 
MHz) δ 26.5, 27.1, 29.4, 31.1, 33.6, 51.4, 121.3, 123.9, 124.3, 138.6, 148.3, 150.8, 150.9, 
172.5; HRMS (EI) calcd for [C14H19N5O2 + H]
+ 290.1617, found 290.1590. 
 
6-(4-tolyl)triazolylhexahydroxamic acid (7g). Reaction of methyl 6-(4-tolyl)-
triazolylhexanoate 6g (0.15 g, 0.52 mmol) and aqueous hydroxylamine (0.34 ml, 5.54 
mmol) within 32 h as described for the synthesis of 4d, gave 94 mg (63%) of 7g as white 
solid. 1H NMR (DMSO-d6, 400 MHz) δ 1.18-1.26 (2H, m), 1.48-1.55 (2H, m), 1.80-1.89 
(2H, m), 1.92 (2H, app. t), 2.31 (3H, s), 4.35 (2H, t, J = 7.4 Hz), 7.23 (2H, d, J = 7.5 Hz), 
7.71 (2H, d, J = 7.8 Hz), 8.50 (1H, s), 10.31 (1H, s); 13C NMR (DMSO-d6, 100 MHz) δ 
20.8, 24.5, 25.4, 29.3, 32.0, 49.3, 120.6, 124.8, 127.8, 29.2, 136.8, 146.0, 168.5; HRMS 
(FAB, MNBA) calcd for [C15H20N4O2 + H]
+ 289.1664, found 289.1636. 
 
6-(3-tolyl))triazolylhexahydroxamic acid (7h). Reaction of methyl 6-(3-tolyl)-
triazolylhexanoate 6h (0.15 g, 0.52 mmol) and aqueous hydroxylamine (0.34 ml, 5.54 
mmol) within 32 h as described for the synthesis of 4d, gave 115 mg (77%) of 7h as 
white solid. 1H NMR (DMSO-d6, 400 MHz) δ 1.17-1.24 (2H, m), 1.44-1.57 (2H, m), 1.83 
(2H, p, J =14.4, 7.1 Hz), 1.92 (2H, t, J = 7.2 Hz), 2.33 (3H, s), 4.35 (2H, t, J = 6.9 Hz), 
7.11 (1H, d, J = 7.5 Hz), 7.29 (1H, t, J = 7.6 Hz), 7.60 (1H, d, J = 7.2 Hz), 7.65 (1H, s), 
8.52 (1H, s); 13C NMR (DMSO-d6, 100 MHz) δ 21.1, 24.5, 25.5, 29.3, 32.0, 49.3, 120.9, 
122.0, 125.4, 128.2, 128.5, 130.5, 137.5, 146.1, 168.6; HRMS (EI) calcd for [C15H20N4O2 




6-(3-tolyl)triazolylhexahydroxamic acid (7i). Reaction of methyl 6-(3-tolyl)-
triazolylhexanoate 6i (0.15 g, 0.52 mmol) and aqueous hydroxylamine (0.34 ml, 5.54 
mmol) within 32 h as described for the synthesis of 4d, gave 116 mg (78%) of 7i as white 
solid. 1H NMR (DMSO-d6, 400 MHz) δ 1.21-1.29 (2H, m), 1.52 (2H, m), 1.82-1.89 (2H, 
m), 1.93 (2H, t, J = 7.9 Hz), 2.41 (3H, s), 4.38 (2H, t, J = 6.9 Hz), 7.23-7.28 (3H, m), 
7.70-7.73 (1H, m), 8.36 (1H, s); 13C NMR (DMSO-d6, 100 MHz) δ 21.2, 24.5, 25.5, 29.4, 
32.0, 49.2, 122.9, 125.7, 127.4, 127.9, 129.9, 130.6, 134.6, 145.2, 168.5; HRMS (EI) 
calcd for [C15H20N4O2 + H]
+ 289.1664, found 289.1681. 
 
6-(4-anisolyl)triazolylhexahydroxamic acid (7j). Reaction of methyl 6-(4-anisolyl)-
triazolylhexanoate 6j (0.15 g, 0.52 mmol) and aqueous hydroxylamine (0.34 ml, 5.2 
mmol) within 32 h as described for the synthesis of 4d, gave 99 mg (60%) of 7j as white 
solid. 1H NMR (DMSO-d6, 400 MHz) δ 1.18-1.26 (2H, m), 1.52 (2H, p, J = 14.5, 6.9 
Hz), 1.83 (2H, p, J = 14.5, 7.1 Hz), 1.93 (2H, t, J = 7.3 Hz), 4.34 (2H, t, J = 7.0 Hz), 6.99 
(2H, d, J =7.9 Hz), 7.74 (2H, d, J = 7.9 Hz), 8.44 (1H, s), 10.31 (1H, s); 13C NMR 
(DMSO-d6, 100 MHz) δ 24.5, 25.4, 29.3, 32.0, 49.2, 55.0, 114.0, 120.0, 123.2, 126.2, 




6-(3-anisolyl)triazolylhexahydroxamic acid (7k). Reaction of methyl 6-((3-
anisolyl)triazolylhexanoate 6k (0.15 mg, 0.52 mmol) and aqueous hydroxylamine (0.34 
ml, 5.2 mmol) within 32 h as described for the synthesis of 4d, gave 75 mg (50%) of 7k 
as white solid. 1H NMR (DMSO-d6, 400 MHz) δ 1.18-1.26 (2H, m), 1.52 (2H, p, J = 
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15.0, 7.4 Hz), 1.84 (2H, p, J = 14.4, 7.0 Hz), 1.93 (2H, t, J = 7.2 Hz), 3.79 (3H, s), 4.36 
(2H, t, J = 6.9 Hz), 6.86-6.89 (1H, m), 7.33 (1H, app. t), 7.39-7.41 (2H, m), 8.59 (1H, s), 
10.3 (1H, s); 13C NMR (DMSO-d6, 100 MHz) δ 24.5, 25.4, 29.3, 32.0, 49.3, 55.0, 110.1, 
113.3, 117.2, 121.2, 129.8, 131.9, 145.9, 159.3, 168.5; HRMS (FAB, thioglycerol) calcd 
for [C15H20N4O3 + H]
+ 305.1613, found 305.1633. 
 
6-(2-anisolyl)triazolylhexahydroxamic acid (7l). Reaction of methyl 6-(2-anisolyl)-
triazolylhexanoate 6l (0.15 mg, 0.52 mmol) and aqueous hydroxylamine (0.34 ml, 5.2 
mmol) within 32 h as described for the synthesis of 4d, gave 82 mg (55%) of 7l as white 
solid. 1H NMR (DMSO-d6, 400 MHz) δ 1.41-1.21 (2H, m), 1.19-1.26 (2H, m), 1.52 (2H, 
p, J = 15.0, 7.5 Hz), 1.80-1.88 (2H, m), 1.93 (2H, t, J = 7.3 Hz), 3.90 (3H, s), 4.38 (2H, t, 
J = 7.0 Hz), 7.03 (1H, app. t), 7.11 (1H, d, J = 8.2 Hz), 7.28-7.33 (1H, m), 8.12 (1H, dd, J 
= 7.6, 1.7 Hz), 8.36 (1H, s), 10.23 (1H, s); 13C NMR (DMSO-d6, 100 MHz) δ 24.5, 25.5, 
29.5, 32.0, 49.1, 55.3, 111.4, 120.3, 123.7, 126.2, 128.5, 141.4, 155.0, 168.5; HRMS 
(FAB, MNBA) calcd for [C15H20N4O3 + H]+ 305.1673, found 305.1576. 
 
7-(3-biphenyl)triazolylheptahydroxamic acid (7q). Reaction of methyl 7-(3-biphenyl)-
triazolylheptanoate 6q (0.1 g, 0.27 mmol) and aqueous hydroxylamine (0.2 ml, 3.26 
mmol) within 32 h as described for the synthesis of 4d, gave 47 mg (48%) of 7q as white 
solid. 1H NMR (CD3OD, 400 MHz) δ 1.18-1.21 (4H, m), 1.39-1.49 (2H, m), 1.72-1.80 
(2H, m), 1.90 (2H, t, J = 7.5 Hz), 2.02 (2H, t, J = 7.5 Hz), 4.21-4.25 (2H, m), 7.14-7.18 
(1H, m), 7.24-7.28 (2H, m), 7.31 (1H, d, J = 7.6 Hz), 7.39-7.41 (1H, m), 7.47-7.50 (2H, 
m), 7.58-7.61 (1H, m), 7.91 (1H, d, J = 1.6 Hz), 8.19 (1H, d, J = 6.1 Hz). 13C NMR 
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(CD3OD, 100 MHz) δ 26.5, 27.1, 29.4, 31.0, 33.6, 51.3, 122.2, 124.9, 125.3, 127.6, 
127.8, 128.4, 129.7, 130.3, 132.0, 141.7, 142.9, 148.5, 172.8. HRMS (EI) calcd for 
[C21H24N4O2 + H]
+ 365.1977, found 365.1954. 
 
6-(4-pyridylphenyl)triazolylhexahydroxamic acid (7s). Reaction of methyl 6-(4-
pyridylphenyl)triazolylhexanoate 6s (0.1 g, 0.28 mmol) and aqueous hydroxylamine (0.2 
ml, 2.7 mmol) within 32 h as described for the synthesis of 4d, gave 54 mg (54%) of 7s 
as white solid. 1H NMR (DMSO-d6, 400 MHz) δ 1.24-1.33 (2H, m), 1.50-1.58 (2H, m), 
1.83-1.98 (4H, m),  4.39 (2H, t, J = 7.3 Hz), 7.75-7.76 (2H, m), 7.90 (2H, d, J = 8.3 Hz), 
7.98 (2H, d, J = 8.3 Hz), 8.64 (1H, s), 8.66-8.68 (2H, m), 10.34 (1H, s). 13C NMR 
(DMSO-d6, 100 MHz) δ 24.5, 25.4, 29.3, 32.0, 49.4, 120.8, 121.5, 125.5, 127.1, 131.5, 
135.9, 145.3, 146.0, 149.9, 168.5. HRMS (FAB, thioglycerol) calcd for [C19H21N5O2 + 
H]+ 352.1773, found 352.1756. 
 
7-(4-pyridylphenyl)triazolylheptahydroxamic acid (7t). Reaction of methyl 7-(4-
pyridylphenyl)triazolylheptanoate 6t (0.1 g, 0.27 mmol) and aqueous hydroxylamine (0.2 
ml, 3.26 mmol) within 32 h as described for the synthesis of 4d, followed by prep TLC 
(silica,  91:9 Dichloromethane/MeOH) gave 54 mg (55%) of 7t as white solid. 1H NMR 
(DMSO-d6, 400 MHz) δ 1.24-1.33 (4H, m), 1.44-1.50 (2H, m), 1.83-1.87 (2H, m),  2.18 
(2H, t, J = 7.3 Hz), 4.39 (2H, t, J = 7.3 Hz), 7.74-7.76 (2H, m), 7.90 (2H, d, J = 8.3 Hz), 
7.98 (2H, d, J = 8.3 Hz), 8.63 (2H, d, J = 4.4 Hz), 8.69 (1H, s), 10.34 (1H, s); 13C NMR 
(DMSO-d6, 100 MHz) δ 24.3, 25.6, 27.9, 29.4, 33.5, 49.5, 120.7, 121.5, 125.5, 127.1, 
50 
 
131.5, 135.9, 145.3, 146.0, 149.9, 174.0; HRMS (FAB, thioglycerol) calcd for 
[C20H23N5O2 + H]
+ 366.1930, found 365.1942. 
 
7-(6-methoxynapthalyl)triazolylheptahydroxamic acid (7v). Reaction of methyl 7-(6-
methoxynapthalyl)triazolylheptanoate 6v (0.217 g, 0.59 mmol)   and aqueous 
hydroxylamine (0.4 ml, 6.52 mmol) within 32 h as described for the synthesis of 4d, gave 
110 mg (51%) of 7v as white solid. 1H NMR (DMSO-d6, 400 MHz) δ 1.26-1.28 (4H, m), 
1.43-1.53 (2H, m), 1.82-1.89 (2H, m), 1.92 (2H, t, J = 7.2 Hz), 3.87 (3H, s), 4.39 (2H, t, J 
= 7.0 Hz), 7.17 (1H, dd, J = 8.9, 2.5 Hz), 7.33 (1H, d, J = 2.3 Hz), 7.85-7.93 (3H, m), 
8.30 (1H, s), 8.63 (1H, s), 8.66 (1H, s), 10.35 (1H, s); 13C NMR (DMSO-d6, 100 MHz) δ 
24.9, 25.6, 28.0, 29.5, 32.1, 49.4, 55.1, 105.8, 118.9, 120.9, 123.1, 123.9, 125.8, 127.1, 
128.3, 129.2, 133.6, 146.2, 157.1, 168.7; HRMS (EI) calcd for [C20H24N4O3 + H]
+ 
369.1926, found 369.1900.  
 
6-(2-quinolyl)triazolylhexahydroxamic acid (7w). Reaction of methyl 6-(2-quinolyl)-
triazolylhexanoate 6w (0.129 g, 0.39 mmol) and aqueous hydroxylamine  (0.26 ml, 3.9 
mmol) within 32 h as described for the synthesis of 4d, gave 77 mg (60%) of 7w as white 
solid. 1H NMR (DMSO-d6, 400 MHz) δ 1.24 (2H, app. p), 1.53 (2H, p, J = 14.7, 7.1 Hz), 
1.86-1.95 (4H, m), 4.45 (2H, t, J = 7.0 Hz), 7.56-7.60 (1H, m), 7.75-7.79 (1H, m), 7.98 
(2H, d, J = 8.4 Hz), 8.21 (1H, d, J = 8.5 Hz), 8.45 (1H, d, J = 8.5 Hz), 8.65 (1H, s), 8.81 
(1H, s), 10.32 (1H, s); 13C NMR (DMSO-d6, 100 MHz) δ 24.5, 25.4, 29.3, 32.0, 49.5, 
117.9, 123.7, 126.1, 127.0, 127.8, 128.2, 129.8, 136.9, 146.9, 147.2, 150.0, 168.6; HRMS 
(FAB, thioglycerol) calcd for [C17H19N5O2 + H]




6-(7-quinolyl)triazolylhexahydroxamic acid (7x). Reaction of  methyl 6-(7-quinolyl)-
triazolylhexanoate 6x (0.1 g, 0.31 mmol) and aqueous hydroxylamine (0.2 ml, 3.1 mmol) 
within 32 h as described for the synthesis of 4d, followed by prep TLC (9 % MeOH in 
Dichloromethane) gave 66 mg (66%) of 7x as white solid. 1H NMR (DMSO-d6, 400 
MHz) δ 1.21-1.29 (2H, m), 1.50-1.57 (2H, m), 1.84-1.95 (4H, m), 4.41 (2H, t, J = 7.3 
Hz), 7.50 (1H, q, J = 8.4, 4.3 Hz), 8.04 (1H, d, J = 8.5 Hz), 8.10 (1H, dd, J = 8.5, 1.6 Hz), 
8.33-8.36 (1H, m), 8.44 (1H, s), 8.61-8.64 (1H, m), 8.82 (1H, s), 8.90 (1H, q, J = 4.2, 4.1 
Hz). 10.31 (1H, s); 13C NMR (DMSO-d6, 100 MHz) δ 26.0, 26.9, 30.9, 33.4, 51.3, 122.4, 
123.1, 124.8, 125.6, 129.8, 129.3, 133.3, 137.9, 147.6, 148.7, 151.6, 172.3;  HRMS (EI) 
calcd for [C17H19N5O2 + H]
+ 326.1617, found 326.1646. 
 
5-(benzyl)triazolylpentahydroxamic acid (7y). Reaction of methyl 5-(benzyl)triazolyl-
pentanoate 6y (0.15 g, 0.52 mmol) and aqueous hydroxylamine (0.5 ml, 8.15 mmol) 
within 32 h as described for the synthesis of 4d, gave 111 mg (78%) of 7y as white solid. 
1H NMR (DMSO-d6, 400 MHz) δ 1.38-1.45 (2H, m), 1.71-1.77 (2H, m), 1.95 (2H, t, J 
=7.28), 3.96 (2H, s), 4.27 (2H, t, J = 7.10), 7.16-7.29 (5H, m), 7.81 (1H, s), 8.67 (1H, s), 
10.34 (1H, s); 13C NMR (DMSO-d6, 100 MHz) δ 22.1, 29.3, 31.3, 31.5, 48.8, 122.1, 
125.8, 128.1, 128.2, 139.4, 145.6, 168.3; HRMS (FAB, thioglycerol) calcd for 
[C14H18N4O2 + H]






Representative Procedure for the Alkyne Transformation Reaction. 
 
4-(4-Ethynylphenyl)pyridine (5l): 
Reaction of 4-(4-formylphenyl)pyridine (0.3 g, 1.64 mmol), anhydrous K2CO3 (0.679 g, 
4.92 mmol) and Bestmann-Ohira reagent (0.627 g, 3.27 mmol) within 24 h followed by 
flash chromatography (silica gel, 2:1 Hexane/EtOAc) gave 261 mg (89%) of 5l as a white 
solid. 1H-NMR (CDCl3, 400MHz) δ 3.16 (1H, s), 7.47 (2H, d, J = 6.4 Hz), 7.59 (4H, s), 
8.66 (2H, d, J = 6.4Hz). HRMS (EI) calc for [C13H9N] 179.0735, found 179.0746. 
 
2-Ethynylquinoline (5p): 
The required quinoline-2-carboxaldehyde was synthesized from the corresponding 2- 
methylquinoline through selenium dioxide oxidation.31 Quionline-2-carboxyladehyde 
(0.21 g, 1.33 mmol), anhydrous K2CO3 (0.551 g, 3.99 mmol) and Bestmann-Ohira 
reagent (513 mg, 2.67 mmol) gave 153 mg (73%) of 5p as white solid. 1H NMR (CDCl3, 
400 MHz) δ 3.20 (1H, s), 7.43-7.48 (2H, m), 7.62-7.66 (1H, m), 7.69 (1H, d, J = 8.1 Hz), 
8.01-8.04 (2H, m). 13C NMR (CDCl3, 100 MHz) δ 76.9, 82.6, 123.2, 126.4, 126.5, 126.6, 
128.5, 129.2, 135.4, 141.4, 147.1 
 
7-Ethynylquinoline (5q): 
The required quinoline-7-carboxaldehyde was synthesized from the corresponding 7- 
methylquinoline through selenium dioxide oxidation.31 Quionline-7-carboxyladehyde 
(0.21 g, 1.33 mmol), anhydrous K2CO3 (0.551 g, 3.99 mmol) and Bestmann-Ohira 
reagent (513 mg, 2.67 mmol) gave 163 mg (78%) of 5q as white solid. 1H NMR (CDCl3, 
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400 MHz) δ 3.16 (1H, s), 7.21 (1H, q, J = 8.28, 4.23), 7.41 (1H, dd, J = 8.4, 1.5 Hz), 7.56 
(1H, d, J = 8.38), 7.91-7.94 (2H, m), 8.76 (1H, dd, J = 4.2, 1.7 Hz) 13C NMR (CDCl3, 
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MOLECULAR ARCHITECTURE OF ZINC CHELATING 
SPLICEOSOME ASSEMBLY INHIBITORS 
 
3.1 Alternative Splicing – 
  Maturation of the eukaryotic precursor messenger RNA (pre-mRNA) is 
catalyzed by the spliceosome, a large and dynamic ribonucleo-particle consisting of 5 
small nuclear RNAs (snRNAs) and close to 150 proteins. The splicing reaction is a 2-step 
transesterifcation reaction which excises the introns and ligates the exons.1 In first step, 
the 2’-OH of adenosine from the branch site nucleophilically attacks the phosphodiester 
bond at the 5’-splice site forming the lariat intermediate. During second step, the 3’-OH 
of the released 5’ exon then performs nucleophilic attack at the 3’splice site, releasing 
intron lariat. The process is tightly controlled by intricate interplays between RNA-
protein, RNA-RNA and protein-protein which ultimately determine the identity of the 
protein formed from a pre-mRNA.2 Understanding the splicing mechanism is of prime 
importance as many human genetic conditions, such as β-thalessemia, inherited breast 
cancer and many types of neurological diseases, are associated with aberrant pre-mRNA 
splicing.3-5 Spliceosome formation proceeds through coordinated assemblies of 
complexes – A, B, B* and C (Figure 3-1).  The detail of molecular interactions between 
the five small nuclear ribonucleoproteins (snRNPs - U1, U2, U4, U5 & U6) and proteins 
in the spliceosome continues to be a subject of intense research. Remarkable advances 
have been made in the characterization and structural elucidation of the various 
spliceosome complexes.6-16 These studies have furnished exquisite information about the 
 
spliceosome assembly at the RNA level. With the increased number of known splicing 
factors, we are now gaining an appreciation that the dynamic nature of th
much more complex than simple addition and release of individual snRNPs proteins. 
However, the order of recruitment, interaction between these splicing factors, and signals 
that trigger their addition and release from the spliceosome 
Additionally, little is known about the 
global conformational changes which ensure the fidelity of splicing.
agents which perturb splicing at specific stages will gr
the workings of the spliceosome. 
Figure 3
 Several small molecules which inhibit splicing have been identified. Examples of 
small molecule splicing inhibitors include: 
FR901464 and spliceostatin A
streptomycin;21 isoginkgetin
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-1: Steps involved in splicing mechanism.18 
 
antitumor drugs such as pladienolide B, 
;19,20 antibiotics such as tetracyclines, neomycin and 






acetyltransferases inhibitors.23-29 The specific spliceosome targets of a subset of these 
compounds have been elucidated; however, targets for several of these compounds 
remain unknown. With few exceptions,30 the structural attributes which conferred 
splicing inhibition on most of these compounds are yet to be elucidated. This lack of clear 
understanding may be partly due to the structural complexities of many of these 
compounds. 
Several spliceosome associated proteins possess potential enzymatic activities 
whose purpose in splicing reaction remain unclear.25,31 Specifically, many of these 
spliceosomal proteins possess zinc binding motifs, suggesting that zinc metal may have 
functional and/or structural roles in splicing. Additionally, histone deacetylases 
(HDACs), classic Zn-metallo-proteases, have been shown to be closely associated with 
spliceosome complexes, although their precise functions in splicing process are not 
clear.24,32,33 In fact, zinc depletion by the random Zn-chelator 1,10-phenanthroline (1,10-
PHE), has been shown to inhibit the second step of splicing.34 We have shown previously 
that specific zinc chelating agents that perturb the protein acetylation state, through 
inhibition of HDAC activity, blocked splicing cycle at distinct stages.25 The exact 
relationship between zinc chelation, protein acetylation state and splicing reaction 
integrity was not clear from this study as limited set of HDACi were screened. We sought 
to clarify this relationship by screening a more structurally diverse HDACi library.35-40 
We report herein the elucidation of unique molecular features that confer splicing 
inhibition to zinc chelating agents with HDAC inhibition activities. Characterization of 
the splicing complexes that accumulate on native gels, demonstrates that these agents 
specifically stalled the spliceosome assembly at A-like complex. Because there is no 
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correlation between HDAC and splicing inhibition activities of these compounds, we 
conclude that the primary target(s) of their splicing inhibition are not HDACs.  
 
3.2 Screening of HDACi as Splicing Assembly Inhibitors 
Premised on earlier work that demonstrated close association of HDACs with 
mixed population of spliceosome,32,33,41 we have previously investigated the prospect of 
splicing inhibition by selected HDACi – hydroxamate based drugs SAHA, scriptaid, and 
trichostatin A (TSA); and non-hydroxamate MS-275 (Figure 3-2). These HDACi stalled 
the spliceosome assembly at A-like complex with sub-micromolar IC50 (concentration 
giving 50% inhibition).25 However, there is no clear evidence linking the effects of these 
HDACi on splicing with HDAC inhibition as their splicing IC50 are several orders of 
magnitude higher than the reported values for HDAC inhibition.   
 
Figure 3-2. Structures of HDACi which stalled the spliceosome assembly at A-like complex. 
 
HDAC has 18 known isoforms, organized into four different classes. Classes I, II, 
and IV depend on a catalytic zinc ion and differ by cellular localization, while Class III 
HDACs require NAD+.42 The prototypical pharmacophore for HDACi consists of three 
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distinct structural motifs: a recognition cap group, a hydrophobic linker, and the zinc 
binding group (ZBG).38,43 The HDACi recognition cap group moieties make interactions 
with amino acid residues on the surface of HDACs and present excellent opportunities 
for the selective modulation of the their biological activities.38 We surmised that profiling 
the splicing inhibition activities of HDACi with diversity within their three distinct 
structural motifs will unravel the links between HDAC inhibition and splicing fidelity. 
Toward this end, we first screened a small (63-member), yet structurally diverse HDACi 
library (Figure 3-3) for their effect on splicing at 50 µM. The activity of HDACi in the 
screened library, against HDAC1 and HeLa cell nuclear extract HDACs, ranges from 
single digit- to mid-nanomolar.35-37,39,40 Despite their potency, these HDACi did not 
broadly inhibit splicing.  
 
Table 3-1: HDACi Library Screened for pre-mRNA Splicing Inhibition  
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 We identified only three compounds – 24, 25 and 56 – which strongly inhibit 
splicing at 50 µM (Figure 3-3a). Subsequent analysis revealed that structurally related 24 
and 25 inhibit splicing in a concentration dependent manner while 56 lacked such 
concentration dependence (Figure 3-4). Both 24 and 25 stalled the spliceosome assembly 
at A-like complex to about the same extent  despite over 15-fold difference in their anti-
HDAC activities (in favor of 24).40 Intriguingly, compound 25 (Figure 3-3), a single 
methylene chain deletion analog of 24 which is over 8-fold stronger HDACi than 24,36 is 
devoid of any splicing inhibition activity. Another interesting fallout from this initial 
screening is the fact that the substitution of the anilide amide of SAHA with HDAC 
inhibition enhancing triazole ring36 abrogated splicing inhibition at 50 µM (see Figure for 
SAHA analog compound 13). All together, these data suggest that the target(s) of 





Figure 3-3 Effects of HDACi on splicing activity. (a) Screening of HDACi library at 50 µM, 
probing for the incorporation of abstrakt protein into the spliceosome on PM5 pre-mRNA, 
revealed three hits compounds (b) Structures of hit compounds 24, 25 and 56. 
 
Figure 3-4. Concentration dependence of splicing inhibition by hit compounds 24, 25 and 56. (a) 
Increasing concentrations of compounds 24, 25, and 56 were tested for their effect on the splicing 
of 32P-labeled MINX pre-mRNA. After splicing, the radiolabeled RNA was analyzed by 
denaturing PAGE followed by autoradiography. Shown on the leftmost lane is the DMSO control 
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experiment. Compound numbers are shown on the top panel while drug concentrations tested are 
shown just below the compound numbers. Analysis revealed that structurally related 24 and 25 
inhibit splicing in a concentration dependent manner while 56 lacked such concentration 
dependence. (b) Quantification of mRNA splicing product bands. (c) Illustrations of the RNA 
splicing states. 
 
3.3 Structure-Activity Relationship (SAR) of Splicing Inhibition 
   The screening of HDACi library for splicing inhibition furnished 6-
methoxynaphthalen-2-yl hydroxamate 24 and 25 as small molecules which inhibit 
splicing in a specific context. Both 24 and 25 stalled the spliceosome assembly at the A-
like complex to about the same extent, with IC50 130 µM and 100 µM respectively (Table 
3-1) 36,40 
 
Figure 3-5. Synthesis of 67a-67d. a) NaN3, DMF, 75 
oC; b) NH2-O-trityl; Isobutyl 
Chloroformate, N-methylmorpholine, THF; c) 2-ethynyl-6-methoxynapthalene, CuI, DIPEA, 




  To establish the structure activity relationship (SAR) of these compounds, we 
synthesized a series of structural analogs of 24 and 25 (Figure 3-5) by adapting similar 
synthetic procedure as depicted in Figure 2-3 (Chapter 2) and investigated their effect on 
the splicing of 32P-labeled MINX pre-mRNA as well as their HDAC inhibition activity 
against representative class I and Class II HDAC isoforms – HDAC1, HDAC6 and 
HDAC8.  This exercise resulted in compounds that display varying splicing inhibition 
which trends with the changes to the compounds’ three distinct structural motifs – the 
substituent on the naphthalene, the methylene linker and the ZBG (Table 3-1). Relative to 
compound 25, a single methylene chain extension (in 67a) abolished splicing inhibition 
while a 2-methylene extension (in 67b) enhanced the splicing inhibition activity by more 
than 3-fold. Further increase in methylene chain length in 67c and 67d did not improve 
splicing inhibition; in fact, such increase compromised splicing inhibition as IC50 
increased to the levels of the lead compounds 24 and 25.  Additionally, we observed that 
these compounds preferentially inhibited the HDAC isoform tested. Compounds 67a and 
67b inhibited HDAC1 and HDAC6 with sub-nanomolar IC50 and completely inactive 
against HDAC8; while 67c potently inhibited HDAC6 and HDAC8 and somewhat 
inactive against HDAC1. Compound 67d, although an equally effective splicing inhibitor 
as the lead compounds 24 and 25, interestingly, has the poorest HDAC inhibition activity 




Figure 3-6 Synthesis of 71a-71d a) TMS-acetylene, PdCl2(PPh3)2, CuI, triethylamine; b) TBAF, 
THF; c) 69a/69b, CuI, DIPEA, THF:DMSO d) Trifluoroacetic acid, Triisopropylsilane, DCM 
 
Figure 3-7 Synthesis of 74a-74b. a) Ethylbromide, K2CO3; THF, 60 
oC; b) 72, CuI, DIPEA, 
THF:DMSO; c) Trifluoroacetic acid, Triisopropylsilane, DCM 
 
    The substitution of the naphthalene cap group 6-methoxy moiety by protic 
electron donating groups such as OH and NH2 is detrimental to function as these changes 
abolished splicing inhibition activity (Table 3-1, comparing 71b and 71c with 24; and 
71d with 25). Synthesis of compounds 71a-d is depicted in Figure 3-6.  Synthesis 
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involves making of alkyne intermediates 69a-b from 6-bromo-2-napthol and 6-
bromonaphthalen-2-amine using Sonogashira coupling with TMS-acetylene to give silyl 
intermediate 68a-b followed by TBAF deprotection of silyl group to give desired alkyne 
intermediate 69a-b. Corresponding hydroxamates 71a-d were prepared using chemistry 
described in chapter 2. Similarly compounds 74a-b (Figure 3-7) and compounds 79a-b 
(Figure 3-8) were synthesized. In contrast, compounds 71b, 71c and 71d are broadly 
active against the HDAC isoform tested, with single digit to sub-nanomolar IC50 against 
HDAC1 and HDAC6. The consequence of the replacement of the naphthalene cap group 
6-methoxy moiety with azide group on splicing inhibition activity is however closely 
linked to the length of the methylene chain of the molecule. The 6-methylene compound 
79a, an azido analog of 24 is inactive while the 7-methylene linked compound 79b is 
twice as potent as its direct congener, compound 25. The extension of the napthalene cap 
6-methoxy group by an additional carbon chain is tolerable but not beneficial to the 
splicing inhibition attributes of the resulting compounds 74a and 74b, relative to the 
corresponding 6-methoxy compounds 25 and 67b respectively. Synthesis of compounds 
74a and 74b is depicted in Figure 3-7. Again, there is no correlation between HDAC 
inhibition and splicing inhibition activities of these compounds as they maintained potent 




Figure 3-8. Synthesis of 79a-79b a) 69b, CuI, DIPEA, THF:DMSO; b)NaNO2, NAN3, HCl/H2O, 
0 oC c) LiOH, THF/H2O; d) NH2-O-trityl; TBTU, DIPEA, DMF; e) Trifluoroacetic acid, 
Triisopropylsilane, DCM. 
 
  To confirm the role of zinc chelation in the splicing inhibition activities of these 
naphthalen-2-yl hydroxamates, we synthesized methyl ester 80 and 81, carboxylic acid 
82, and carboxamide 83.36,40 These compounds are derivatives of most active 
hydroxamates 24, 25 and 67b. Expectedly, all of these non-hydroxamate analogs lacked 
HDAC inhibition activity. More importantly however, they did not perturb the splicing of 
MINX pre-mRNA (Table 3-1). This data suggests a role for zinc chelation in the 
mechanism of splicing inhibition by these hydroxamates. Additionally, the results herein 




Figure 3-9. Standard in vitro splicing test with radioactively labeled MINX pre-mRNAa 
aPre-mRNA splicing activities determined by Dr. Timur Samatov from Dr. Reinhard Luhrmann 































NT NT 100 µM 
 
67a 
55 ± 4 
nM 





155 ± 17 
nM 
212 ± 26 
nM 





400 ± 29 
nM 













NI 120 µM 
 
71a 
6.0 ±  0.4 
nM 







1.0 ±  0.1 
nM 
2.0 ± 0.1 
nM 





1.0 ± 0.1 
nM 







5.0 ± 0.4 
nM 







25 ± 2 
nM 







Table 3-2 continued. 
 
74b 
311 ± 32 
nM 







3.0 ± 0.1 
nM 







16.0 ±  
0.2 nM 




< 50 µM 
 
80 
NT NT NT NI 
 
81 
NT NT NT NI 
 
82 
NT NT NT NI 
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Table 3-2 continued. 
 
83 
NI 22% 27% NI 
 
aCited from refs 36,40 – activities against HeLa nuclear extract (HDAC 1 & 2). 
bPre-mRNA splicing activities determined by Dr. Timur Samatov from Dr. Reinhard Luhrmann 
lab at Max Plack Institute of biophysical chemistry, Germany. Included here to clarify SAR 
NT – Not Tested 
NI – No significant Inhibition (below 20% Inhibition) 




 The precise role of Zn-ion in splicing is not yet well understood. It is known that 
several spliceosomal proteins possess zinc binding motifs which could play both 
structural and functional roles. Additionally, zinc metalloenzymes such as HDACs are 
known to closely associate with mixed population of spliceosome. The study herein 
presented has revealed molecular architecture of a novel class of zinc-chelating agents 
with splicing inhibitory activities. An interesting aspect of this data suggests that these 
compounds may be inhibiting the functional role of Zn-ion in splicing since only a subset 
of them, with well-defined structure, is active. Ongoing efforts are on identifying the 
spliceosome associated target(s) of these compounds using pull down approaches. 
 
3.5 General Procedure & Experimental 
               Bromoalkanoic acid, 2-ethynyl-6-methoxynapthalene and 6-bromo-2-naphthol 
were purchased from Sigma–Aldrich. 6-bromonapthalen-2-amine was purchased from 
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Astatech, Inc. Anhydrous solvents and other reagents were purchased and used without 
further purification.  Analtech silica gel plates (60 F254) were used for analytical TLC, 
and Analtech preparative TLC plates (UV 254, 2000 µm) were used for purification.  UV 
light was used to examine the spots. Silica gel (200–400 Mesh) was used in column 
chromatography.  NMR spectra were recorded on a Varian-Gemini 400 magnetic 
resonance spectrometer.  1H NMR spectra were recorded in parts per million (ppm) 
relative to the peak of CDCl3, (7.24 ppm), CD3OD (3.31 ppm), or DMSO-d6 (2.49 ppm). 
13C spectra were recorded relative to the central peak of the CDCl3 triplet (77.0 ppm), 
CD3OD (49.0 ppm), or the DMSO-d6 septet (39.7 ppm), and were recorded with 
complete heterodecoupling.  Multiplicities are described using the abbreviation s, singlet; 
d, doublet, t, triplet; q, quartet; m, multiplet; and app, apparent.  High-resolution mass 
spectra were recorded at the Georgia Institute of Technology mass spectrometry facility 
in Atlanta. Azidoalkanoic acids 64a-64d and 6-azido-O-tritylhexahydroxamate, 7-azido-
O-tritylheptahydroxamate, 8-azido-O-trityloctahydroxamate and 9-azido-O-
tritylnonahydroxamate were synthesized according to literature protocol.40 
 
Representative Procedure for coupling of trityl protected hydroxylamine with 
azidoalkanoic acid – 
 
10-Azido-O-trityldecahydroxamate (65b) 
Carboxylic acid 64b (1.50 g, 6.98 mmol) was dissolved in anhydrous THF (35 mL).  N-
methylmorpholine (0.21 mL, 6.98 mmol) was added to the solution.  The reaction 
mixture was then cooled down to -15 oC and stirred for 5 min. Isobutylchloroformate 
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(0.91 mL, 6.98 mmol) was added and the mixture was stirred for 10 min at -15 oC.  O-
tritylhydroxylamine (1.92 g, 6.98 mmol) was added followed by 2 more equivalents of N-
methylmorpholine.  Stirring continued for 15 min at -15 oC and 2 h at room temperature.  
Afterwards the mixture was poured into CH2Cl2 (90 mL) and water (90 mL). Organic 
layer was separated and extracted 3 times (60 mL) in each case with water, sodium 
bicarbonate solution (5%) and water. After washing with brine (1 X 50 mL) and drying 
over Na2SO4, solvent was evaporated in vacuo. Column chromatography with eluent 
system CH2Cl2-acetone (step gradientfrom 0-12% of acetone) gave 2.55 g of compound 
65b (78 %) as a white solid. 1H NMR (400 MHz, CDCl3) δ 7.34 (m, 17H), 3.25 (t, J = 6.9 
Hz, 2H), 1.59 (m, 4H), 1.23 (m, 12H). 13C NMR (100 MHz, CDCl3) δ 128.98, 128.90, 
128.80, 127.92, 127.44, 127.34, 126.95, 126.85, 51.29, 29.06, 28.96, 28.90, 28.66, 26.52.  
 
11-Azido-O-tritylundecahydroxamate (65c) – 
Reaction of carboxylic acid 64c (4.50 g, 19.82 mmol), N-methylmorpholine (6.51 mL, 
59.46 mmol), Isobutylchloroformate 2.59 mL, 19.82 mmol), and O-tritylhydroxylamine 
(5.45 g, 19.82 mmol) within 2h as described for the synthesis of 65b gave compound 65c 
(6.87 g, 74%) as a white solid. 1H NMR (400 MHz, DMSO) δ 10.11 (s, 1H), 7.27 (m, 
15H), 3.27 (t, J = 6.9 Hz, 2H), 1.76 (m, 2H), 1.49 (m, 2H), 1.16 (m, 14H) 13C NMR (100 
MHz, DMSO) δ 170.88, 142.95, 129.41, 127.90, 105.12, 92.18, 51.08, 32.48, 29.32, 





12-Azido-O-trityldodecahydroxamate (65d) – 
Reaction of carboxylic acid 64d (2.20 g, 9.12 mmol), N-methylmorpholine (3.00 mL, 
27.36 mmol), isobutylchloroformate (1.19 mL, 9.12 mmol), and O-tritylhydroxylamine 
(2.51 g, 9.12 mmol) within 2h as described for the synthesis of 65b gave compound 65d 
(3.51 g, 80%) as a white solid. 1H NMR (400 MHz, DMSO) δ 10.11 (s, 1H), 7.26 (m, 
15H), 3.28 (t, J = 6.9 Hz, 2H), 1.50 (m, 2H), 1.12 (m, 16H). 13C NMR (100 MHz, 
DMSO) δ 170.33, 142.45, 128.91, 127.40, 127.30, 104.63, 91.65, 50.58, 31.98, 28.85, 
28.77, 28.64, 28.49, 28.30, 28.20, 26.10, 24.72.  
Representative Procedure for Cu(I)-catalyzed cycloaddition reaction – 
O-Trityl-6-methoxynapthyltriazolylnonahydroxamate (66a) – 
2-ethynyl-6-methoxynapthalene (0.08 g, 0.44 mmol) and 65a (0.24 g, 0.53 mmol) were 
dissolved in anhydrous THF:DMSO (8mL:8 mL) and stirred under argon at room 
temperature.  Copper (I) iodide (0.011 g, 0.07 mmol) and Hunig’s base (0.16 mL) were 
then added to the reaction mixture, and stirring continued for 12 h.  The reaction mixture 
was diluted with CH2Cl2 (40 mL) and washed with 1:4 NH4OH/saturated NH4Cl (3 x 30 
mL) and saturated NH4Cl (30 mL).  The organic layer was dried over Na2SO4 and 
concentrated in vacuo. Crude product was purified by prep-TLC (Eluent - 
CH2Cl2:Acetone:MeOH:EtOH (25:1:0.2:0.2))  to give 66a (0.16 g, 59%) as white solid.  
O-Trityl-6-methoxynapthyltriazolyldecahydroxamate (66b) – 
Reaction of 2-ethynyl-6-methoxynapthalene (0.07 g, 0.38 mmol) and 65b (0.21 g, 0.45 
mmol) within 12 h as described for synthesis of 66a  gave compound 66b (0.14 g, 60%) 
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as a white solid. 1H NMR (400 MHz, CDCl3) δ 8.24 (s, 1H), 7.88 (dd, J = 8.5, 1.5 Hz, 
1H), 7.76 (m, 3H), 7.33 (m, 15H), 7.14 (m, 2H), 4.34 (t, J = 7.1 Hz, 2H), 3.90 (s, 3H), 
1.81 (m, 4H), 1.21 (m, 14H). 13C NMR (100 MHz, CDCl3) δ 157.71, 147.67, 140.99, 
134.14, 129.50, 128.86, 128.83, 127.93, 127.18, 125.81, 124.25, 124.05, 119.28, 119.08, 
105.66, 93.17, 77.31, 76.99, 76.67, 55.15, 50.43, 50.23, 30.13, 28.90, 28.74, 26.28.  
O-Trityl-6-methoxynapthyltriazolylundecahydroxamate (66c) – 
Reaction of 2-ethynyl-6-methoxynapthalene (0.06 g, 0.34 mmol) and 65c (0.20 g, 0.41 
mmol) within 12 h as described for synthesis of 66a  gave compound 66c (0.14 g, 63%) 
as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 10.09 (s, 1H), 8.61 (s, 1H), 8.28 (s, 
1H), 7.88 (m, 3H), 7.23 (m, 21H), 4.39 (t, J = 7.0 Hz, 2H), 3.87 (s, 3H), 1.85 (m, 2H), 
1.74 (t, J = 6.6 Hz, 2H), 1.18 (m, 14H). 13C NMR (100 MHz, CDCl3) δ 157.70, 147.67, 
140.94, 134.13, 129.51, 128.87, 128.82, 127.94, 127.18, 125.83, 124.25, 124.04, 119.25, 
119.10, 105.62, 104.83, 55.16, 50.25, 31.04, 30.19, 29.56, 29.07, 28.83, 26.32, 23.30.  
O-Trityl-6-methoxynapthyltriazolyldodecahydroxamate (66d) – 
Reaction of 2-ethynyl-6-methoxynapthalene (0.06 g, 0.33 mmol) and 65d (0.20 g, 0.40 
mmol) within 12 h as described for synthesis of 66a  gave compound 66d (0.21 g, 91%) 
as a white solid. 1H NMR (400 MHz, dmso) δ 10.10 (s, 1H), 8.62 (s, 1H), 8.29 (s, 1H), 
7.88 (m, 3H), 7.32 (m, 17H), 7.18 (dd, J = 9.0, 2.5 Hz, 1H), 4.39 (t, J = 7.0 Hz, 2H), 3.88 
(s, 3H), 1.87 (m, 2H), 1.73 (m, 2H), 1.12 (dd, J = 71.8, 64.7 Hz, 17H). 13C NMR (100 
MHz, CDCl3) δ 157.70, 147.65, 134.13, 129.49, 128.86, 127.91, 127.16, 125.85, 124.25, 
124.03, 119.24, 119.07, 105.65, 55.14, 50.24, 30.17, 29.15, 29.02, 28.83, 26.33. 
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Representative Procedure for Deprotection of Trityl Group – 
9-(6-Methoxynapthyl)triazolylnonahydroxamic acid (67a) – 
 
To a solution of 66a (0.12 g, 0.19 mmol) in CH2Cl2 (7 ml) was added triisopropylsilane 
(0.2 mL) and trifluoroacetic acid (TFA) (0.15 mL) dropwise at room temperature. 
Additional triisopropylsilane was added till reaction mixture became colorless. After 15 
min of stirring at RT, solvent was evaporated and thick brown-black liquid was treated 
with petroleum ether (~15 mL) to give yellowish suspension.  Suspension was filtered 
and residue was again washed with petroleum ether (~30 mL) then with 
CH2Cl2:petroleum ether (1:1) mixture (~30 mL), followed by more washing with CH2Cl2 
(~50 mL) to give 65 mg (83%) of pure 67a as a white solid. 1H NMR (400 MHz, dmso) δ 
10.30 (s, 1H), 8.64 (m, 2H), 8.29 (s, 1H), 7.89 (dd, J = 22.1, 9.3 Hz, 3H), 7.32 (m, 1H), 
7.17 (d, J = 8.8 Hz, 1H), 4.39 (t, J = 7.0 Hz, 2H), 3.87 (s, 3H), 1.88 (m, 2H), 1.48 (m, 
2H), 1.18 (m, 10H). ).  13C NMR (100 MHz, DMSO-d6) δ 157.25, 146.25, 133.61, 
129.14, 128.37, 126.97, 126.00, 123.90, 123.14, 120.70, 118.64, 106.07, 54.99, 49.29, 
41.21, 29.26, 28.19, 27.96, 25.57. HRMS (EI) calcd for C22H28N4O3 [M]
+ 396.2161 found 
396.2170. 
10-(6-Methoxynapthyl)triazolyldecahydroxamic acid  (67b) – 
Reaction of 66b (0.05 g, 0.076 mmol) with triisopropylsilane (0.4 ml) & TFA (0.15 ml) 
in CH2Cl2 (7 ml) at RT within 15 min as described for the synthesis of 67a, gave 28 mg 
(90%) of 67b as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 10.30 (s, 1H), 8.63 (s, 
1H), 8.30 (s, 1H), 7.89 (dd, J = 23.0, 9.6 Hz, 3H), 7.32 (d, J = 2.3 Hz, 1H), 7.17 (dd, J = 
9.0, 2.5 Hz, 1H), 4.39 (t, J = 7.1 Hz, 2H), 3.87 (s, 3H), 1.89 (dd, J = 15.5, 7.9 Hz, 4H), 
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1.45 (d, J = 6.6 Hz, 2H), 1.24 (d, J = 20.6 Hz, 10H).  13C NMR (100 MHz, DMSO-d6) δ 
169.12, 157.42, 146.49, 133.85, 129.51, 128.56, 127.35, 126.12, 124.13, 123.33, 121.14, 
119.13, 106.02, 55.23, 49.55, 32.26, 29.65, 28.76, 28.66, 28.55, 28.39, 25.88, 25.11. 
HRMS (EI) calcd for C23H30N4O3 [M]
+ 410.2318 found 410.2322. 
11-(6-Methoxynapthyl)triazolylundecahydroxamic acid (67c) – 
Reaction of 66c (0.15 g, 0.22 mmol) with triisopropylsilane (0.4 ml) & TFA (0.15 ml) in 
CH2Cl2 (7 ml) at RT within 15 min as described for the synthesis of 67a, gave 72 mg 
(76%) of 67c as a white solid. 1H NMR (400 MHz, DMSO) δ 10.54 (s, 1H), 8.62 (s, 1H), 
8.28 (s, 1H), 7.88 (m, 3H), 7.31 (s, 1H), 7.16 (d, J = 7.9 Hz, 1H), 4.38 (t, J = 7.0 Hz, 2H), 
3.86 (s, 3H), 1.87 (m, 4H), 1.47 (m, 2H), 1.21 (m, 12H). 13C NMR (100 MHz, 
CDCl3+CD3OD) δ 157.79, 134.25, 129.48, 128.79, 127.30, 125.27, 124.18, 124.07, 
119.68, 119.14, 105.61, 92.65, 55.12, 50.40, 30.03, 29.47, 29.00, 28.65, 26.17. HRMS 
(MALDI) calcd for C24H33N4O3 [M+H]
+ 425.2553 found 425.2550. 
12-(6-Methoxynapthyl)triazolyldodecahydroxamic acid (67d) – 
Reaction of 66d (0.18 g, 0.26 mmol) with triisopropylsilane (0.4 ml) & TFA (0.15 ml) in 
CH2Cl2 (7 ml) at RT within 15 min as described for the synthesis of 67a, gave 78 mg 
(66%) of 67d as a white solid. 1H NMR (400 MHz, DMSO) δ 10.28 (s, 1H), 8.62 (s, 1H), 
8.29 (s, 1H), 7.89 (m, 3H), 7.32 (s, 1H), 7.17 (d, J = 6.7 Hz, 1H), 4.39 (t, J = 7.0 Hz, 2H), 
3.87 (s, 3H), 1.89 (m, 4H), 1.43 (m, 2H), 1.24 (m, 14H). 13C NMR (100 MHz, DMSO) δ 
157.24, 146.26, 133.62, 129.19, 128.75, 128.37, 128.02, 127.01, 125.99, 123.91, 123.13, 
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120.78, 118.72, 106.03, 55.02, 49.32, 29.31, 28.57, 28.51, 28.42, 28.10, 25.62, 24.79. 
HRMS (MALDI) calcd for C25H35N4O3 [M+H]
+ 439.2709 found 439.2715. 
6-((Trimethylsilyl)ethynyl)-2-naphthol (68a) –  
Dry round bottom flask was charged with 6-bromo-2-napthol (0.20 g, 0.89 mmol) and 
triethylamine (3 mL) under inert atmosphere and the solution was stirred for 5 min at RT. 
Following addition of PdCl2(PPh3)2 (20 mg, 0.028 mmol) & CuI (6 mg, 0.031 mmol), the 
solution was degassed. Under slow flow of argon TMS-acetylene was added quickly and 
reaction mixture was heated overnight at 80 oC. The reaction mixture was slowly cooled 
at RT and dry THF was added and stirred at room temperature for 1 h. The mixture was 
concentrated in vacuo, diluted with CH2Cl2, organic layers were combined and dried over 
Na2SO4. Column chromatography with gradient Hexane:EtOAC (step gradient, 20-33 % 
of EtOAc) gave 0.193 g, 90% of pure 68a as brown solid. 1H NMR (400 MHz, CDCl3) δ 
7.99 (s, 1H), 7.68 (d, J = 8.8 Hz, 1H), 7.52 (m, 2H), 7.15 (m, 2H), 0.38 (s, 9H). 13C NMR 
(100 MHz, CDCl3) δ 154.11, 134.13, 131.85, 129.70, 129.07, 128.11, 126.31, 118.42, 
117.74, 109.61, 105.92, 93.86, -0.02.  
6-((Trimethylsilyl)ethynyl)-naphalen-2-amine (68b) – 
Reaction of 6-bromonapthalen-2-amine (1.00 g, 4.50 mmol), triethylamine (15 mL), 
PdCl2(PPh3)2 (100 mg, 0.14 mmol), CuI (30 mg, 0.16 mmol), TMS-acetylene (0.66 g, 
6.75 mmol) as described for synthesis of 68a, gave 0.64 g (60%) of 68b as a brown solid. 
1H NMR (400 MHz, CDCl3) δ 7.86 (s, 1H), 7.57 (d, J = 8.5 Hz, 1H), 7.47 (d, J = 8.5 Hz, 
1H), 7.40 (dd, J = 8.5, 1.3 Hz, 1H), 6.89 (m, 2H), 3.87 (s, 2H), 0.28 (s, 9H). 13C NMR 
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(100 MHz, CDCl3) δ 145.05, 134.53, 131.94, 129.16, 129.07, 127.11, 125.63, 118.59, 
116.50, 108.18, 106.10, 93.06, 0.07.  
6-Ethynyl-2-naphthol (69a) – 
To a stirring reaction mixture of 68a (1.85 g, 7.72 mmol) in THF (10 mL), 1M TBAF in 
THF (9.26 mL) was added dropwise. After 45 min stirring at room temperature, reaction 
mixture was diluted with EtOAC (80 mL) and washed with water (80 mL). Aqueous 
layer was washed with EtOAc (2 X 60 mL). Combined organic layer was washed with 
brine (1 x 50 mL) and dried over Na2SO4. Column chromatography with hexane:ether 
(2:1), gave 1.07 g (83%) pure 69a as brown solid. 1H NMR (400 MHz, CDCl3) δ 7.95 (m, 
1H), 7.67 (m, 1H), 7.55 (d, J = 8.6 Hz, 1H), 7.47 (m, 1H), 7.14 (m, 2H), 6.33 (s, 1H), 
3.16 (s, 1H). 13C NMR (100 MHz, CDCl3) δ 154.58, 134.46, 132.27, 129.90, 129.25, 
128.21, 126.54, 118.82, 116.88, 109.83, 84.37, 77.45. HRMS (EI) calcd for C12H8O [M]
+ 
168.0575 found 168.0574. 
 6-Ethynylnaphthalen-2-amine (69b) – 
Reaction of 68b (0.46 g, 1.92 mmol), 1M TBAF in THF (2.31 mL) as described for 
synthesis of 69a, gave 0.23 g (72%) of 69b as a dark orange solid. 1H NMR (400 MHz, 
CDCl3) δ 7.87 (s, 1H), 7.54 (d, J = 8.8 Hz, 1H), 7.42 (m, 2H), 6.90 (dd, J = 8.7, 2.3 Hz, 
1H), 6.85 (d, J = 2.3 Hz, 1H), 4.02 (s, 2H), 3.14 (s, 1H). 13C NMR (100 MHz, CDCl3) δ 
145.34, 134.52, 132.01, 128.88, 128.75, 126.73, 125.63, 118.69, 114.98, 107.83, 84.50, 
76.24. HRMS (EI) calcd for C12H9N [M]




O-Trityl-6-hydroxynaphthyltriazolylhexahydroxamate (70a) – 
Reaction of 6-ethynyl-2-napthol (0.12 g, 0.72 mmol) and 6-azido-O-
tritylhexahydroxamate (0.25 g, 0.60 mmol) within 12 h as described for synthesis of 66a 
gave compound 70a (0.30 g, 86%) as a white solid. 1H NMR (400 MHz, DMSO) δ 10.16 
(s, 1H), 9.78 (s, 1H), 8.55 (s, 1H), 8.24 (s, 1H), 7.80 (m, 3H), 7.28 (m, 15H), 7.10 (m, 
2H), 4.30 (t, J = 7.0 Hz, 2H), 1.75 (m, 4H), 1.25 (m, 2H), 0.99 (m, 2H). 13C NMR (100 
MHz, DMSO) δ 155.99, 152.20, 147.06, 142.89, 134.59, 129.99, 129.39, 128.18, 127.95, 
127.08, 125.69, 124.34, 123.81, 121.32, 119.61, 109.21, 92.19, 49.76, 32.19, 29.75, 
25.68, 24.58.  
O-Trityl-6-hydroxynaphthyltriazolylheptahydroxamate (70b) – 
Reaction of 6-ethynyl-2-napthol (0.19 g, 1.12 mmol) and 7-azido-O-
tritylheptahydroxamate (0.40 g, 0.93 mmol) within 12 h as described for synthesis of 66a 
gave compound 70b (0.53 g, 95%) as a white solid. 1H NMR (400 MHz, DMSO – d6) δ 
10.15 (s, 1H), 9.78 (s, 1H), 8.58 (s, 1H), 8.24 (s, 1H), 7.80 (m, 3H), 7.31 (m, 15H), 7.11 
(m, 2H), 4.34 (t, J = 6.9 Hz, 2H), 1.76 (m, 4H), 1.07 (m, 6H). 13C NMR (100 MHz, 
DMSO) δ 155.99, 151.74, 147.07, 146.89, 142.92, 134.59, 129.99, 129.39, 128.18, 
127.92, 127.82, 127.08, 125.70, 124.34, 123.82, 121.33, 119.61, 109.20, 100.43, 92.16, 
50.00, 32.36, 29.91, 28.17, 26.00, 25.02. 
O-Trityl-6-aminonaphthyltriazolylheptahydroxamate (70c) – 
Reaction of 6-ethynylnapthalen-2-amine (0.10 g, 0.60 mmol) and 7-azido-O-
tritylheptahydroxamate (0.26 g, 0.60 mmol) within 12 h as described for synthesis of 66a 
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gave compound 70c (0.24 g, 67%) as a dark orange solid. 1H NMR (400 MHz, DMSO – 
d6) δ 10.16 (s, 1H), 8.51 (s, 1H), 8.09 (s, 1H), 7.66 (m, 3H), 7.31 (m, 15H), 6.94 (d, J = 
8.8 Hz, 1H), 6.81 (s, 1H), 5.45 (s, 2H), 4.32 (t, J = 6.6 Hz, 2H), 1.76 (m, 4H), 1.12 (m, 
6H). 13C NMR (100 MHz, DMSO) δ 146.87, 144.63, 142.46, 134.60, 128.94, 127.49, 
126.25, 123.69, 123.45, 120.43, 118.90, 105.80, 91.73, 49.42, 31.89, 29.49, 27.74, 25.56, 
24.63.  
O-Trityl-6-aminonaphthyltriazolyloctahydroxamate (70d) – 
Reaction of 6-ethynylnapthalen-2-amine (0.10 g, 0.60 mmol) and 8-azido-O-
trityloctahydroxamate (0.26 g, 0.60 mmol) within 12 h as described for synthesis of 66a 
gave compound 70d (0.22 g, 59%) as a dark orange solid. 1H NMR (400 MHz, DMSO) δ 
10.13 (s, 1H), 8.52 (s, 1H), 8.08 (s, 1H), 7.66 (m, 3H), 7.29 (m, 15H), 6.93 (dd, J = 8.7, 
2.1 Hz, 1H), 6.80 (d, J = 1.9 Hz, 1H), 5.44 (s, 2H), 4.35 (t, J = 7.0 Hz, 2H), 1.77 (m, 4H), 
1.07 (m, 8H). 13C NMR (100 MHz, CDCl3) δ 148.04, 144.45, 140.99, 134.60, 129.47, 
128.95, 128.05, 127.81, 126.29, 124.61, 124.31, 124.29, 119.05, 118.65, 108.36, 104.75, 
50.68, 50.27, 31.04, 30.16, 28.56, 26.18, 23.23. 
6-(6-hydroxynaphthyl)triazolylhexahydroxamate (71a) – 
Reaction of 70a (0.11 g, 0.19 mmol) with triisopropylsilane (0.4 ml) & TFA (0.15 ml) in 
CH2Cl2 (7 ml) at RT within 15 min as described for the synthesis of 67a, gave 55 mg 
(86%) of 71a as a white solid. 1H NMR (400 MHz, DMSO) δ 10.33 (s, 1H), 8.60 (s, 1H), 
8.24 (s, 1H), 7.80 (m, 3H), 7.11 (m, 2H), 4.39 (t, J = 6.9 Hz, 2H), 1.91 (m, 4H), 1.54 (m, 
2H), 1.24 (m, 2H). 13C NMR (100 MHz, DMSO) δ 168.98, 155.60, 146.67, 136.69, 
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134.19, 129.60, 127.77, 126.69, 125.25, 123.93, 123.43, 120.97, 119.21, 108.79, 49.44, 
32.08, 29.40, 25.51, 24.55. HRMS (MALDI) calcd for C18H21N4O3 [M+H]
+ 341.1614 
found 341.1633. 
7-(6-hydroxynaphthyl)triazolylheptahydroxamate (71b) – 
Reaction of 70b (0.09 g, 0.15 mmol) with triisopropylsilane (0.4 ml) & TFA (0.15 ml) in 
CH2Cl2 (7 ml) at RT within 15 min as described for the synthesis of 67a, gave 48 mg 
(92%) of 71b as a white solid. 1H NMR (400 MHz, DMSO) δ 10.32 (s, 1H), 9.79 (s, 1H), 
8.65 (s, 1H), 8.60 (s, 1H), 8.23 (s, 1H), 7.80 (m, 3H), 7.09 (m, 2H), 4.38 (t, J = 7.0 Hz, 
2H), 1.88 (m, 4H), 1.47 (m, 2H), 1.27 (m, 4H). 13C NMR (100 MHz, DMSO) δ 155.57, 
146.65, 134.16, 129.58, 127.74, 126.67, 125.24, 123.92, 123.40, 120.94, 119.19, 108.77, 
49.49, 32.17, 29.54, 28.00, 25.62, 24.95. HRMS (MALDI) calcd for C19H23N4O3 [M+H]
+ 
355.1774 found 355.1770. 
7-(6-aminonaphthyl)triazolylheptahydroxamate (71c) – 
Reaction of 70c (0.065 g, 0.15 mmol) with triisopropylsilane (0.4 ml) & TFA (0.15 ml) in 
CH2Cl2 (7 ml) at RT within 15 min as described for the synthesis of 67a, gave 32 mg 
(quantitative) of 71c as an off white solid. 1H NMR (400 MHz, DMSO) δ 10.35 (s, 1H), 
8.68 (s, 1H), 8.37 (s, 1H), 7.97 (m, 3H), 7.63 (s, 1H), 7.35 (dd, J = 8.8, 1.4 Hz, 1H), 4.39 
(t, J = 7.0 Hz, 2H), 1.89 (m, 4H), 1.47 (m, 2H), 1.27 (m, 4H). 13C NMR (100 MHz, 
DMSO) δ 169.12, 158.62, 158.26, 146.21, 132.83, 129.81, 127.82, 124.72, 123.39, 
121.60, 121.22, 117.15, 48.62, 32.18, 29.55, 28.01, 25.63, 24.97. HRMS (MALDI) calcd 
for C19H24N5O2 [M+H]
+ 354.1930 found 354.1889. 
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8-(6-aminonaphthyl)triazolyloctahydroxamate (71d) – 
Reaction of 70d (0.05 g, 0.15 mmol) with triisopropylsilane (0.4 ml) & TFA (0.15 ml) in 
CH2Cl2 (7 ml) at RT within 15 min as described for the synthesis of 67a, gave 27 mg 
(90%) of 71d as a off white solid. 1H NMR (400 MHz, DMSO) δ 8.67 (s, 1H), 8.37 (s, 
1H), 8.29 (d, J = 1.2 Hz, 2H), 7.97 (m, 3H), 7.61 (s, 1H), 7.35 (d, J = 8.8 Hz, 1H), 4.40 (t, 
J = 6.9 Hz, 2H), 1.89 (m, 4H), 1.46 (m, 2H), 1.25 (m, 6H). HRMS (MALDI) calcd for 
C20H26N5O2 [M+H]
+ 368.2087 found 368.2039.  
 
6-Ethoxy-2-ethynylnapthalene (72) – 
In a sealed pressure tube 6a (0.10 g, 0.59 mmol), ethylbromide (0.19 g, 1.78 mmol), 
K2CO3 (0.24 g, 1.78 mmol) were dissolved in THF (10 mL). Reaction mixture was stirred 
overnight at 60 oC. Reaction mixture was then quenched with water (40 mL) and CH2Cl2 
(50 mL). Organic layer was washed subsequently with water (2X30 mL) and brine (1X30 
mL) and dried over Na2SO4. Column chromatography with Hexane:EtOAC (4:1) gave 
pure 72 (0.07 g, 57%) as brown solid. 1H NMR (400 MHz, CDCl3) δ 7.93 (s, 1H), 7.66 
(m, 2H), 7.48 (dd, J = 8.5, 1.6 Hz, 1H), 7.15 (dd, J = 8.9, 2.5 Hz, 1H), 7.07 (d, J = 2.4 
Hz, 1H), 4.12 (q, J = 7.0 Hz, 2H), 3.11 (s, 1H), 1.47 (t, J = 7.0 Hz, 3H).  13C NMR (100 
MHz, CDCl3) δ 157.75, 134.39, 132.02, 129.22, 129.02, 128.17, 126.74, 119.71, 116.77, 
106.45, 84.22, 63.48, 14.71. HRMS (EI) calcd for C14H12N5O [M]





O-Trityl-6-ethoxynapthyltriazolyloctahydroxamate (73a) – 
Reaction of 72 (0.063 g, 0.32 mmol) and 8-azido-O-trityloctahydroxamate (0.17 g, 0.39 
mmol) within 12 h as described for synthesis of 66a gave compound 73a (0.15 g, 72%) as 
a white solid. 1H NMR (400 MHz, DMSO) δ 10.13 (s, 1H), 8.61 (s, 1H), 8.29 (s, 1H), 
7.89 (m, 3H), 7.30 (m, 16H), 7.15 (m, 1H), 4.37 (t, J = 6.7 Hz, 2H), 4.13 (q, J = 6.9 Hz, 
2H), 1.79 (m, 3H), 1.38 (t, J = 7.0 Hz, 4H), 1.04 (m, 8H). 13C NMR (100 MHz, CDCl3) δ 
176.99, 157.02, 147.67, 141.74, 140.90, 134.16, 129.45, 128.85, 128.72, 127.95, 127.14, 
125.68, 124.16, 124.01, 119.35, 119.25, 106.35, 93.15, 63.31, 51.21, 50.16, 30.90, 30.05, 
28.58, 26.05, 23.12, 14.66. HRMS (MALDI) calcd for C41H42N4O3 [M+Na]
+ 661.3149 
found 661.3099.  
O-Trityl-6-ethoxynapthyltriazolyldecahydroxamate (73b) – 
Reaction of 72 (0.066 g, 0.34 mmol) and 10-azido-O-trityldecahydroxamate (0.17 g, 0.37 
mmol) within 12 h as described for synthesis of 66a gave compound 73b (0.13 g, 56%) 
as a white solid. 1H NMR (400 MHz, DMSO) δ 10.11 (s, 1H), 8.62 (s, 1H), 8.28 (s, 1H), 
7.87 (m, 3H), 7.29 (m, 16H), 7.15 (dd, J = 9.0, 2.2 Hz, 1H), 4.38 (t, J = 7.0 Hz, 2H), 4.13 
(q, J = 7.0 Hz, 2H), 1.77 (m, 4H), 1.38 (t, J = 6.9 Hz, 3H), 1.12 (m, 14H). 13C NMR (100 
MHz, CDCl3) δ 157.03, 147.69, 141.77, 140.92, 134.18, 129.46, 128.86, 128.74, 127.95, 
127.58, 127.14, 125.68, 124.17, 124.03, 119.36, 119.25, 106.36, 63.33, 50.46, 50.23, 
31.02, 30.77, 30.15, 28.94, 26.29, 14.67. HRMS (MALDI) calcd for C43H46N4O3 




8-(6-Ethoxynapthyl)triazolyloctahydroxamic acid (74a) – 
Reaction of 73a (0.09 g, 0.15 mmol) with triisopropylsilane (0.4 ml) & TFA (0.15 ml) in 
CH2Cl2 (7 ml) at RT within 15 min as described for the synthesis of 67a, gave 48 mg 
(92%) of 74a as a white solid. 1H NMR (400 MHz, DMSO) δ 10.32 (s, 1H), 8.65 (s, 1H), 
8.62 (s, 1H), 8.28 (s, 1H), 7.87 (m, 3H), 7.30 (d, J = 2.3 Hz, 1H), 7.15 (dd, J = 8.9, 2.4 
Hz, 1H), 4.38 (t, J = 7.0 Hz, 2H), 4.13 (q, J = 7.0 Hz, 2H), 1.88 (m, 5H), 1.37 (m, 10H). 
13C NMR (100 MHz, DMSO) δ 169.12, 156.68, 146.53, 133.90, 129.52, 128.50, 127.36, 
126.06, 124.09, 123.34, 121.15, 119.35, 106.66, 63.19, 49.55, 32.24, 29.65, 28.43, 28.14, 
25.81, 25.06, 14.68. HRMS (MALDI) calcd for C22H29N4O3 [M+H]
+397.2234 found 
397.2229. 
10-(6-Ethoxynapthyl)triazolyldecahydroxamic acid (74b) – 
Reaction of 73b (0.12 g, 0.18 mmol) with triisopropylsilane (0.4 ml) & TFA (0.15 ml) in 
CH2Cl2 (7 ml) at RT within 15 min as described for the synthesis of 67a, gave 63 mg 
(83%) of 74b as a white solid. 1H NMR (400 MHz, DMSO) δ 10.29 (s, 1H), 8.61 (s, 1H), 
8.28 (s, 1H), 7.87 (m, 3H), 7.30 (s, 1H), 7.16 (d, J = 9.0 Hz, 1H), 4.38 (t, J = 7.1 Hz, 2H), 
4.14 (q, J = 6.9 Hz, 2H), 1.89 (m, 4H), 1.34 (m, 15H). 13C NMR (100 MHz, DMSO) δ 
169.44, 156.63, 146.48, 133.85, 129.46, 128.46, 127.29, 126.04, 124.05, 123.29, 121.08, 
119.29, 106.64, 63.14, 49.53, 32.24, 29.61, 28.72, 28.63, 28.52, 28.36, 25.85, 25.07, 
14.62. HRMS (MALDI) calcd for C24H33N4O3 [M+H]





Ethyl 7-(6-amino-2-napthyl)triazolylheptanoate (75a) – 
Reaction of 69b (0.20 g, 1.19 mmol) and Ethyl 7-azidoheptanoate (0.36 g, 1.79 mmol) 
within 12 h as described for synthesis of 66a gave compound 75a (0.34 g, 77%) as a dark 
orange solid. 1H NMR (400 MHz, CDCl3) δ 8.12 (s, 1H), 7.74 (dd, J = 8.5, 1.4 Hz, 1H), 
7.66 (s, 1H), 7.59 (d, J = 9.3 Hz, 1H), 7.52 (d, J = 8.5 Hz, 1H), 6.87 (m, 2H), 4.21 (t, J = 
7.2 Hz, 2H), 3.98 (m, 4H), 2.20 (t, J = 7.4 Hz, 2H), 1.80 (m, 2H), 1.53 (m, 2H), 1.21 (m, 
7H). 13C NMR (100 MHz, CDCl3) δ 173.32, 147.72, 144.61, 134.42, 129.13, 127.44, 
126.02, 124.29, 124.03, 123.99, 119.03, 118.53, 107.93, 59.95, 49.87, 33.80, 29.77, 
28.13, 25.83, 24.35, 13.97.  
Ethyl 8-(6-amino-2-napthyl)triazolyloctanoate (75b) – 
Reaction of 69b (0.20 g, 1.19 mmol) and Ethyl 8-azidooctanoate (0.38 g, 1.79 mmol) 
within 12 h as described for synthesis of 66a gave compound 75b (0.31 g, 73%) as a dark 
orange solid. 1H NMR (400 MHz, CDCl3) δ 8.13 (d, J = 1.2 Hz, 1H), 7.75 (dd, J = 8.5, 
1.7 Hz, 1H), 7.70 (s, 1H), 7.63 (m, 1H), 7.55 (d, J = 8.6 Hz, 1H), 6.89 (m, 2H), 4.26 (t, J 
= 7.2 Hz, 2H), 4.08 (q, J = 7.1 Hz, 2H), 3.96 (s, 2H), 2.23 (t, J = 7.5 Hz, 2H), 1.87 (m, 
2H), 1.55 (m, 2H), 1.21 (m, 9H). 13C NMR (100 MHz, CDCl3) δ 173.55, 147.80, 144.56, 
134.46, 129.23, 127.54, 126.10, 124.38, 124.10, 124.07, 119.02, 118.56, 108.06, 60.00, 
50.06, 33.99, 30.00, 28.61, 28.42, 26.06, 24.56, 14.04. HRMS (EI) calcd for C22H28N4O2 





Ethyl 7-(6-azido-2-napthyl)triazolylheptanoate (76a) – 
The amine 75a (0.33 g, 0.9 mmol) was suspended in HCl/H2O (1:1; 14 mL) and cooled to 
0 oC. An aqueous solution of NaNO2 (0.08, 1.13 mmol) was added dropwise and then 
reaction mixture was stirred for 1h. An aqueous solution of NaN3 (0.18 g, 2.70 mmol) 
was added dropwise. The reaction mixture was stirred at RT for another 3h and extracted 
with EtOAc (3X30 mL). The organic layers were washed with brine (2 X 30 mL), dried 
over Na2SO4 and concentrated under vacuo to give 0.31 g (86%) of pure 76a as brown 
solid. 1H NMR (400 MHz, CDCl3) δ 8.28 (d, J = 0.9 Hz, 1H), 7.91 (dd, J = 8.5, 1.7 Hz, 
1H), 7.79 (m, 3H), 7.40 (d, J = 2.2 Hz, 1H), 7.13 (dd, J = 8.7, 2.3 Hz, 1H), 4.38 (t, J = 7.2 
Hz, 2H), 4.10 (q, J = 7.1 Hz, 2H), 2.26 (t, J = 7.5 Hz, 2H), 1.93 (m, 2H), 1.58 (m, 2H), 
1.30 (m, 5H), 1.22 (t, J = 7.1 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 173.61, 147.34, 
137.58, 133.49, 130.99, 130.04, 127.59, 127.47, 124.90, 124.10, 119.60, 119.20, 115.59, 
60.12, 50.32, 34.10, 30.16, 28.73, 28.55, 26.20, 24.66, 14.15. HRMS (EI) calcd for 
C22H26N6O2 [M]
+  406.2117 found 406.2118. 
Ethyl 8-(6-azido-2-napthyl)triazolyloctanoate (76b) – 
Reaction of amine 75b (0.30 g, 0.82 mmol), NaNO2 (0.07 g, 1.02 mmol), NaN3 (0.16 g, 
2.46 mmol) in HCl/H2O (1:1; 14 mL) within 4h as described for synthesis of 76b gave 
compound 13b (0.29 g, 74%) as a brown solid. 1H NMR (400 MHz, CDCl3) δ 8.29 (d, J 
= 0.9 Hz, 1H), 7.92 (dd, J = 8.5, 1.7 Hz, 1H), 7.84 (m, 2H), 7.78 (m, 1H), 7.42 (d, J = 2.2 
Hz, 1H), 7.15 (dd, J = 8.7, 2.3 Hz, 1H), 4.40 (t, J = 7.2 Hz, 2H), 4.10 (q, J = 7.1 Hz, 2H), 




7-(6-azido-2-napthyl)triazolylheptanoic acid (77a) – 
To a stirring reaction mixture of ester 76a (0.20 g, 0.51 mmol) in THF:water (3:1; 12 
mL) was added LiOH:H2O (0.11 g, 2.55 mmol). After overnight stirring at RT, reaction 
mixture was quenched with addition of water (35 mL) and was extracted with EtOAc 
(2X30 mL). Aqueous layer was isolated and  1N HCl was added to bring pH ~ 2. 
Aqueous layer was extracted with EtOAC (3X30 mL). Combined organic layer was 
washed with water (1X35 mL), brine (1X30 mL), dried over Na2SO4 to give 77a (0.17 g) 
as a crude off white solid which was used for next step without further purification. 
8-(6-azido-2-napthyl)triazolyloctanoic acid (77b) – 
Reaction of ester 76b (0.20 g, 0.49 mmol), LiOH:H2O (0.10 g, 2.46 mmol) within 12h as 
described for synthesis of 77a gave compound 77b (0.17 g) as a crude off white solid 
which was used for next step without further purification. 
O-Trityl-6-azido-2-napthyltriazolylheptahydroxamate (78a) – 
Carboxylic acid 77a (92 mg, 0.25 mmol) was dissolved in anhydrous DMF (8 mL).  
Diisopropylethylamine (65 mg, 0.50 mmol), TBTU (162 mg, 0.50 mmol) and finally O-
tritylhydroxylamine (91 mg, 0.32 mmol)  was added sequentially. After 2 h of stirring 
reaction mixture was poured into CH2Cl2 (50 mL) and water (50 mL). Organic layer was 
separated and extracted 3 times in each case with water, sodium bicarbonate solution 
(5%) and water. After washing with brine and drying over Na2SO4, solvent was 
evaporated in vacuo.  Column chromatography with eluent system CH2Cl2-acetone (step 
gradient, 0-12% of acetone) gave 0.13 mg of compound 78a (85%) as a white solid.  1H 
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NMR (400 MHz, DMSO) δ 10.15 (s, 1H), 8.66 (s, 1H), 8.39 (s, 1H), 8.00 (m, 3H), 7.68 
(d, J = 2.3 Hz, 1H), 7.29 (m, 15H), 4.36 (t, J = 7.0 Hz, 2H), 1.78 (m, 4H), 1.08 (m, 6H). 
13C NMR (100 MHz, DMSO) δ 146.09, 142.43, 137.02, 133.07, 130.78, 130.15, 128.91, 
127.94, 127.68, 127.45, 124.71, 123.30, 121.53, 119.44, 115.78, 91.68, 54.82, 49.50, 
31.90, 29.41, 27.68, 25.51.  
O-Trityl-6-azido-2-napthyltriazolyloctahydroxamate (78b) – 
Reaction of carboxylic acid 77b (0.30 g, 1.07 mmol), DIPEA (0.10 mL, 0.58 mmol), 
TBTU (0.19 g, 0.58 mmol), and O-tritylhydroxylamine (0.10 g, 0.35 mmol) within 2h as 
described for the synthesis of 78a gave compound 78b (0.15 g, 82%) as a white solid. 1H 
NMR (400 MHz, CDCl3) δ 8.29 (s, 1H), 7.92 (dd, J = 8.5, 1.7 Hz, 1H), 7.83 (m, 2H), 
7.77 (d, J = 8.6 Hz, 1H), 7.41 (m, 3H), 7.27 (m, 12H), 7.14 (dd, J = 8.7, 2.3 Hz, 1H), 4.36 
(t, J = 7.1 Hz, 2H), 1.86 (m, 2H), 1.55 (m, 2H), 1.21 (m, 6H), 1.03 (m, 2H). 13C NMR 
(100 MHz, CDCl3) δ 171.16, 147.32, 140.97, 137.58, 133.50, 131.01, 130.04, 128.90, 
127.98, 127.60, 127.46, 124.91, 124.12, 119.62, 119.18, 115.60, 60.27, 50.29, 30.07, 
28.48, 26.08, 24.59, 20.92, 14.09.  
7-(6-Azido-2-napthyl)triazolylheptahydroxamic acid (79a) – 
Reaction of 78a (0.065 g, 0.10 mmol) with triisopropylsilane (0.2 ml) & TFA (0.10 ml) 
in CH2Cl2 (7 ml) at RT within 15 min as described for the synthesis of 67a, gave 27 mg 
(70%) of 79a as a white solid. 1H NMR (400 MHz, DMSO) δ 10.31 (s, 1H), 8.68 (s, 1H), 
8.64 (s, 1H), 8.39 (s, 1H), 7.99 (m, 3H), 7.68 (d, J = 2.3 Hz, 1H), 7.28 (dd, J = 8.8, 2.3 
Hz, 1H), 4.41 (t, J = 7.0 Hz, 2H), 1.90 (m, 4H), 1.48 (m, 2H), 1.28 (m, 4H). 13C NMR 
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(100 MHz, dmso) δ 168.98, 146.10, 137.06, 133.08, 130.78, 130.16, 127.96, 127.69, 
123.32, 121.57, 119.45, 115.78, 105.85, 49.52, 32.13, 29.47, 27.95, 25.57, 24.89.  
8-(6-Azido-2-napthyl)triazolyloctahydroxamic acid (79b) – 
Reaction of 78b (0.04 g, 0.063 mmol) with triisopropylsilane (0.2 ml) & TFA (0.10 ml) 
in CH2Cl2 (7 ml) at RT within 15 min as described for the synthesis of 67a, gave 24 mg 
(quantitative) of 79b as a white solid. 1H NMR (400 MHz, DMSO) δ 10.31 (s, 1H), 8.69 
(s, 1H), 8.64 (s, 1H), 8.39 (s, 1H), 7.99 (m, 3H), 7.69 (s, 1H), 7.28 (dd, J = 8.8, 2.3 Hz, 
1H), 4.41 (t, J = 7.0 Hz, 2H), 1.90 (m, 4H), 1.46 (m, 2H), 1.24 (m, 6H). 13C NMR (100 
MHz, DMSO) δ 169.06, 146.09, 137.04, 133.09, 130.79, 130.17, 127.94, 127.69, 124.72, 
123.32, 121.59, 119.45, 115.79, 49.54, 32.19, 29.56, 28.37, 28.07, 25.74, 24.98.  
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DUAL ACTING HDAC – TOPOISOMERASES (TOPO) INHIBITORS 
 
4.1 INTRODUCTION 
Several rational pharmacological strategies, including vaccination, gene therapy, 
immunotherapy, and new target identification and validation, have emerged for the 
treatment of metastatic diseases. Despite these advances, chemotherapy remains the 
primary treatment of choice for most cancer cases.1 However, almost all 
chemotherapeutic agents suffer from severe toxicities and other undesirable side-effects. 
To address these problems, the ideal chemotherapeutics will incorporate, within a single 
molecule, elements that allow for simultaneous targeting of multiple cancer-fighting 
targets while maintaining lower side effects.1c,2,3 This realization has spawned immense 
efforts in the literature. Studies aimed at identifying multivalent ligands as promising 
pharmacological tools, that may be more efficacious for various human diseases than 
highly selective single-target drugs, are ongoing in several academic and pharmaceutical 
labs.4-7  A subset of these studies has revealed that balanced modulation of a small 
number of targets may have superior efficacy and fewer side effects than single-target 
treatments.1c,7,8  
Epigenetic control has become widely accepted as a mechanism for cell 
regulation.9-11 Specifically, HDAC is a class of epigenetic enzymes that has generated 
much interest in cancer therapeutics literature.  HDACs are known to associate with 
many oncogenes and tumor suppressors, leading to altered expression patterns, and have 
consequently become attractive targets for small-molecule inhibition.12,13  HDACi have 
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been shown to cause growth arrest, differentiation, and apoptosis in tumor cells and in 
animal models by inducing histone hyperacetylation and p21waf1 expression.14-17  
Additionally, modulation of activities of HDACs alters the activity of a diverse range of 
proteins, many of which are attractive therapeutic targets themselves, including p53, E2F, 
tubulin, and Hsp90.18-22  HDAC inhibition has been clinically validated as a therapeutic 
strategy for cancer treatment with the FDA approvals of suberoylanilide hydroxamic acid 
(SAHA) and romidepsin (FK-228) for treatment of cutaneous T cell lymphoma.23-25  
However, a large number of the currently known HDACi have elicited only limited in 
vivo antitumor activities and have not progressed beyond preclinical characterizations.26-
28 HDACi that modulate the functions of additional intracellular targets, other than the 
various HDAC isoforms, may be able to ameliorate many of the shortcomings of current 
inhibitors.  
We modified the cap group to introduce additional warhead in HDACi design to 
combat cancer effectively. As many essential enzymes are overexpressed in cancer cells, 
multi-targeting therapy might be more beneficial, not only to eliminate cancer cells but 
also to combat the emergence of drug resistance. To explore the prospect in cancer 
therapy of a bivalent agent that combines two complimentary chemo-active groups within 
a single molecular architecture, we have synthesized dual-acting HDAC - Topoisomerase 
II (Topo II) and HDAC – Topoisomerase I (Topo I) inhibitors. We have identified single 
agents that simultaneously inhibit topoisomerase and HDAC activities for the first time. 





4.2 HDAC – TOPOISOMERASE II (TOPO II) INHIBITORS 
 
Due to the presence of large hydrophobic patches at the HDAC surface rim,29,30 it 
is conceivable that appropriate conjugation of the surface recognition group of a 
prototypical HDACi (Figure 4-1) to other hydrophobic anti-tumor pharmacophores could 
furnish a new class of bifunctional agents.  To date, there exist only a few examples of 
this subtype of bifunctional HDACi derived compounds.31  Expansion of the repertoire of 
such bifunctional compounds could lead to broad acting, therapeutically-viable anti-
cancer agents. 
 
Figure 4-1. SAHA pharmacophoric model showing proposed modification at cap group. 
 
   An attractive starting point for a secondary target is the topoisomerase class of 
enzymes (Topo I and Topo II), which are validated targets for many small molecule 
inhibitors including clinically useful anthracyclines, such as doxorubicin (DOX) and 
daunomycin (DAU) (Figure 4-2), and camptothecins such as irinotecan and topotecan.32 
Topo inhibitors elicit anticancer activities primarily by stabilizing the DNA-enzyme 
cleavable complex through intercalation between DNA base pairs.  However, DNA does 
not exist as a naked structure in the nucleus. It is non-covalently associated with histones 
to form the nucleosomes which make up chromatin subunits.  Agents, such as HDACi, 
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that induce hyperacetylation of histone proteins complexed with DNA could increase the 
accessibility of DNA within chromatin and consequently potentiate the anticancer 
activities of Topo inhibitors.33,34  Moreover, recent observations have shown that 
HDAC1, HDAC2 and Topo II co-localize in vivo as part of functionally coupled 
complexes.35,36  This evidence suggests simultaneous Topo and HDAC inhibition could 
be a viable alternative approach in cancer therapy.  
 
4.2.1 Design of HDAC-Topoisomerase II Conjugates 
Anthracyclines are one of the most thoroughly studied classes of anticancer 
agents with copious structure activity relationship (SAR) data to aid the design and 
characterization of new anthracycline-containing compounds. 37-39,40,41     
 
Figure 4-2. Representative Structures of Anthracycline Antibiotics 
 
Specifically, N-benzylated anthracyclines such as AD-288 (Figure 4-2) have enhanced 
Topo II inhibitory activities, reduced cardiotoxicity activity, and reduced susceptibility to 
the p-gp mediated multidrug resistance.42-46 We postulated that introduction of the 
HDACi via N-benzylation of the DAU amino group would be compatible with Topo II 
inhibition and possibly engender the positive attributes of AD-288 to the resulting 
conjugates.  In turn, the anthracycline moiety could serve two other purposes:  i) as a 
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surface recognition cap group, allowing favorable orientation of hydroxamic acid within 
the zinc binding pocket of HDAC, and ii) as a delivery vehicle, since the transport of the 
anthracycline via proteasome could facilitate nuclear accumulation of HDACi.41 Based 
on the former, we designed two classes of conjugates - a direct DAU-SAHA conjugate 
and DAU-triazolylaryl hydroxamate conjugates (Figure 4-3). The later conjugates were 
inspired by our previous studies which revealed that the triazole moiety could be 
incorporated in lieu of an amide bond as a surface recognition connecting group in 
prototypical HDACi.47  
 
Figure 4-3. Design of dual-acting Topo II-HDAC inhibitors. 
 
4.2.2 Synthesis of HDAC-Topoisomerase II Conjugates 
Crucial to the successful synthesis of all the conjugates described in this report is 
the reductive amination reaction between DAU and appropriate aldehyde intermediates 5 
and 10a-d (Figure 4-4 and 4-5).  Synthesis of aldehyde intermediate 5 started with the 
coupling of 4-aminobenzyl alcohol 1 to suberic anhydride 2 to give benzyl alcohol 3.  In 
order to assess the suitable oxidizing agent for conversion of alcohol 3 to aldehyde 4, we 
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employed MnO2, PCC and Dess-Martin periodinane (DMP) oxidation.  All yielded the 
desired aldehyde, with DMP giving the optimum yield among them.  To synthesize the 
protected hydroxamate 5, we coupled 4 to O-trityl hydroxylamine using standard EDC 
coupling chemistry.  Interestingly, the amide bond of compound 4 was also susceptible to 
nucleophilic attack and led to a substantially lower yield under this condition.  Using 
TBTU as coupling reagent resulted in the same outcome.  Gratifyingly, the use of 
isobutylchloroformate (IBCF), as a coupling reagent gave coupled requisite product 5 in 
66% yield within 2 h.  Longer reaction times didn’t improve the yield and led to 
degradation of product.  Reductive amination with DAU hydrochloride was the major 
hurdle in making the DAU-SAHA conjugate.  Initial investigation with NaBH3CN as a 
reducing agent with acetonitrile–water solvent system at room temperature led to a 
complex reaction mixture.  Employing a non-aqueous solvent system, as well as a milder 
reducing agent such as NaBH(OAc)3, didn’t produce any detectable amount of product.  
Previous studies in the literature indicated that generation of free amine by addition of 
base and elevated temperature might promote the imine formation.48,49  Indeed, adding 
Hunig’s base to the reductive amination reactions between DAU and aldehyde 5 in the 
presence of NaBH3CN at 70 
oC, gave the desired coupled product 6, albeit in low yield.  
Reducing the reaction temperature to 50 oC and below worsened the yield, as did 
employing NaBH(OAc)3 as a reducing agent.  The deprotection of the acid sensitive trityl 
group of compound 6 was accomplished by treatment with the Lewis acid boron 
trifluoride etherate.50 This led to the removal of the trityl group to give the desired 
conjugate 7 in good yield without any need for further purification.  
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 Similar chemistry was applied for the synthesis of triazole-based conjugates.  The 
synthesis of the requisite aldehydes 10a-d started with Cu(I)-catalyzed cycloaddition of 
4-ethynylbenzaldehyde 8 with trityl-protected azido hydroxamates 9a-d (Figure 4-5).  
Reductive amination of triazole aldehydes 10a-d with DAU proceeds readily at room 
temperature in CH3CN:H2O (3:1) to give the triazole-based conjugates 11a-d in slightly 
improved yields compared to conjugate 6. Boron trifluoride etherate promoted 
deprotection of the trityl group of 11a-d yielded the desired triazole-based conjugates 














































































Figure 4-5.  Synthesis of the SAHA-like, triazole-based Topo II-HDACi. 
 
4.2.3 In vitro HDAC Inhibition of HDAC & Topoisomerase II Conjugates 
We first tested the HDAC inhibition activity of compounds 7 and 12a-d against 
crude HeLa cell nuclear extract HDACs using a cell free assay (Fluor de Lys) as 
previously described.47  Overall, these compounds showed inhibition activities against 
HeLa cell nuclear extract HDACs which are comparable to or exceed that of the standard 
SAHA (Table 4-1).  It is particularly interesting that 7 has identical anti-HDAC activity 
to SAHA.  This result suggests that the attachment of DAU does not impair the 
interaction between the HDACi component of the conjugate and the HDAC enzyme outer 
surface residues.  It is also conceivable that the conjugate may adopt a conformation 
whereby the anthracycline moiety can contribute positively to the interaction with the 
crucial active site or surface residues.  All triazole-linked conjugates potently inhibit 
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HeLa cell nuclear extract HDACs with IC50 in the low to mid-nanomolar range.  Among 
these conjugates, 12a is the least active, closely followed by 12d, which is about 20-fold 
more potent.  Compounds 12b and 12c have the most potent anti-HDAC activity, with a 
slight preference for the six methylene-linked 12c.  Interestingly, the triazole-linked 
compound 12b is 40-fold more potent than the amide-linked 7, despite their similar linker 
length. Relative to the standard SAHA, 12c, the most potent compound in this series, is 
70-fold more potent (Table 4-1).  The foregoing results showed that these conjugates 
followed a trend similar to that which we noted for the previously reported, structurally 
unrelated, triazole-based HDACi.47 
To obtain evidence for the HDAC isoform selectivity, we tested these dual acting 
Topo II –HDACi conjugates against selected recombinant HDACs – HDAC 1, HDAC 6 
and HDAC 8.  The pattern of the anti-HDAC activities of these compounds against 
HDAC 1 and HDAC 6 is similar to what we observed for the HeLa cell nuclear extract 
HDACs with few exceptions.  Specifically, compounds 7 and 12b have indistinguishable 
activity against HDAC 1 and HDAC 6 (Table 4-1).  Additionally, 12a which has mid-
nanomolar IC50 against HeLa cell nuclear extract HDACs is almost inactive against 
HDAC 1 (IC50 = 4.6 µM) while it maintains decent activity against HDAC 6  (IC50 = 0.6 
µM).  We are not exactly sure of the cause of this disparity.  In general, these compounds 
are weaker inhibitors of HDAC 8 with the exception of 7, whose anti-HDAC 8 activity is 
only 2-fold less than its anti-HDAC 1 activity (Table 4-1).  These data suggest that 7 is a 






Table 4-1.  In vitro HDAC Inhibition. 
Compound n 
















SAHA - 65.0 38+/- 2 27+/- 2 294+/- 35 
DAU - N.D. N.T. N.T. N.T. 
7 - 64.7 47+/- 3 20+/- 1 87+/- 6 
12a 1 89.9 4,600+/- 240 555+/- 36 N.D. 
12b 2 1.6 54+/- 3 30+/- 2 2000+/- 243 
12c 3 0.9 8+/- 0.4 20+/- 0.4 674+/- 81 
12d 4 4.2 11+/- 0.4 19+/- 1 294+/- 14 
aInhibition was assayed using the Biomol HDAC Fluorimetric Assay/Drug Discovery Kit by 
William Guerrant. bData obtained through contract arrangement with BPS Bioscience (San 




4.2.4 Molecular Docking Analysis of HDAC & Topoisomerase II Conjugates 
 
To obtain information on the structural basis of the observed disparity in the 
HDAC inhibitory activity of these compounds, we performed molecular docking using a 
validated molecular dock program (AutoDock) 47,51  Docking analysis was performed on 
a HDAC 1 homology model built from human HDAC 2 X-ray structure 3MAX 
coordinates.52  We chose to dock the compound which had the least HDAC inhibitory 
activity (12a) and the compound which had the best HDAC inhibitory activity (12c) to 
delineate the basis of the ~600 fold activity difference between the two.  Additionally, we 
performed docking on compound 7 because of its distinct structural feature compared to 
12a-12c. 
 Interestingly, compound 12a and 12c, differing only in linker length, do not bind 
to the same pocket, but instead localize to two different pockets (Figure 4-6a).  For the 
six methylene-linked compound 12c, the hydroxyl group of the daunosamine sugar could 
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potentially make hydrogen bonding contact with the guanidinium group of Arg270 and 
the linker region could facilitate the presentation of the hydroxamic acid to the catalytic 
zinc by entering through the top of the hydrophobic channel that leads to the active site 
(Figure 4-6a, 4-7c, 4-7d).  In addition, two of the hydroxyl groups from the anthracycline 
ring of 12c could take part in the H-bonding interaction with the backbone carbonyl 
group of Arg270 and the N-H group of Gly272.  Possibly to accommodate the shorter 
linker length, 12a loses the H-bonding interaction between the hydroxyl group of its 
daunosamine sugar and the enzyme’s Arg270.  Though other hydroxyl groups of the 12a 
anthracycline ring make potentially compensatory H-bonding contacts with the phenolic 
group of Tyr201 and the backbone carbonyl groups of Gly207 and Pro206 (See Figure 4-
7a, 4-7b), its binding pocket is more solvent-exposed, compared to the binding pocket of 
12c (Figure 4-6a).  
Compound 7 binds close to the same pocket as 12c; it however derives its binding 
affinity through different sets of interactions.  Unlike 12c which enters the active site 
associating with the top of the hydrophobic channel, 7 traverses the same channel more 
closely associated with residues on the opposite side of the channel (Figure 4-6b).  
Consequently, the daunosamine hydroxyl group of 7 could not interact with Arg270 in a 
similar way as that of 12c.  In lieu of this interaction, the anthracycline ring of 7 may 
engage in other H-bonding interactions with the backbone carbonyl groups of Gly272, 
Gly268, and Thr304 on the enzyme surface rim (Figure 4-6, Figure 4-7, Figure 4-8 and 4-
9).  These apparent differences in the binding orientation at the enzyme surface rim could 
account for the disparity in the potency of compounds 7, 12a and 12c against HDAC1. 
 
                                 (a)                                                         (b)
Figure 4-6.  Docked structure of Topo II
Superposition of low energy conformations of 
energy conformations of 12c (pink) and 
 
(a)                                                                                         
 Figure 4-7. (a) Docked structure of compound 
anthracycline ring and Gly207, Pro
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(c)                                                                                       (d)
Figure 4-8. (a) Docked structure of compo
anthracycline ring and Arg270 and Gly
active site. 
 
                                   (a)                                                        
Figure 4-9. (a) Docked structure of compound 
anthracycline ring and Gly272, Gly268, Thr
at active site.  
 
4.2.5 Biological Activities 
These dual acting inhibitors were subjected to topoisomerase  II decatenation 
analysis to determine topoisomerase II inhibition signature of these compounds.  
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Conjugate 12b and 7 inhibited Topo II actvitiy at comparable levels to that of 
daunorubicin at the same drug concentration while 12c showed enhanced topo II 
inhibition activity relative to daunorubicin. In addition, a subset of these compounds 
potently inhibits the proliferation of representative cancer cell lines.  Josh Canzoneri and 
William Guerrant will present details of these biological experiments in their respective 
theses soon.   
 
4.3 HDAC – Topoisomerase I (TOPO I) Inhibitors 
 
Another proven anticancer target is topoisomerase I (topo I).  Topo I enzymes 
relieve the torsional strain on DNA during DNA replication by cutting one strand of the 
DNA double helix and passing one strand over the other.53,54 Due to the inherent need for 
rapid replication in cancer, inhibitors of topoisomerases result in DNA double strand 
breaks, cell cycle arrest, and apoptosis.55-59  Many small molecule inhibitors of topo I 
have proven clinically effective and are currently FDA approved for cancer 
chemotherapy.57 Since both HDAC and topo I enzymes are localized to the nucleus, the 
opportunity for dual inhibition from a single agent is a promising possibility. 
 Creating a dual-acting HDAC-Topo I inhibitor could prove beneficial for many 
reasons.  First, HDACi have been shown to act synergistically with topo I inhibitors, 
resulting in enhanced apoptosis in cancer.60,61 Also, since both enzymes are nuclear 
localized, dual-targeted agents may have better therapeutic indices. As a follow-up to our 
work on dual-acting HDAC-topo II inhibitors, we have designed and synthesized dual-
acting HDAC-Topo I inhibitors derived from the camptothecin ring system and the linker 
region of SAHA-like HDACi. We present evidence here that these compounds retain 
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inhibitory activities against both target enzymes and potently inhibit the proliferation of 
selected cancer cell lines. 
 
4.3.1 Design of HDAC-Topoisomerase I Conjugates 
We chose 10-hydroxycamptothecin and 7-ethyl-10-hydroxycamptothecin (SN-38) 
(Figure 4-10) as the topo I inhibiting templates for the design of the proposed topo I-
HDAC inhibitors due to their promising activity against a range of tumor types and the 
presence of functionalizable phenolic group at their C-10 position. Also, both inhibitors 
have demonstrated more potency and less toxicity than camptothecin. 62-64 From SAR  
 
Figure 4-10.  Representative HDAC and Topo I inhibitors. 
 
studies on camptothecins, substitution at the 10-hydroxy group has been found to be 
tolerable.65 We have already reported the suitability of the 1,2,3-triazole ring as a surface 
recognition cap group-linking moiety in SAHA-like HDAC inhibitors.66 These studies 
showed cap group-dependent preference for five- to six- methylene linkers. In the 
designed dual acting compounds, the linker region of SAHA-like HDACi is coupled 
through a triazole moiety to the camptothecin template, which in turn is anticipated to act 
as an aromatic surface recognition cap group essential for HDAC inhibition that also 
retains its topo I inhibition activity (Figure 4-11). We introduced variations into the linker 
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region to test the linker length-dependent potency of these dual inhibitors. Additionally, 
incorporation of the triazole ring into the compound design helps to simplify synthesis 
and SAR studies of these dual topo I-HDAC inhibitors.  
 




4.3.2 Synthesis of HDAC-Topoisomerase I Conjugates 
               The reaction route to all the designed compounds is shown in Figure 4-12. The 
phenolic OH-group of 10-hydroxycamptothecin and 7-ethyl-10-hydroxycamptothecin 
was alkylated with propargyl bromide to yield the alkyne intermediate 14a-b. Cu-
catalyzed Huisgen cycloaddition67 with known azido intermediates 15a-e68 afforded trityl 
protected compounds 16a-h. TFA deprotection of 16a-h yielded the desired compounds 
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Figure 4-12. Synthesis of dual acting Topoisomerase I-HDAC inhibitors. Reagents and 
conditions: (i) propargyl bromide, K2CO3, DMSO, rt, 48 h (ii) 15a-15e, CuI, 
THF:DMSO:Hunig’s base 10:1:0.1 (iii) TFA, thioanisole, CH2Cl2, 0 
oC.  
 
4.3.3 In vitro HDAC Inhibition of HDAC & Topoisomerase I Conjugates 
  Building on our previous observations about the linker length-dependent potency 
of aryltriazolyl HDACi,66,68 we first synthesized and evaluated the anti-HDAC activity of 
7-ethylcamptothecin derived compounds 17d-h against HeLa cell nuclear extract HDACs 
as described previously with slight modification.66 Camptothecin has a fluorescence 
emission close to the wavelength (460nm) of the fluorescence generated by the HDAC 
enzyme cleavage of its substrate. To circumvent this potential interference, controls 
containing the same concentration of the test compound without the enzyme were used, 
and the background fluorescence of these controls were subtracted from the experimental 
fluorescence readings. Compound 17d, an analog with three methylene spacers 
separating the triazole ring and the hydroxamate moiety, has no measurable anti-HDAC 
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activity at concentrations greater than 10 uM. The inactivity of 17d may be due to the 
fact that its linker region is too short to effectively position its hydroxamate moiety 
within the active site while maintaining the crucial surface residue contacts. Conversely, 
compounds 15e-h displayed spacer-length dependent HDAC inhibitory activities with 
compound 17g, an analog with six methylene linkers, having inhibition activities 
comparable to SAHA (Table 4-2). The anti-HDAC activities of these compounds 
followed linker length-dependence similar to what we observed for other aryltriazolyl 
HDACi.  
 To test the influence of the ethyl group at the C-7 of 7-ethylcamptothecin on 
HDAC inhibition activity, we synthesized camptothecin derived compounds 17a-c, 
analogs with four, five and six methylene linkers respectively. Our choice of this linker 
range is based on the forgoing observation that this range conferred the optimum activity 
to the 7-ethylcamptothecin derived compounds 17e-g. A comparison of the anti-HDAC 
activities of 17a-c and 17e-g, against the HeLa cell nuclear extract HDACs, reveals that 
pairs with the same linker length have nearly identical HDAC inhibition activity (Table 
4-2).  These results suggest that the presence or lack thereof of the ethyl group at the C-7 
of camptothecin ring system has no significant effect on inhibition HeLa cell nuclear 
extract HDACs. As expected, SN-38 has no measurable HDAC inhibition activity. 
 To obtain additional evidence for HDAC isoform selectivity, we tested selected 





Table 4-2. In vitro HDAC inhibition activity of novel HDAC/Topo I inhibitors. 
N.D. – Nondeterminable within tested range; 1 nM – 10 µM; NT – Not tested. 
 
4.3.4 In vitro Topo I Inhibition
a 
  Topo I inhibition was then quantified via a plasmid relaxation assay to ensure 
the dual-targeted inhibitors retained Topo I inhibition activity.69 SN-38 was used as a 
positive control for Topo I inhibition.  Compounds 17a-c inhibited Topo I function, as 
shown by both the reduction of relaxed plasmid and increase in nicked plasmid compared 
to the control, while there was a slight preference for 17b (Figure 4-13). 7-Ethyl 
compounds 17d-h also inhibited Topo I with no apparent drop in activity compared to 
SN-38 (Figure 4-13b).  This result, taken together with the HDAC inhibition result, 
showed that these dual-targeted inhibitors can function to inhibit either target enzyme in 
vitro and conjugation of the two inhibitors did not appreciably decrease activity. 
 









17a 2 -H 144.5 116+/- 40 260+/- 40 ND 
17b 3 -H 112.2 NT NT NT 
17c 4 -H 56.2 37+/-7 81+/- 26 1046+/- 316 
17d
+
 1 -CH2CH3 ND ND 85+/- 34 1726+/- 577 
17e
+ 2 -CH2CH3 155.4 NT NT NT 
17f
+
 3 -CH2CH3 120.7 129+/- 33 42+/- 6 ND 
17g
+
 4 -CH2CH3 64.65 50+/- 7 36+/- 5 ND 
17h
+
 5 -CH2CH3 212.3 369+/- 111 75+/- 34 2599+/- 475 
SN-38 - - ND NT NT NT 




















Figure 4-13 – Topoisomerase I-Induced Plasmid Relaxation Assay. (a)  (1) PBR322 Plasmid 
DNA, (2) DNA and Topo I, (3-8) DNA, Topo I, and 50 µM:  (3) SN-38, (4) 17a, (5) 17b, (6) 17c. 
(b)  (1) PBR322 Plasmid DNA, (2) DNA and Topo I, (3-8) DNA, Topo I, and 50 µM: (3) SN-38, 
(4) 17d, (5) 17e, (6) 17f, (7) 17g, (8) 17h.  


































To critically delineate the benefits of simultaneous topoisomerase and HDAC 
inhibition in cancer therapy, it will be of interest to identify agents that possess 
topoisomerase and HDAC inhibition activities within a single molecule. Toward this end, 
we have created dual-acting topoisomerase I & II/HDAC inhibitors. A subset of these 
compounds potently inhibits the proliferation of representative cancer cell lines. When 
subjected to target-specific screening, these agents present both HDAC and 
topoisomerase inhibition signatures under cell-free conditions and intracellularly. This 
observation suggests that the cytotoxic activities and potency of these dual-acting 
compounds could be dictated by either of the two anti-tumor pharmacophores.  
Overall, these compounds show promise as potent dual-targeted agents against 
cancer.  Their demonstrated ability to inhibit HDAC and topoisomerases has the potential 
to broadly arrest cancer by inhibiting essential enzymes.  Future work will undoubtedly 
lead to a better understanding of both the specific mechanism of action and the interesting 
pharmacokinetic properties observed with this bifuntional class of compounds. 
 
4.5 General Procedures and Experimental 
4.5.1 General Procedures  
Suberic acid, 4-aminobenzyl alcohol, 4-ethynylbenzyl alcohol, ω−bromoalkanoic acids, 
7-bromoheptane nitrile, propargyl bromide were purchased from Sigma–Aldrich. 10-
hydroxy camptothecin and 7-ethyl-10-hydroxycamptothecin were purchased from Shilpa 
Medicare Ltd and GreenField Chemical Inc respectively. Anhydrous solvents and other 
reagents were purchased and used without further purification. Analtech silica gel plates 
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(60 F254) were used for analytical TLC, and Analtech preparative TLC plates (UV 254, 
2000 µm) were used for purification. UV light was used to examine the spots. Silica gel 
(200–400 Mesh) was used in column chromatography. NMR spectra were recorded on a 
Varian-Gemini 400 magnetic resonance spectrometer. 1H NMR spectra were recorded in 
parts per million (ppm) relative to the peak of CDCl3, (7.24 ppm), CD3OD (3.31 ppm), or 
DMSO-d6 (2.49 ppm).  
13C spectra were recorded relative to the central peak of the 
CDCl3 triplet (77.0 ppm), CD3OD (49.0 ppm), or the DMSO-d6 septet (39.7 ppm), and 
were recorded with complete heterodecoupling.  Multiplicities are described using the 
abbreviation s, singlet; d, doublet, t, triplet; q, quartet; m, multiplet; and app, apparent. 
High-resolution mass spectra were recorded at the Georgia Institute of Technology mass 
spectrometry facility in Atlanta. HPLC analyses were performed on a Beckman Coulter 
instrument using a Phenomenex RP C-18 column (250 mm x 4.6 mm), eluting with 
solvent A (0.1% formic acid/water) and solvent B (0.1% formic acid/acetonitrile) at a 
gradient of 5-50% over 30 min, with detection at 498 nm and a flow rate of 1 mL/min. 
Sample concentrations were 250 µM, injecting 50 µL. O-Trityl-protected hydroxamates 
9a-d,66,68 4-ethynylbenzaldehyde 8,70 and suberic anhydride 271 were prepared according 









4.5.2 HDAC & Topoisomerase II Conjugates Experimental 
8-(4-(hydroxymethyl)phenylamino)-8-oxooctanoic acid (3) – 
 
To a stirring solution of suberic anhydride 2 (1.0 g, 6.40 mmol) in THF (15 mL), was 
added (4-aminophenyl)methanol 1 (0.78 g, 6.34 mmol) and resulting mixture was stirred 
at room temperature for 1 h.  Ethyl acetate was added (60 mL) followed by washing with 
water (2 x 50 mL), brine (1 x 40 mL).  Organic layer dried on Na2SO4 and solvent 
evaporated under reduced pressure to give crude compound 2 which was purified by 
column chromatography (silica, CH2Cl2:MeOH (step gradient, 0-10% methanol) to give 
0.92 g of compound 3 (52 %).  1H NMR (DMSO-d6, 400 MHz) δ 1.25-1.32 (4H, m), 
1.49-1.61 (4H, m), 2.21 (2H, t, J = 7.2 Hz), 2.29 (2H, t, J = 8.0 Hz), 4.42 (2H, s), 5.10 
(1H, s), 7.23 (2H, d, J = 8.4 Hz), 7.54 (2H, d, J = 8.8 Hz), 9.84 (1H, s), 12.0 (1H, s).  13C 
NMR (DMSO-d6, 100 MHz) δ 24.4, 25.0, 28.3, 28.4, 33.6, 36.3, 62.5, 118.5, 126.6, 
136.7, 137.7, 170.7, 174.1.  HRMS (MALDI) calcd for C15H21NO4Na [M + Na]
+ 
302.1363 found 302.1343.  
 
8-((4-formylphenyl)amino)-8-oxooctanoic acid (4)  
 
To a stirring solution of alcohol 3 (1.71 g, 6.13 mmol) in CH2Cl2, was added Dess Martin 
reagent (3.898 g, 9.19 mmol) at 0 oC.  The reaction mixture was stirred for the next 16 h 
at room temperature.  The reaction was quenched by adding an aqueous solution of 
saturated sodium bicarbonate and saturated sodium thiosulfate (1:1, 40 mL) with stirring 
for 15 min.  Methanol/CH2Cl2 1:9 (70 mL) was added after the cessation of bubbling.  
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The organic layer was isolated, washed subsequently with sodium bicarbonate-sodium 
thiosulfate mixture (1:1, 40 mL), brine (40 mL) and dried on Na2SO4.  Solvent was 
evaporated under reduced pressure and the crude product was purified by column 
chromatography using CH2Cl2: methanol (step gradient, 0-12% methanol) to give 1.10 g 
of compound 4 (65 %).  1H NMR (DMSO-d6, 400 MHz) δ 1.24-1.30 (4H, m), 1.47 (2H, 
p, J = 7.2, 15.6 Hz), 1.56 (2H, p, J = 7.2, 14.0 Hz), 2.17 (2H, t, J = 7.6 Hz), 2.33 (2H, t, J 
= 7.2 Hz), 7.77-7.83 (4H, m), 9.84 (1H, s), 10.28 (1H, s), 11.99 (1H, s).  13C NMR 
(DMSO-d6, 100 MHz) δ 24.3, 24.7, 28.3, 28.4, 33.6, 36.4, 118.6, 130.8, 131.0, 144.8, 
172.0, 174.4, 191.5.  HRMS (EI) calcd for C15H19NO4 [M + H]
+ 277.1314 found 
277.1315. 
 
N-(4-formylphenyl)-N-(trityloxy)octanediamide (5)  
 
Carboxylic acid 4 (0.30 g, 1.07 mmol) was dissolved in anhydrous THF.  N-
methylmorpholine (0.12 mL, 1.07 mmol) was added to the solution.  The reaction 
mixture was then cooled down to -15 oC and stirred for 5 min.  Isobutylchloroformate 
(0.14 mL, 1.07 mmol) was added and the mixture was stirred for 10 min at -15 oC.  O-
tritylhydroxylamine (0.29 g, 1.07 mmol) was added followed by 2 more equivalents of N-
methylmorpholine.  Stirring continued for 15 min at -15 oC and 2 h at room temperature.  
Afterwards the mixture was poured into CH2Cl2 (50 mL) and water (50 mL). Organic 
layer was separated and extracted 3 times in each case with water, sodium bicarbonate 
solution (5%) and water. After washing with brine and drying over Na2SO4, solvent was 
evaporated in vacuo.  Column chromatography with eluent system CH2Cl2-acetone (step 
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gradient, 0-12% acetone) gave 0.37 g of compound 5 (66 %) as a white solid.  1H NMR 
(DMSO-d6, 400 MHz) δ 1.10-1.21 (4H, m), 1.44-1.51 (2H, m), 1.73-1.77 (2H, m), 7.23-
7.35 (15H, m), 7.78-7.84 (4H, m), 9.84 (1H, s), 10.16 (1H, s), 10.29 (1H, s).  13C NMR 
(DMSO-d6, 100 MHz) δ 24.7, 28.3, 31.9, 36.4, 55.1, 91.5, 118.6, 127.4, 128.9, 130.9, 
142.6, 144.6, 170.4, 172.1, 191.2.  HRMS (ESI) calcd for C34H34N2O4Na [M + Na]
+ 
557.2207 found 557.2219. 
 
Daunorubicin-N-benzyl-4-amino-8-oxo-N-(trityloxy)octanediamide (6)  
A solution of daunorubicin (0.07 g, 0.12 mmol), aldehyde 5 (0.07 g, 0.12 mmol) and 
diisopropylethylamine (0.03 mL, 0.25 mmol) in DMF (2.5 mL) and MeOH (2.5 mL) was 
heated at 70 oC for 3 h and then allowed to cool to room temperature.  Sodium 
cyanoborohydride (0.03 g, 0.50 mmol) was added and stirring was continued at 70 oC for 
additional 24 h and allowed to cool at ambient temperature.  The reaction was partitioned 
between CH2Cl2 (30 mL) and 5 % NaHCO3 (25 mL).  The two layers were separated and 
the aqueous layer was extracted with CH2Cl2 (2 X 30 mL).  The combined organic layer 
was washed with water (2 X 30 mL), brine (1X 20 mL) and dried over Na2SO4.  Solvent 
was evaporated off and crude was purified on preparative TLC plates, eluting with 
mixture of CH2Cl2/MeOH (12:1) to give 0.05 g of compound 6 (38%).  
1H NMR 
(DMSO-d6, 400 MHz) δ 0.93-0.98 (3H, m), 1.04-1.21 (8H, m), 1.38-1.53 (4H, m), 1.60-
1.64 (2H, m), 1.71-1.75 (2H, m), 2.06-2.18 (4H, m), 2.24 (3H, s), 2.80-2.98 (3H, m), 3.15 
(1H, d, J = 4.4 Hz ), 3.57 (1H, s), 3.67-3.70 (1H, m), 4.05 (1H, q, J = 6.4, 12.8 Hz ), 4.91 
(1H, t, J = 4.4 Hz ), 5.21 (1H, s), 5.42 (1H, s), 7.17 (2H, d, J = 8.4 Hz), 7.25-7.34 (15H, 
m), 7.42 (2H, d, J = 8.0 Hz). 7.58-7.62 (1H, m), 7.85-7.87 (2H, m), 9.70 (1H, s), 10.12 
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(1H, s).  13C NMR (CD3OD, 100 MHz) δ 17.0, 24.7, 25.1, 25.5, 28.4, 29.6, 30.0, 30.9, 
33.1, 34.8, 37.2, 49.7, 52.5, 56.5, 66.6, 66.7, 67.9, 69.7, 100.8, 111.1, 111.3, 118.3, 119.6, 
119.8, 120.7, 127.7, 128.0, 128.6, 128.9, 134.2, 134.3, 135.3, 135.6, 137.2, 141.0, 155.7, 
156.3, 160.9, 171.5, 186.5, 186.8, 211.8.  HRMS (MALDI) calcd for C61H64N3O13 [M + 
H]+  1046.4439 found 1046.4415. 
 
Daunorubicin-N-benzyl-4-amino-8-oxooctahydroxamic Acid (7)   
 
To a solution of trityl-protected compound 6 (0.025 g, 0.024 mmol) in CH2Cl2 – MeOH 
(1:1, 4 mL) was added BF3.OEt2 (0.05 mL) at room temperature.  The reaction mixture 
stirred for 30 min at room temperature.  Reaction was quenched by addition of water (25 
mL) and 10% MeOH in CH2Cl2 (30 mL).  Aqueous layer was isolated and its pH was 
adjusted to 8-9 by addition of sat. NaHCO3.  This aqueous layer was then extracted with 
10% MeOH in CH2Cl2 (3 X 30 mL).  Combined organic layer was washed with sat. 
brine, dried over Na2SO4 and solvent was evaporated under reduced pressure.  Trituration 
of crude product with CH2Cl2 (20 mL) gave pure 0.013 g of 7 (68 %) as red solid. 
Retention time 6.46 min (Solvent Gradient: 5% - 60% solvent B over 20 min);  1H NMR 
(CD3OD, 400 MHz) δ 1.28-1.33 (9H, m), 1.50-1.60 (4H, m), 1.79-1.85 (1H, m), 1.93-
1.94 (1H, m), 2.04-2.12 (2H, m), 2.23-2.30 (3H, m), 2.34 (3H, s), 2.85-3.08 (5H, m), 
3.69-3.83 (3H, m), 3.97 (3H, s), 4.18-4.23 (1H, m), 5.04 (1H, s), 5.40 (1H, s), 7.22 (2H, 
d, J = 7.6 Hz), 7.39 (2H, d, J = 8.4), 7.47 (1H, d, J = 8 Hz), 7.74 (1H, t, J = 8 Hz), 7.82 
(1H, d, J = 7.2 Hz).  13C NMR (CDCl3 with drops of CD3OD, 100 MHz) δ 17.2, 24.7, 
26.2, 26.3, 29.5, 29.6, 30.4, 33.2, 33.5, 36.4, 37.6, 53.3, 54.4, 57.0, 67.5, 68.2, 71.1, 77.2, 
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101.7, 111.8, 112.1, 115.3, 119.8, 120.3, 121.0, 121.2, 128.3, 130.1, 135.3, 135.4, 136.0, 
136.8, 139.2, 155.9, 157.1, 162.0, 172.5, 174.1, 187.3, 187.7, 213.5.  HRMS (MALDI) 
calcd for C42H50N3O13 [M + H]
+ 804.3343 found 804.336 and calcd for [M + Na]+  
826.3163, found 826.3153. 
 
Representative Procedure for Cu(I)-catalyzed Cycloaddition Reaction. O-Trityl-4-
formylphenyltriazolylpentahydroxamate (10a)  
 
5-Azido-O-tritylpentahydroxamate 9a (0.15 g, 0.37 mmol) and 4-ethynylbenzaldehyde 8 
(0.06 g, 0.49 mmol) were dissolved in anhydrous THF (10 mL) and stirred under argon at 
room temperature.  Copper (I) iodide (9 mg, 0.05 mmol) and Hunig’s base (0.1 mL) were 
then added to the reaction mixture, and stirring continued for 24 h.  The reaction mixture 
was diluted with CH2Cl2 (30 mL) and washed with 1:4 NH4OH/saturated NH4Cl (3 X 30 
mL) and saturated NH4Cl (30 mL).  The organic layer was dried over Na2SO4 and 
concentrated in vacuo.  The crude product was purified by flash chromatography 
(CH2Cl2:Acetone, gradient 12:1, 10:1, 8:1) to give 0.16 g of 10a (82%) as a white solid.   
1H NMR (DMSO-d6, 400 MHz) δ 1.13-1.20 (2H, m), 1.49-1.56 (2H, m), 1.82 (2H, t, J = 
7.2), 4.27 (2H, t, J = 6.8 Hz), 7.24-7.28 (15H, m), 7.97 (2H, d, J = 8.8 Hz), 8.05-8.07 
(2H, d, J = 8.4 Hz), 8.68 (1H, s), 9.99 (1H, s), 10.23 (1H, s).  13C NMR (CDCl3, 100 
MHz) δ 20.0, 29.2, 30.1, 50.0, 93.4, 120.8, 125.8, 127.7, 128.0, 128.8, 130.2, 135.5, 
136.3, 140.8, 146.1, 176.2, 191.6.  HRMS (MALDI) calcd for C33H30N4O3Na [M + Na]
+ 






Reaction of 6-azido-O-tritylhexahydroxamate 9b (0.24 g, 0.58 mmol) and 4-
ethynylbenzaldehyde 8 (0.09 g, 0.69 mmol) as described for the synthesis of 10a, 
followed by purification using column chromatography (CH2Cl2:Acetone, gradient 12:1, 
10:1, 8:1) gave 0.19 g of 10b (61 %) as a white solid.  1H NMR (DMSO-d6, 400 MHz) δ 
0.92-0.99 (2H, m), 1.19-1.26 (2H, m), 1.70-1.78 (4H, m), 4.30 (2H, t, J = 6.8), 7.26-7.29 
(15H, m), 7.96 (2H, d, J = 8.0 Hz), 8.05 (2H, d, J =8.4 Hz), 8.72 (1H, s), 9.99 (1H, s), 
10.15 (1H, s).  13C NMR (CDCl3, 100 MHz) 22.2, 25.5, 29.6, 30.7, 49.9, 93.1, 120.8, 




Reaction of 7-azido-O-tritylheptahydroxamate 9c (0.30 g, 0.70 mmol) and 4-
ethynylbenzaldehyde 8 (0.09g, 0.70 mmol) as described for the synthesis of 10a, 
followed by purification using column chromatography (CH2Cl2:Acetone, gradient 12:1, 
10:1, 8:1) gave 0.25 g of 10c (65 %)  as a white solid.  1H NMR (DMSO-d6, 400 MHz) δ 
0.96-1.17 (6H, m), 1.71-1.78 (4H, m), 4.34 (2H, t, J = 7.2 Hz), 7.24-7.34 (15H, m), 7.96 
(2H, d, J = 7.6 Hz), 8.06 (2H, d, J = 8.0 Hz), 8.75 (1H, s), 9.99 (1H, s), 10.14 (1H, s).  
13C NMR (CDCl3, 100 MHz) δ 22.8, 25.8, 28.0, 29.7, 30.7, 50.1, 93.2, 120.7, 125.7, 







Reaction of 8-azido-O-trityloctahydroxamate 9d (0.25 g, 0.57 mmol) and 4-
ethynylbenzaldehyde 8 (0.07g, 0.57 mmol) as described for the synthesis of 10a, 
followed by purification using column chromatography (CH2Cl2:Acetone, gradient 12:1, 
10:1, 8:1) gave 0.19 g of 10d (59 %) as a white solid.  1H NMR (DMSO-d6, 400 MHz) δ 
0.85-0.93 (2H, m), 1.08-1.17 (6H, m), 1.72-1.80 (4H, m), 4.38 (2H, t, J = 7.2), 7.24-7.28 
(15H, m), 7.96 (2H, d, J = 7.6 Hz), 8.06 (2H, d, J = 8.0 Hz), 8.77 (1H, s), 9.99 (1H, s), 
10.13 (1H, s).  13C NMR (CDCl3, 100 MHz) δ 23.0, 26.0, 28.3, 28.5, 30.0, 30.8, 50.3, 
93.1, 120.7, 125.8, 127.9, 128.8, 130.2, 135.4, 136.3, 140.8, 141.7, 146.1, 176.9, 191.5. 
HRMS (MALDI) calcd for C36H36N4O3Na [M + Na]




A solution of daunorubicin hydrochloride (0.08 g, 0.14 mmol) and 10a (0.15 g, 0.28 
mmol) in acetonitrile (9 mL) and water (3 mL) was stirred at room temperature for 30 
min.  A suspension of sodium cyanoborohydride in THF was added within 1 min and 
stirring continued overnight at room temperature during which all of the starting material 
got consumed.  The reaction mixture was partitioned between CH2Cl2 (30 mL) and water 
(30 mL), and the two layers separated.  The aqueous layer was extracted with CH2Cl2 (30 
mL), and the combined organic layer was dried over Na2SO4.  Solvent was removed 
under reduced pressure and the crude was purified by preparative TLC, eluting with 12:1 
CH2Cl2/MeOH to give 0.065 g of 11a (44%) as red solid.  
1H NMR (DMSO-d6, 400 
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MHz) 1.23-1.27 (5H, m), 1.36 (3H, d, J = 6.4 Hz), 1.60-1.68 (5H, m), 1.76-1.83 (2H, m), 
2.10-2.15 (1H, m), 2.34-2.39 (1H, m), 2.88-2.93 (1H, m), 2.99-3.03 (1H, m), 3.21-3.26 
(1H, m), 3.64 (1H, s), 3.67-3.70 (1H, m), 3.79-3.83 (1H, m), 3.97 (1H, q, J = 6.4 Hz), 
4.06 (3H, s), 4.16-4.19 (2H, m), 4.73 (1H, s), 4.76 (1H, s), 5.30 (1H, s), 5.51 (1H, d, J = 
3.2 Hz), 7.26-7.33 (15H, m), 7.36-7.42 (3H, m), 7.64 (1H, s), 7.71 (2H, d, J = 8.0 Hz), 
7.76 (1H, t, J = 8.4 Hz), 8.01 (1H, d, J = 7.2 Hz).  13C NMR (CDCl3, 100 MHz) δ 17.4, 
20.4, 29.7, 29.9, 30.4, 34.2, 35.7, 50.2, 50.3, 52.5, 56.9, 65.7, 67.0, 67.1, 69.5, 101.0, 
111.6, 111.7, 118.6, 119.6, 120.0, 121.1, 126.0, 127.4, 128.1, 128.4, 128.7, 129.2, 129.9, 
133.8, 134.0, 135.7, 136.0, 139.6, 141.1, 155.9, 156.4, 161.3, 186.9, 187.3, 213.9. HRMS 
(ESI) calcd for C60H60N5O12 [M + H]




Reaction of daunorubicin hydrochloride (0.055 g, 0.097 mmol) with 10b (0.159 g, 0.29 
mmol) and sodium cyanoborohydride (0.018 g, 0.29 mmol) in acetonitrile-water solvent 
system, as described in the synthesis of 11a, gave 0.05 g of 11b (49%) as red solid.   1H 
NMR (DMSO-d6, 400 MHz) 1.23-1.28 (5H, m), 1.38 (3H, d, J = 6.4 Hz), 1.56-1.60 (3H, 
m), 1.66-1.85 (6H, m), 2.12-2.17 (1H, m), 2.35-2.41 (1H, m), 2.91-2.94 (1H, m), 2.99-
3.04 (1H, m), 3.23-3.28 (1H, m), 3.66-3.72 (2H, m), 3.81-3.84 (1H, m), 3.99 (1H, q, J = 
6.8 Hz), 4.07 (3H, s), 4.28 (2H, t, J = 7.6 Hz), 4.74 (1H, s), 4.78 (1H, s), 5.29-5.32 (1H, 
m), 5.53 (1H, d, J = 2.8 Hz), 7.30-7.35 (15H, m), 7.37-7.45 (3H, m), 7.67 (1H, s), 7.73-
7.80 (3H, m), 8.02 (1H, d, J = 7.2 Hz).  13C NMR (CDCl3, 100 MHz) δ 17.1, 22.5, 25.7, 
29.6, 29.8, 30.2, 30.7, 33.9, 35.4, 49.9, 50.0, 52.3, 56.6, 65.4, 66.7, 66.8, 69.3, 100.8, 
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111.3, 111.5, 118.4, 119.4, 119.8, 120.8, 125.8, 127.8, 128.1, 128.4, 128.9, 129.7, 133.5, 
133.8, 135.4, 135.7, 139.5, 141.1, 147.3, 155.6, 156.2, 161.0, 186.7, 187.0, 213.7.  
HRMS (ESI) calcd for C61H62N5O12 [M + H]




Reaction of daunorubicin hydrochloride (0.055 g, 0.097 mmol) with 10c (0.162 g, 0.29 
mmol) and sodium cyanoborohydride (0.018 g, 0.29 mmol) in acetonitrile-water solvent 
system, as described in the synthesis of 11a, gave 0.05 g of 11c (48%) as a red solid.  1H 
NMR (DMSO-d6, 400 MHz) δ 0.99-1.07 (2H, m), 1.13-1.25 (6H, m), 1.36 (3H, d, J = 6.4 
Hz), 1.52-1.57 (2H, m), 1.70-1.83 (5H, m), 2.02-2.10 (2H, m), 2.14 (1H, s), 2.33 (1H, s), 
2.85-2.88 (1H, m), 2.93 (1H, s), 2.97-3.00 (1H, s), 3.14-3.19 (1H, m), 3.67-3.70 (2H, m), 
3.80-3.83 (1H, m), 4.04 (3H, s), 4.28 (3H, t, J = 6.8 Hz), 4.66-4.69 (1H, m), 5.24 (1H, s), 
5.50 (1H, d, J = 3.2 Hz), 7.26-7.30 (15H, m), 7.34-7.43 (3H, m), 7.63 (1H, s), 7.66-7.79 
(3H, m), 7.97 (1H, d, J = 7.6 Hz).  13C NMR (CDCl3, 100 MHz) δ 17.1, 23.1, 24.8, 25.9, 
28.2, 29.7, 30.0, 30.9, 30.9, 33.2, 34.9, 49.9, 50.2, 52.3, 56.6, 66.6, 66.7, 69.9, 100.6, 
111.3, 111.5, 118.4, 119.4, 119.9, 120.9, 125.7, 127.8, 128.1, 128.4, 128.9, 129.9, 134.2, 
134.2, 135.4, 135.7, 139.5, 141.1, 147.3, 155.6, 156.2, 161.0, 186.7, 187.1, 212.0.  
HRMS (ESI) calcd for C62H64N5O12 [M + H]








Reaction of daunorubicin hydrochloride (0.055 g, 0.097 mmol) with 10d (0.166 g, 0.29 
mmol) and sodium cyanoborohydride (0.018 g, 0.29 mmol) in acetonitrile-water solvent 
system, as described in the synthesis of 11a, gave 0.048 g of 11d (46%) as a red solid.  1H 
NMR (DMSO-d6, 400 MHz) δ 0.98-1.06 (2H, m), 1.19-1.24 (8H, m), 1.37 (3H, d, J = 6.4 
Hz), 1.53-1.58 (2H, m), 1.69-1.85 (5H, m), 2.07-2.10 (2H, m), 2.35 (1H, s), 2.88-2.92 
(1H, m), 2.96-2.99 (1H, m), 3.15-3.20 (1H, m), 3.67-3.70 (2H, m), 3.79-3.83 (1H, m), 
4.05 (3H, s), 4.31 (3H, t, J = 6.8 Hz), 4.68 (1H, s), 5.25 (1H, s), 5.50 (1H, s), 7.27-7.31 
(15H, m), 7.35-7.47 (3H, m), 7.66 (1H, s), 7.69-7.77 (3H, m), 7.98 (1H, d, J = 7.6 Hz).  
13C NMR (CDCl3, 100 MHz) δ 17.0, 23.1, 24.8, 26.1, 28.5, 29.6, 30.1, 30.2, 31.0, 33.2, 
34.8, 50.0, 50.2, 52.5, 56.6, 66.5, 66.7, 69.8, 100.9, 111.1, 111.2, 118.3, 119.2, 119.7, 
120.7, 125.7, 127.8, 128.0, 128.4, 128.9, 129.6, 134.2, 134.3, 135.4, 135.6, 139.5, 141.0, 
147.3, 155.7, 156.3, 160.9, 186.5, 186.8, 211.8.  HRMS (ESI) calcd for C63H66N5O12 [M 
+ H]+ 1084.4702 found 1084.4657. 
 
Daunorubicin-N-benzyl-4-triazolylpentahydroxamic Acid (12a) 
 
Reaction of 11a (0.05 g, 0.048 mmol) and BF3:OEt2 (0.1 mL in CH2Cl2/MeOH (4 mL/4 
mL) within 2 h, as described for the synthesis of 7, followed by preparative TLC (eluent, 
CH2Cl2/MeOH 7:1) to give 0.028 g of 12a (73%) as red solid. Retention time 15.06 min 
(Solvent Gradient: 0% - 100% solvent B over 30 min); 1H NMR (DMSO-d6, 400 MHz) δ 
1.11-1.21 (7H, m), 1.42-1.50 (4H, m), 1.74-1.80 (2H, m), 1.96 (2H, t, J = 7.6 Hz), 2.06-
2.22 (5H, m), 2.84-2.97 (3H, m), 3.63-3.80 (1H, m), 3.96 (3H, s), 4.07-4.09 (1H, m), 4.33 
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(2H, t, J = 6.8 Hz), 4.91 (1H, m), 5.22 (1H, s). 5.47 (1H, s), 7.37 (2H, d, J = 8.0 Hz), 
7.61-7.63 (1H, m), 7.69-7.71 (2H, d, J = 8.0 Hz), 7.87-7.92 (2H, m), 8.46 (1H, s), 10.37 
(1H, s).  13C NMR (CDCl3 with drops of CD3OD, 125 MHz) δ 15.1, 22.5, 24.1, 24.2, 
27.3, 27.4, 28.3, 31.0, 31.3, 34.2, 35.4, 51.1, 52.2, 54.8, 65.4, 66.1, 68.9, 75.1 99.5, 109.7, 
109.9, 113.1, 117.6, 118.2, 118.8, 119.0, 126.3, 127.9, 133.1, 133.2, 133.8, 134.7, 137.0, 
153.7, 154.9, 159.8, 170.4, 172.0, 185.1, 185.5, 211.1.  HRMS (ESI) calcd for 
C41H46N5O12 [M + H]
+ 800.3137 found 800.3088. 
 
Daunorubicin-N-benzyl-4-triazolylhexahydroxamic Acid (12b) 
 
Reaction of 11b (0.05 g, 0.047 mmol) and BF3:OEt2 (0.1 mL) in CH2Cl2/MeOH (4 mL/4 
mL) within 2 h, as described for the synthesis of 7, followed by preparative TLC (eluent, 
CH2Cl2/MeOH 7:1) gave 0.028 g of 12b (76%) as red solid. Retention time 15.20 min 
(Solvent Gradient: 0% - 100% solvent B over 30 min); 1H NMR (CDCl3+CD3OD, 400 
MHz) δ 0.74-0.84 (2H, m), 1.25-1.31 (7H, m), 1.54-1.62 (3H, m), 1.72-1.73 (2H, m), 
1.83-1.93 (2H, m), 1.99 (1H, t, J = 7.6 Hz), 2.03-2.08 (1H, m), 2.19-2.33 (2H, m), 3.57-
3.60 (5H, m), 3.68-3.73 (2H, m), 4.00 (3H, s), 4.30 (2H, q, J = 7.2 Hz), 4.65-4.66 (1H, 
m), 5.22-5.23 (1H, m), 5.44 (1H, s), 7.24-7.25 (1H, m), 7.34 (2H, d, J = 8.4 Hz), 1.61-
1.65 (2H, m), 7.70-7.72 (1H, m), 7.74-7.75 (1H, m), 7.95 (1H, d, J = 7.6 Hz).  13C NMR 
(CDCl3 with drops of CD3OD, 100 MHz) δ 16.8, 22.5, 24.3, 25.4, 29.5, 30.7, 32.2, 33.6, 
35.3, 50.0, 50.1, 51.9, 56.5, 65.0, 67.0, 67.2, 69.0, 100.6, 111.3, 111.4, 118.4, 119.7, 
119.9, 125.7, 127.8, 128.6, 129.1, 133.7, 133.8, 135.3, 135.7, 147.3, 160.9, 170.2, 186.7, 
187.1, 213.5.  HRMS (ESI) calcd for C42H48N5O12 [M + H]
+ 814.3294 found 814.3323. 
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Daunorubicin-N-benzyl-4-triazolylheptahydroxamic Acid (12c) 
 
Reaction of 11c (0.05 g, 0.047 mmol) and BF3:OEt2 (0.1 mL) in CH2Cl2/MeOH (4 mL/4 
mL) within 2 h, as described for the synthesis of 7, followed by preparative TLC (eluent, 
CH2Cl2/MeOH 7:1) gave 0.030 g of 12c (78%) as red solid. Retention time 16.98 min 
(Solvent Gradient: 5% - 60% solvent B over 20 min); 1H NMR (DMSO-d6, 400 MHz) δ 
1.17-1.26 (8H, m), 1.37-1.49 (3H, m), 1.70-1.83 (5H, m), 1.89-1.92 (1H, m), 1.99 (1H, t, 
J = 7.2 Hz), 2.09-2.23 (5H, m), 2.83-2.99 (4H, m), 3.63-3.84 (2H, m), 3.92-3.96 (3H, m), 
4.08 (1H, t, J = 6.8 Hz), 4.31 (2H, t, J = 6.8 Hz), 4.93-4.96 (1H, m), 5.25 (1H, s). 5.34 
(1H, s), 7.36 (2H, d, J = 8.0 Hz), 7.53-7.60 (1H, m), 7.70 (2H, d, J = 8.0 Hz), 7.79-7.80 
(1H, m), 7.85-7.86 (1H, m), 8.41 (1H, s), 10.21 (1H, s).  13C NMR (DMSO-d6, 100 MHz) 
δ 17.7, 24.6, 25.5, 25.8, 26.1, 26.2, 27.2, 28.4, 28.6, 28.6, 30.1, 32.4, 32.8, 37.0, 50.1, 
57.3, 67.4, 70.7, 76.1, 101.2, 111.5, 119.8, 120.6, 120.9, 121.8, 125.6, 128.6, 129.0, 
129.5, 135.6, 136.4, 136.9, 146.8, 155.2, 155.9, 161.7, 186.8, 212.0.  HRMS (ESI) calcd 
for C43H50N5O12 [M + H]
+ 828.3450 found 828.3407. 
 
Daunorubicin-N-benzyl-4-triazolyloctahydroxamic Acid (12d)  
Reaction of 11d (0.05 g, 0.046 mmol) and BF3:OEt2 (0.1 mL) in CH2Cl2/MeOH (4 mL/4 
mL) within 2 h, as described for the synthesis of 7, followed by preparative TLC (eluent, 
CH2Cl2/MeOH 7:1) gave 0.028 g of 12d (73%)  as red solid. Retention time 16.93 min 
(Solvent Gradient: 5% - 60% solvent B over 20 min); 1H NMR (DMSO-d6, 400 MHz) δ 
1.15-1.20 (8H, m), 1.41-1.44 (2H, m), 1.64-1.67 (2H, m), 1.77-1.80 (2H, m), 1.88 (2H, t, 
J = 7.6), 1.95-1.20 (2H, m), 2.23-2.24 (3H, m), 2.80-2.94 (3H, m), 3.60-3.67 (2H, m), 
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3.76-3.79 (1H, m), 3.89-3.94 (3H, m), 4.05-4.10 (1H, m), 4.30 (2H, t, J = 7.2), 4.88-4.91 
(1H, m), 5.21 (1H, m), 5.42 (1H, s), 7.33-7.35 (2H, m), 7.57-7.59 (1H, m), 7.65-7.73 (2H, 
m), 7.83-7.86 (2H, m), 8.44 (1H, s), 10.29 (1H, m). 13C NMR (DMSO-d6,, 125 MHz) δ 
17.2, 24.0, 24.8, 25.5, 27.9, 29.4, 30.8, 31.5, 32.1, 36.2, 48.4, 49.3, 51.8, 54.8, 56.5, 66.8, 
70.0, 75.1, 75.2, 100.6, 110.5, 110.6, 118.8, 119.5, 119.9, 120.8, 124.9, 128.3, 129.1, 
134.4, 134.6, 135.5, 136.1, 146.2, 154.1, 155.8, 160.6, 169.0, 186.3, 211.5. HRMS (ESI) 
calcd for C44H50N5O12 [M + H]
+ 842.3607 found 842.3626. 
 
4.5.3 HDAC & Topoisomerase I Conjugates Experimental 
Representative procedures for O-alkylation reactions. 
10-(Prop-2-ynyloxy) camptothecin (14a) – 
 
To a stirring solution of 1a (1.00 g, 2.75 mmol), K2CO3 (0.61 g, 4.4 mmol) in DMSO (15 
mL), propargyl bromide (0.51 g, 3.44 mmol) was added dropwise. Reaction mixture was 
stirred for 24 h at room temperature and then diluted with 10 % MeOH in CH2Cl2 (80 
mL). The resulting suspension was filtered and the residue was washed with 10 % MeOH 
in CH2Cl2 (~ 20 mL). The filtrate was washed sat. K2CO3 (2 x 50 mL), sat. brine (1 x  40 
mL) and dried on Na2SO4. Solvent was evaporated off to 1/10
th of volume. 
Hexane:EtOAc (1:1 ratio, 60 mL) was added to reaction mixture. Suspension was filtered 
and washed again with hexane:EtOAc (1:1 ratio, 40 mL) to give pure pale yellow solid 2 
(0.75 g, 68%). 1H NMR (DMSO-d6, 400 MHz) δ 0.87 (3H, t, J = 7.2 Hz), 1.78-1.92 (2H, 
m), 3.65 (1H, s), 4.96-4.99 (2H, m), 5.17 (2H, s), 5.39 (2H, s), 6.50 (1H, s), 7.22 (1H, s), 
7.44-7.55 (2H, m), 8.01 (1H, d, J = 9.2 Hz), 8.46 (1H, s); 13C NMR (DMSO-d6, 100 
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MHz) δ 7.79, 30.2, 50.1, 55.9, 65.2, 93.9, 96.1, 107.6, 118.4, 122.8, 128.9, 130.0, 130.5, 
144.0, 145.5, 150.0, 155.8, 156.7, 172.5. HRMS (FAB, mnba) calcd for [C23H18N2O5 + 
H]+ 403.1294, found 403.1289. 
 
7-ethyl-10-(Prop-2-ynyloxy) camptothecin (14b) – 
 
Reaction of 1b (1.00 g, 2.55 mmol) with propargyl bromide (0.36 mL, 3.21 mmol) within 
24 h as described for synthesis of 2a gave 0.84 g (77%) of product as white brown solid.  
1H NMR (DMSO-d6, 400 MHz) δ 0.86 (3H, t, J = 7.2 Hz), 1.30 (3H, t, J = 7.6 Hz), 1.79-
1.90 (2H, m), 3.15 (2H, q, J = 7.6 Hz), 3.65 (1H, t, J = 2.4 Hz), 5.03 (2H, d, J = 2.8 Hz), 
5.25 (2H, s), 5.40 (2H, s), 6.50 (1H, s), 7.24 (1H, s), 7.48-7.51 (1H, dd, J = 2.4, 9.2 Hz), 
7.57 (1H, d, J = 2.8 Hz), 8.06 (1H, d, J = 9.2 Hz). 13C NMR (DMSO-d6, 100 MHz) δ 7.8, 
13.5, 22.3, 30.2, 49.4, 55.9, 65.2, 72.3, 78.7, 95.9, 103.8, 118.1, 122.0, 127.3, 128.1, 
131.2, 143.6, 144.2, 145.9, 149.5, 149.7, 155.5, 156.5, 172.2.  
 
Experimental procedure for 5-azido-O-tritylpentahydroxamate (15a) – 
5-azidopentanoic acid – 
 
To a stirred solution of 5-bromo pentanoic acid (5.00 g, 27.6 mmol) in DMF (20 mL) was 
added sodium azide (5.74 g, 88.4 mmol), and the reaction mixture was heated at 85 oC 
overnight. The reaction mixture was diluted with CH2Cl2, and was washed with 0.1 N aq. 
HCl. The organic layer was dried over anhydrous Na2SO4, filtered, and concentrated 
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under reduced pressure to give 5-azido pentanoic acid (3.10 g, 79%) as colorless oil, 
which was used without further purification.  
 
5-azido-O-tritylpentahydroxamate (15a) – 
5-azidopentanoic acid (1.10 g, 7.69 mmol) was dissolved in anhydrous THF. N-
methylmorpholine (0.84 mL, 7.69 mmol) was added to the solution. The reaction mixture 
was then cooled down to -15 oC and stirred for 5 min. Isobutylchloroformate (1.00, 7.69 
mmol) was added and the mixture was stirred for 10 min at -15 oC. O-
tritylhydroxylamine (2.11 g, 7.69 mmol) was added followed by 2 more equivalents of N-
methylmorpholine. Stirring continued for 15 min at -15 oC and 2 h at room temperature. 
Afterwards the mixture was poured into 2M HCl and extracted 3 times in each case with 
water, sodium bicarbonate solution (5%) and water. After washing with brine and drying 
over Na2SO4, solvent was evaporated in vacuo to yield compound 15a (2.78 g, 90%) as a 
white solid with no further purification required. 1H NMR (DMSO-d6, 400 MHz) δ 1.17-
1.25 (4H, m), 1.79 (2H, t, J = 5.8 Hz), 3.15 (2H, t, J = 6.1 Hz), 7.27-7.31 (15H, m), 10.22 
(1H, s); 13C NMR (CDCl3, 100 MHz) δ 20.1, 27.7, 30.1, 50.6, 93.0, 127.8, 128.6, 140.6, 
176.0.  
 
Representative Procedure for Cu(I)-catalyzed Cycloaddition Reaction. O-trityl-10-
hydroxycamptothecintriazolylpentahydroxamate (16a). 
 
5-Azido-O-tritylpentahydroxamate 15a (0.116 g, 0.29 mmol) and 10-(Prop-2-ynyloxy) 
camptothecin (14a) (0.09 g, 0.22 mmol) were dissolved in anhydrous THF:DMSO(10:1 
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mL) and stirred under argon at room temperature. Copper iodide (0.009 g, 0.048 mmol) 
and Hunig’s base (0.1 mL) were then added to the reaction mixture, and stirring 
continued for 24 h. The reaction mixture was diluted with CH2Cl2 (30 mL) and washed 
with 1:4 NH4OH/saturated NH4Cl (3 x 30 mL) and saturated NH4Cl (30 mL). The 
organic layer was dried over Na2SO4 and concentrated in vacuo. The crude product was 
purified by preparative TLC (silica, 14:1 CH2Cl2:MeOH) to give 0.131 g (73 %) of 16a 
as a pale yellow solid. 1H NMR (DMSO-d6, 400 MHz) δ 0.86 (3H, t, J = 7.2 Hz), 1.12-
1.19 (2H, m), 1.48 (2H, p, J = 7.6 Hz), 1.80-1.90 (4H, m), 4.23 (2H, t, J = 7.2 Hz), 5.26 
(2H, s), 5.33 (2H, s), 5.41 (2H, s), 6.51 (1H, s), 7.26-7.29 (15H, m), 7.52 (1H, dd, J = 2.8, 
8.8 Hz), 7.71 (1H, d, J = 2.4 Hz), 8.07 (1H, d, J = 9.2 Hz), 8.23 (1H, s), 8.54 (1H, s), 
10.24 (1H, s); 13C NMR (CDCl3, 100 MHz) δ 7.80, 20.1, 29.4, 30.3, 31.5, 50.0, 62.3, 
66.3, 72.7, 77.1, 97.4, 106.7, 118.0, 122.8, 123.7, 128.1, 128.9, 129.0, 129.3, 129.6, 
131.2, 140.8, 145.1, 146.6, 150.1, 150.3, 157.4, 157.6, 173.9. HRMS (ESI) calcd for 
[C47H42N6O7 + H]
+ 803.3187, found 803.3227. 
 
O-trityl-10-hydroxycamptothecintriazolylhexahydroxamate (16b) – 
 
Reaction of 6-Azido-O-tritylhexahydroxamate 15b (0.120 g, 0.29 mmol) and 10-(Prop-2-
ynyloxy) camptothecin (14a) (0.09 g, 0.22 mmol) within 24 h as described for synthesis 
of 16a, followed by preparative TLC (silica, eluent 19:1 CH2Cl2:MeOH) gave 0.131g (72 
%) of compound 16b as pale yellow solid. 1H NMR (DMSO-d6, 400 MHz) δ 0.86 (3H, t, 
J = 7.2 Hz), 0.92-0.96 (2H, m), 1.18-1.23 (2H, m), 1.65-1.69 (2H, m), 1.75 (2H, t, J = 
7.2 Hz), 1.80-1.90 (2H, m), 4.26 (2H, t, J = 7.2 Hz), 5.25 (2H, s), 5.31 (2H, s), 5.41 (2H, 
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s), 6.51 (1H, s), 7.27-7.30 (15H, m), 7.51 (1H, dd, J = 2.8, 9.2 Hz), 7.70 (1H, d, J = 2.8 
Hz), 8.06 (2H, d, J = 9.2 Hz), 8.28 (1H, s), 8.53 (1H, s), 10.17 (1H, s); 13C NMR (CDCl3, 
100 MHz) δ 7.79, 22.4, 25.7, 29.8, 31.5, 40.9, 50.0, 62.2, 66.2, 72.7, 77.1, 97.4, 106.6, 
118.0, 122.9, 123.5, 128.1, 128.9, 129.0, 129.2, 129.6, 131.1, 140.9, 143.1, 144.9, 146.4, 
150.1, 150.2, 157.3, 157.5, 173.8. HRMS (ESI) calcd for [C48H44N6O7 + H]
+ 817.3344, 
found 817.3415.  
 
O-trityl-10-hydroxycamptothecintriazolylheptahydroxamate (16c) – 
 
Reaction of 7-Azido-O-tritylheptahydroxamate 15c (0.124 g, 0.29 mmol) and 10-(Prop-2-
ynyloxy) camptothecin (14a) (0.09 g, 0.22 mmol) within 24 h as described for synthesis 
of 16a, followed by preparative TLC (silica, eluent 19:1 CH2Cl2:MeOH) gave 0.143 g 
(77 %) of compound 16c as pale yellow solid. 1H NMR (DMSO-d6, 400 MHz) δ 0.86 
(3H, t, J = 7.2 Hz), 0.92-0.98 (2H, m), 1.03-1.16 (4H, m), 1.66-1.76 (4H, m), 1.81-1.88 
(2H, m), 4.31 (2H, t, J = 6.8 Hz), 5.26 (2H, s), 5.32 (2H, s), 5.41 (2H, s), 7.28-7.30 (15H, 
m), 7.52 (1H, dd, J = 2.8, 9.6 Hz), 7.71 (1H, d, J = 2.4 Hz), 8.06 (1H, d, J = 9.2 Hz), 
8.30 (1H, s), 8.53 (1H, s); 13C NMR (CDCl3, 100 MHz) δ 8.06, 30.1, 31.8, 41.1, 50.2, 
50.5, 62.5, 66.5, 73.0, 77.4, 97.7, 107.0, 118.3, 123.0, 123.9, 128.3, 129.2, 129.3, 129.5, 
129.8, 131.4, 143.4, 145.2, 146.7, 150.4, 157.6, 157.8, 174.1. HRMS (ESI) calcd for 
[C49H46N6O7 + H]
+ 831.3500, found 831.3567. 
 





5-(10-hydroxycamptothecin)triazolylpentahydroxamic acid (17a). 
To a solution of O-trityl-10-hydroxycamptothecintriazolylpentahydroxamate 16a (0.09 g, 
0.11 mmol) in CH2Cl2 (7 ml) was added trifluoroacetic acid (TFA) (0.2 mL) and 
thioanisole (0.2 mL) dropwise at 0 oC. After 2 h stirring at 0 oC, solvent was evaporated 
and thick brown-black liquid was treated with Et2O (~15 mL) to give yellowish 
suspension.  Suspension was filtered and residue was washed with cold Et2O (~30 mL) 
then with CH2Cl2:Et2O (1:1) mixture (~30 mL), followed by more washing with CH2Cl2 
(~100 mL) to give 0.042 g (67%) of pure 17a as a yellow solid.  1H NMR (DMSO-d6, 
400 MHz) δ 0.86 (3H, t, J = 7.6 Hz), 1.43-1.49 (2H, m), 1.75-1.88 (4H, m), 1.97 (2H, t, J 
= 6.8 Hz), 4.37 (2H, t, J = 7.2 Hz), 5.27 (2H, s), 5.32 (2H, s), 5.41 (2H, s), 7.27 (1H, s), 
7.53 (1H, d, J = 9.2 Hz), 7.71 (1H, s), 8.07 (1H, d, J = 9.2 Hz), 8.31 (1H, s), 8.54 (1H, s), 
10.37 (1H, s); 13C NMR (DMSO-d6, 100 MHz) δ 7.78, 22.1, 29.3, 30.2, 30.7, 31.5, 49.1, 
50.2, 61.6, 65.2, 72.4, 96.1, 107.4, 118.4, 123.1, 124.7, 129.2, 130.2, 130.5, 142.0, 144.0, 
145.7, 150.0, 150.2, 156.8, 168.7, 172.5. HRMS (ESI) calcd for [C28H28N6O7 + H]
+ 
561.2092, found 561.2123. 
 
6-(10-hydroxycamptothecin)triazolylhexahydroxamic acid (17b). 
 
Reaction of O-trityl-10-hydroxycamptothecintriazolylhexahydroxamate 16b (0.075 g, 
0.09 mmol) with TFA (0.2 ml) and thioanisole (0.2 ml) in CH2Cl2 (7 ml) at 0 
oC within 2 
h as described for the synthesis of 17a, gave 0.036 g (68 %) of 17b as a yellow solid. 1H 
NMR (DMSO-d6, 400 MHz) δ 0.86 (3H, t, J = 7.2 Hz), 1.07 (2H, t, J = 7.2 Hz), 1.17-
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1.24 (2H, m), 1.46-1.53 (2H, m), 1.78-1.93 (4H, m), 4.36 (2H, t, J = 7.2 Hz), 5.25 (2H, 
s), 5.32 (2H, s), 5.41 (2H, s), 7.27 (1H, s), 7.52 (1H, d, J = 8.8 Hz), 7.70 (1H, s), 8.06 
(1H, d, J = 9.2 Hz), 8.32 (1H, s), 8.53 (1H, s), 10.33 (1H, s); 13C NMR (DMSO-d6, 100 
MHz) δ 7.7, 24.4, 25.3, 29.3, 30.1, 31.9, 49.2, 50.1, 61.5, 65.1, 72.3, 96.0, 107.3, 118.3, 
123.0, 124.5, 128.8, 129.2, 130.0, 130.2, 130.4, 142.0, 143.9, 145.6, 149.9, 150.2, 156.7, 
168.8, 172.4. HRMS (EI) calcd for [C29H30N6O7 + H]
+ 575.2254, found 575.2216. 
 
7-(10-hydroxycamptothecin)triazolylheptahydroxamic acid (17c). 
Reaction of O-trityl-10-hydroxycamptothecintriazolylheptahydroxamate 16c (0.09 g, 
0.108 mmol) with TFA (0.2 ml) and thioanisole (0.2 ml) in CH2Cl2 (7 ml) at 0 
oC within 
2 h as described for the synthesis of 17a, gave 0.041 g (65 %) of 17c as a yellow solid. 1H 
NMR (DMSO-d6, 400 MHz) δ 0.85 (3H, t, J = 7.2 Hz), 1.18-1.26 (4H, m), 1.39-1.47 
(2H, m), 1.77-1.91 (6H, m), 4.34 (2H, t, J = 6.8 Hz), 5.20 (2H, s), 5.29 (2H, s), 5.39 (2H, 
s), 7.24 (1H, s), 7.47 (1H, d, J = 8.8 Hz), 7.65 (1H, s), 8.02 (1H, d, J = 9.2 Hz), 8.30 (1H, 
s), 8.49 (1H, s), 10.33 (1H, s);  13C NMR (DMSO-d6, 100 MHz) δ 7.7, 24.9, 25.5, 27.9, 
29.6, 30.2, 32.1, 49.4, 50.2, 61.6, 65.2, 72.4, 96.1, 107.4, 118.4, 123.1, 124.6, 129.2, 
130.0, 130.2, 130.5, 142.1, 144.0, 145.6, 150.0, 150.2, 156.8, 172.5. HRMS (ESI) calcd 
for [C30H32N6O7 + H]
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IDENTIFICATION OF NOVEL ZINC BINDING GROUP (ZBG) 
FOR HDAC INHIBITION 
5.1 Introduction 
Effect of global acetylation of histones and non histone proteins by HDAC 
inhibitors is so vast and complex that inhibiting multiple isoforms of HDAC can 
undermine their use in treating disease conditions due to deleterious side effects.1-10 
Therefore, significant efforts are directed towards developing isoform selective inhibitors 
to understand the roles of the eighteen HDAC isoforms. These HDAC isoforms are 
implicated in cell cycle regulation, cell proliferation, development of human diseases 
including cancer, cardiovascular diseases, neurological diseases, inflammatory, and 
parasitic conditions.11 Research over the years has developed our understanding of 
relationship between each HDAC isoform and their role in specific disease condition. For 
example, HDAC 1, 6, and 8 are crucial for breast cancer; HDAC 1-3 are overexpressed in 
ovarian; HDAC 1 and 3 are implicated in lung cancers, HDAC 2 is associated with 
gastric cancer; there is possible correlation between HDAC8 and acute myeloid leukemia 
(AML).12-16 Despite this progress, exact cellular function of HDAC isoforms are still not 






Figure 5-1. Prototypical HDACi – SAHA fits into classical pharmacophoric model of 
HDACi 
 
The classical pharmacophoric model of HDAC inhibitor consists of zinc binding 
group (ZBG) which interacts at active site of enzyme. Linker region and surface 
recognition cap group provides support for placing zinc binding group at appropriate 
position for optimum chelation with zinc metal ion (Figure 5-1).17 Earlier chapter focused 
on SAR studies of surface recognition cap group, cap linking moiety and optimization of 
linker region for effective HDACi design to generate more potent HDACi. In this 
chapter, emphasis will be on development of novel ZBG for HDAC inhibition.   
ZBG is crucial for binding to catalytic zinc active site thereby rendering HDAC 
enzymes inactive.18 Hydroxamic acid has been widely used in the literature as a ZBG of 
choice owing to its strong chelation to Zn2+ metal ion.19-20 Despite strong Zn2+ metal ion 
chelation, hydroxamic acid presents metabolic and pharmacokinetic issues such as 
glucuronidation, sulfation, and enzymatic hydrolysis.21 For example, hydroxamic acid 
can readily hydrolyze into carboxylic acid in vivo, therefore the in vivo activities doesn’t 
compare to in vitro potencies. In addition, most of the hydroxamates have poor 
bioavailability.21 Furthermore, hydroxamic acids have binding affinities for other 
biological relevant metals such as iron (III), copper (II) that are similar or exceed those 
measured for Zn2+ ion.22 Extensive reports have been published to improve the HDAC 
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inhibition profile by manipulating the surface recognition cap group and linker region 
while keeping hydroxamic acid as ZBG intact. Indeed, many of these efforts have 
resulted in compounds showing nanomolar or even subnanomolar activities in vitro.23-24 
In some cases, isoform-selectivity was achieved.24 However, significantly fewer efforts 
have focused on replacement of hydroxamic acids as ZBG to gain isoform selectivity.17,25 
Many of the HDAC inhibitors which contain hydroxamates as ZBG show pan-inhibition 
of HDAC isoforms. For example, SAHA and TSA which have hydroxamic acid as ZBG 
are generally pan-inhibitiors.26 However, when hydroxamic acid moiety of SAHA was 
replaced with benzamide zinc binding group class I selectivity was seen.27 Moreover, 
benzamide based HDACi MS-275 displayed class I selectivity with at least 135-fold 
HDAC1 preference over HDAC1 vs HDAC6 and HDAC8.28 It has been suggested that 
benzamide may take advantage of sequence difference in the region adjacent to the 
catalytic zinc ion by positioning itself favorably within 14 Å internal cavity. 28 In lieu of 
liabilities seen in hydroxamate based compounds and to expand library of potential ZBG, 
we started exploring other functional groups that can serve as effective ZBGs in HDACi 
design. 
Cohen et al have reported novel heterocyclic zinc binding fragments (Figure 5-2), 
which are more potent and selective than acetohydroxamic acid (AHA) tested against 
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Figure 5-2. Heterocyclic aromatic ZBGs29a 
 
Monodentate ZBGs (Figure 5-3) generally exhibit weaker binding affinity for 
Zn2+ ion and therefore, are less likely to be effective chelators than hydroxamic acid. 
Several bindentate ZBGs containing heterocyclic aromatic fragments such as 
hydroxypyrones, hydroxypyridinones and their thione derivatives were shown to be more 
potent inhibitors of MMPs than corresponding hydroxamic acid fragment 
(acetohydroxamic acid).30 
 
                                
 
      Thiols          Carboxylic acid    Phosphonic Acid     Thiadiazole        Sulfodiimine     Thiadiazine  
 
Figure 5-3. Monodentate ZBGs29a 
 
 
However, these ZBGs showed relatively low toxicities against MMPs in cell studies.30 
The thione derivatives such as thiopyrones and hydroxypyridinethiones exhibited 
significant increase in potency likely due to apparent thiophilicity of these chelators to 
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Zn2+ ion.31 Therefore we decided to test feasibility of these heterocyclic aromatic ZBG 
for incorporation into HDACi design. 
 
5.2 Fragment-based Approach for Identification of Novel ZBG  
 Fragment based lead design (FBLD) is relatively new concept for designing small 
molecule inhibitors. It employs relatively small fragment library for screening against 
target protein to identify lead fragments.32.33 Knowledge of exactly how the fragments 
bind to the protein target allows the hits to be optimized by growing the fragments or by 
combining and linking different fragments. FBLD offers two unique advantages over 
traditional high throughput screening – First, smaller fragments explore chemical space 
more effectively and hence more likely to generate novel compounds. Secondly, the small 
size of the fragments (usually less than 250 Daltons) makes optimization relatively easier 
by decreasing the synthetic efforts since only the selected fragments need to be assembled 
and tested with the target protein(s).32-35 
Several studies have shown successful implementation FBLD for the 
development of novel inhibitors of zinc metalloenzymes.29a,30a,36 However, these 
approaches used either X-ray crystallography or NMR-based screening for evaluation of 
fragment screening. These methods typically require large quantities of protein and time-
consuming data analysis, and therefore may not be necessary for ZBG fragment 
screening.32,34,36 Recently, Li and coworkers successfully employed multiple ligand 
simultaneous docking to screen fragments to generate novel STAT3 inhibitor with 
improved potency and ADMET profiles.37 We have explored a standard molecular 
docking approach and in vitro screening to test fragments against HDAC isoforms. We 
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have focused on pyridinone and their thione analogs as potential ZBG in HDACi design. 
In addition to their superior IC50 values compared to acetohydroxamic acid fragments, 
pyridinones were chosen for this study because – i) these fragments are monoanionic 
ligands that are expected to bind the zinc ion in a bindentate fashion similar to 
hydroxamic acid; ii) their proven biocompatibility in biological systems;29 iii) ubiquity of 
synthetic procedures for pyridinones36,38,54 modifications that will enable easy 
incorporation into HDACi design. A fragment based approach coupled with structure-
based drug design as described here is expected to provide novel and selective HDAC 
inhibitors. 
 
5.3 Design of 1
st
 Generation Novel ZBG in HDACi Design  
 
In order to test the feasibility of pyridinone fragments in HDACi design, 
fragments were docked against HDAC crystal structures using validated molecular dock 
program (AutoDock 4.2) as previously described.39 We selected representative 
pyridinone fragments 3-hydroxypyridin-2-thiones; 3-hydroxypyridin-4-thiones and 1-
hydroxypyridin-2-thione to dock against HDAC macromolecules. We postulated that N-1 
position of 3-hydroxypyridin-2-thiones & 3-hydroxypyridin-4-thiones can be modified to 
include prototypical HDACi linker region coupled to surface recognition cap group. 
Small fragments tend to have lower binding energy and non-specific interaction at the 
surface. These problems were addressed by – i) selecting compact grid size around the 
Zn2+ active site. ii) Selecting thione analogs of pyridinone fragments which is expcted to 
bind more tightly with Zn2+ metal ion than their carbonyl counterpart thereby improving 





                             
         a                                  b                                c 
 i)                                ii)                                 iii) 
Figure 5-4. Docked fragments a) 3-hydroxy pyridin-2-thiones (3-HPT) a; b) 3-hydroxypyridin-4-
thiones b; c) 1-hydroxypyridin-2-thione c. 
 
We chose to dock these fragments against class I HDAC enzymes HDAC1 and 
HDAC8. Both the isoforms are phylogenetically similar9 yet there are distinct structural 
differences at the Zn2+ active site. Any evidence of isoform selectivity against any one of 
them should establish broader isoform profile. Docking analyses were performed on a 
HDAC 1 homology model built from human HDAC 2 X-ray structure 3MAX 
coordinates,40 while HDAC8 crystal structure (PDB code: 1VKG)41 has been solved and 
was used to obtain in silico data for fragment interaction at active sites. Preliminary 
docking analysis against HDAC1 and HDAC8 revealed that 3-hydroxypyridin-2-thiones 
(3-HPT) (a), 3-hydroxypyridin-4-thiones (b) and 1-hydroxypyridin-2-thione (c) bound to 
vicinity of Zn2+ ion at active sites of HDAC1 and HDAC8, confirming our hypothesis 
that pyridinones can very well be tolerated in HDACi design. 
 Closer analyses of docked structure revealed that the orientation of N-1 position 
of 3-hydroxypyridin-4-thione is pointing towards the base of  the active site pocket 
instead of pointing toward surface as seen with 3-HPT (Figure 5-5 and Figure 5-6; 
comparing b and c). Although, 1-hydroxypyridin-2-thione bound very well in vicinity of 
Zn2+ ion (Figure 5-5d and Figure 5-6d), substitution on the aromatic ring to introduce the 
 
linker region can be synthetically challenging. Therefore, we focused on
hydroxypyridin-2-ones fragment for further investigation. 
(i) 
 
                                    (iii)                                                                    (iv)
 
Figure 5-4. (i) HDAC1 active site (homology model); (ii) Docked fragment 3
thiones (3-HPT; a) against HDAC1; (iii) Docked fr


















(i)                                                               (ii)
 
                                    (iii)                                                                   
Figure 5-5. (i) HDAC8 active site (homology model); (ii) Docked fragment 3
thiones (a) against HDAC8; Figure 5
against HDAC8; (iv) Docked fragment 1
 
 
To further verify our docking results, we subjected these fragments to HDAC 
inhibition assay to determine their effect on enzyme activity. HDAC inhibition was 
assayed initially using cell free assay 
150 
     
 
      
(iv) 
-hydroxypyridin
-6. (iii) Docked fragment 3-hydroxypyridin
-hydroxypyridin-2-thione (c) against HDAC8.









there were discrepancies in data obtained when we tried to reproduce the data using 
fluorescence based analysis (data not shown). There is precedence that fluorescently 
labeled substrates can perturb enzyme activity and the effect of inhibitors. Trypsin 
inhibition can also lead to false positive signal. In one example, the discovery that 
resveratrol and various analogues activate the deacetylase sirtuin 1 (SIRT1) was found to 
be an artifact of the fluorescent assay.43 Indeed, many recommended Fluor de Lys 
substrates have been shown not to be active toward their corresponding enzymes, 
including HDAC8, in the absence of fluorophore.44,45 Additionally, these fragments are 
highly colored solids and might lead to false positive signal. Mindful of these 
observations, we sought to validate these data using the label-free SAMDI (self-
assembled monolayers for MALDI) mass spectrometry assay.46 
The SAMDI technique, wherein self-assembled monolayers (SAM) of 
alkanethiolates on gold are analyzed by matrix assisted laser desorption/ionization 
(MALDI) mass spectrometry, has been used to characterize many biochemical activities, 
including the deacetylase enzyme family.45-47 The SAMDI assay is also amenable to 
analysis of homogeneous reactions, as the substrates are immobilized to the SAMs after 
the reaction has been terminated.48 We employed the SAMDI technique to measure the 
inhibition constant (Ki) of fragments against HDAC1 and HDAC8 using a previously 
identified preferred HDAC substrate.45 Interestingly, 3-hydroxypyridin-2-one was found 
to be inactive against the two HDAC isoforms. However, thione derivative showed low 
micromolar IC50 values against the HDAC8 isoform and inactive against HDAC1 (Table 
5-1). After this promising result which showed a glimpse of isoform selectivity, we 
focused on building the lead 3-HPT from N-1 nitrogen to investigate if the linker 
 
substitution at this position can be tolerated. Accordingly, we substituted the 3
hydrogen with methyl group and docked the resulting 1
thione against HDAC8. We focused on HDAC8 due to the observed evidence of 
compounds selectivity for this HDAC isoform (Table 5




    *Activities determined by SAMDI analysis by James Kornacki from Dr. Milan Mrksich 
      University of Chicago. SAHA is used for a positive control.
      NI – No significant Inhibition (below 20% Inhibition)




         
      (a)                                            (b)                                                         c)
 
Figure 5-7 (a) Structure of 1-
orientation 1-methyl-3-hydroxypyridin














 10 µM are given if the IC50 was above 10 µM.
    
 
methyl-3-hydroxypyridin-2-thiones (a) Surface view of docked 
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Substitution with N-methyl group didn’t alter the docked pose of 3-HPT fragment 
(Figure 5-7). We analyzed amino acid residues surrounding the docked structure of 1-
methyl-3-hydroxypyridin-2-thiones to further refine our design of the linker region. The 
12 Å hydrophobic tunnel which joins the ZBG active site to the surface consists of amino 
acid (AA) residues Phe152, Phe208, Tyr306, Trp141, His180, Asp267. Moreover, 
hydrophobic aromatic AA residues Phe152, Phe208, Tyr306, Trp141 are placed in close 
proximity of N-methyl group of docked 1-methyl-3-hydroxypyridin-2-thiones structure 
(Figure 5-7c). Therefore, we hypothesized that aromatic linkers such as phenyl, biphenyl 
or triazole rings might contribute to pi-stacking interactions with Phe152, Phe208 thereby 
reduce binding energy and improve compounds’ affinity for HDAC8. Based on this 
rationale, we proposed the following structures and studied their orientation at the active 
site by performing another set of docking experiments.  
 
 
                    1                                          2                                                3 






                              (a)                                                                              (b)
 
Figure 5-9. (a) Docked structure of 
(c) Docked structure of 3 against HDAC8
               
            Analysis of the docked poses of 
(Figure 5-9) and the triazole group made fruitful pi
AA Trp141. In compound 
adjacent to ZBG maintained its 
orients in deep subpocket near active site, albeit without any significant interaction 
(Figure 5-9 b). A closer look at docked structure 
Tyr111 are present surrounding 2
envisoned that the substitution on
hydrophobic groups might lower binding energy and improve potency. 
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1 against HDAC8 (b) Docked structure of 2 against HDAC8. 
. 
1, 2 and 3 revealed that indeed the 
-stacking interaction with aromatic 
2 containing a biphenyl substitution, the 1st
pi-stacking interaction with Trp141 and 2nd
2 revealed that Pro35, Ile34, Cys28, 
nd phenyl ring compound 2 (Figure 5-10). Therefore we 
 the 2nd phenyl ring with hydrogen bonding or 
 
    
phenyl ring 
 phenyl ring 
 phenyl ring 
 
 
Figure 5-10. AA residues surrounding 2
 
 
              To investigate the effect of incorporation 
group of compound 2 and thus to flush out rest of SAR we proposed compounds as 
shown in Figure 5-11. The proposed modifications can take part can take part in 
hydrogen bonding as well as hydrophobic interactions with A














nd phenyl ring of docked compound against HDAC8.
of fuctional groups on the 2












X = O, S
 
 











5.4 Synthesis of 1
st
 Generation Novel HDACi 
 
                Initial fragments 5a-5c and 7a-7c were synthesized within 2 to 3 steps as 
indicated in Figure 4-12. Synthesis involved coupling of methyl iodide and corresponding 
benzyl bromides with commercially available 3-methoxypyridin-2-one to give the O-
methyl protected intermediates 4a-4c. Thione intermediates were synthesized from their 
carbonyl precursors using lawesson’s reagent chemistry.49 Finally, deprotection of O-
methyl group by lewis acid BBr3 gave the desired products 5a-5c and 7a-7c.  
 
Figure 5-12. Synthesis of the 3-DHP based ZBG HDACi. For 4a  a) MeI, KOH, MeOH; For 4b, 
4c; a) R-CH2Br, K2CO3, DMF, 100 
oC. b) Lawesson’s reagent, toluene, reflux. c) BBr3, CH2Cl2. 
 
 
                The proposed routes to the biphenyl fragments require crucial intermediate 8 
which was obtained by coupling of 4-bromobenzylbromide with 3-methoxypyridin-2-
ones (Figure 5-13). Standard Suzuki coupling50 with corresponding boronic acids gave 
intermediates 9a-9i. Similarly, Lawesson’s chemistry49 was used to prepare thione 
intermediates. Deprotection of the O-methyl group yielded the final biphenyl compounds 
11a-11i and 12a-12i (Figure 5-13). Synthesis of triazole based compounds 16a-16b and 
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17a-17b is shown in Figure 5-14. It involves the intermediacy of terminal alkyne 13, by 
N-alkylation reaction of 3-methoxypyridin-2-one with propargyl bromide. Cu(I)-
catalyzed Huisgen cycloaddition51 gave the cyclized product 14a-14b. Lawesson’s 
chemistry was again used to gain access to thiolated analogs. Deprotection of O-methyl 




























9a - 9i 10a - 10i













Figure 5-13. Synthesis of the 3-DHP based ZBG HDACi - I. (a) 4-bromobenzylbromide, K2CO3, 
THF, reflux b) R-B(OH)2, Pd(PPh3)4, K2CO3, toluene:ethanol:H2O; 80 
oC c) Lawesson’s reagent, 
toluene, reflux; d) BBr3, CH2Cl2 
 
Figure 5-14. Synthesis of the 3-DHP based ZBG HDACi - II. (a) propargyl bromide, K2CO3, 
THF, reflux b) azido intermediates (phenyl azide, 4-azido-N, N-dimethylaniline), CuI, DIPEA, 





5.5 In vitro HDAC Inhibition of 1
st
 Generation HDACi 
  With the compounds in hand, we tested them against SAMDI analysis as 
previously described.46 There is clear distinction in the HDAC inhibition activities of the 
carbonyl and thione analogs with the latter showing higher potency (Table 5-2). The 
enhanced anti-HDAC activity of the thione analogs could be attributed to thiophilicity 
which favors Zn2+ binding.31 Most of the compounds in this series showed distinct 
selectivity towards HDAC8 compared to HDAC1. A head to head comparison of 
HDAC8 inhibition showed that compound 7b which contains one phenyl ring has better 
activity than biphenyl compound 7c.  This observation is consistent with the docking 
result as the 2nd phenyl ring doesn’t take part in any meaningful interactions with residues 
on HDAC8 outer rim (Figure 5-9). However, replacement of the 2nd phenyl ring of 
compound 7c with a 4-pyridyl ring results in better activity (7c IC50 = 4.28 µM Vs 12i 
IC50 = 2.78 µM against HDAC8) indicating that para-pyridine substitution contributed to 
lowering binding energy and hence better interaction than 7c with AA residues on 
surface. Substitution of 2nd phenyl ring with electron donating N,N-dimethylamino group 
at para position (in 12g) has similar effect as the para-pyridine substitution (in 12i) (Table 
5-2). However combination of pyridine and N,N-dimethylamine substitutions in 
compound 12h is not comparable with HDAC8 inhibition. Incorporation of methyl 
group, another electron donating group, at the para position (in 12d) resulted in the best 
IC50 value (800 nM) in this series (Table 5-2). However meta- (compound 12e) and 
ortho- (compound 12f) methyl substitution did not surpass the activity of 12d. This trend 
in HDAC8 inhibition did not hold for electron withdrawing cyano group. Meta- and 
ortho- substituted compounds 12b and 12c respectively showed better potency when 
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compared to para- substituted compound 12a. Interestingly triazole substituted 
compounds 17a was found to be more active than corresponding biphenyl compound 7c. 
However a para-N,N-dimethylamino substitution of 17a which resulted in compound 17b 
was not beneficial. This is contrary to the effect of a similar substitution on the biphenyl 
compound (Table 5-2, comparing 7c and 12g; 17a and 17b). 
Table 5-2. In-vitro HDAC inhibition of 1st generation HDACi 
COMPOUNDS 
IC50 (nM)* COMPOUNDS 
IC50 (nM)* 






























NI  35% 
7c 
NI 4283±1548  
12g 
NI  2858±944 
 
11a 






































































SAHA is used for a positive control. 
NI – No significant Inhibition (below 20% Inhibition) 
% inhibitions of the compounds at 10 µM are given if the IC50 was above 10 µM. 
 
5.6 Further Molecular Docking
(a) 
                                    
 
Figure 5-15. (a) Docked structure of 
with key AA residues near Zn
substituted compounds (comparing 
 
 
     Most of the biphenyl compounds with 3
activity in the range of 0.8-
generation compound to gain better understanding in binding mode of these compounds. 
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12d against HDAC8 (b) Docked structure of 12d
2+ active site (c) Overlap of ortho-, meta- and 
12d, 12e, 12f) 
-HPT as ZBG shows biological 








We chose to dock compound 12d-f and 12a-c which showed substitution pattern 
dependent HDAC8 inhibition activities.  Results for this experiment are shown in Figure 
5-15. Interestingly, the head groups of all these inhibitors are directed towards a second 
subpocket which is minimally solvent exposed near the zinc active site pocket. AA 
residues near the aromatic head group formed a second subpocket consisting of 
hydrophobic residues such as ILE34 and PRO35 (see Figure 5-15b) which interact with 
para-methyl substitution on head group of compound 12d. However when methyl group 
substitution moves to meta position, there is lost interaction with Ile34 and Pro35, 
however it still manages a hydrophobic interaction with Arg37 (Figure 5-15c). Ortho 
substitution doesn’t indulge in any hydrophobic interactions similar to para and meta 
position. However, ortho position manages to interact with ILE34. Therefore movement 
of methyl substitution on aromatic head group from para to meta to ortho, resulted in 
drop off in the activity.   
 
5.7 Design of 2
nd
 Generation 3-HPT based HDACi 
 
                 An important conclusion from the experiments described above is that isoform 
selectivity in favor of HDAC8 over HDAC1 was achieved by using hetercyclic aromatic 
ZBG. This finding provides 3-hydroxypyridin-2-thione as an alternative which might 
address the pharmacokinetic issues of hydroxamic acids. However there is room for the 
enhancement of compound potency since the best compound is still less active compared 
to prototypical hydroxamate based HDACi.  Towards improving potency, we further 
explored the SAR around the linker region. The common linker moiety of HDACi 
consists of aliphatic methylene group which traverses the hydrophobic tunnel to present 
the cap group on surface. We investigated the consequences of the substitution of the 
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aromatic linker with methylene group on the HDAC inhibition activities of these 3-HPT 
HDACi. We synthesized and tested compounds with variable methylene group linker 
length –from one (as seen in compound 17a) to seven (as seen in SAHA).   
 
5.8 Synthesis of 2
nd
 generation 3-HPT based HDACi 
 
                    Synthesis of 2nd generation 3-HPT based compounds is depicted in Figure 5-
16. The crucial azidoalkyl methanesulfonates are synthesized in two steps. The reaction 
of corresponding bromoalkanols with sodium azide furnished azidoalkanols 18a-18f 
which were subsequently mesylated to give methanesulfonate intermediates 19a-19f in 
almost quantitative yields. As described earlier, N-alkylation of O-methyl or O-benzyl 
protected 3-hydroxypyridin-2-one with the mesylate intermediates gave azido 
intermediates 20a-20f in moderate to good yields. Aromatic surface recognition cap 
group was linked to these azido intermediates via 1,2,3-triazole ring. Cu(I)-catalyzed 
Huisgen cycloaddition51 between phenylacetylene and azido intermediates 20a-20f, 
followed by deprotection of methyl ether by Lewis acid BBr3 furnished the desired 
compounds in good to excellent yields. All the higher linker thione compounds were 
synthesized from their carbonyl counterparts by using P4S10 chemistry as previously 
reported.52 However 2 methylene linker compound 22a did not tolerate the rigorous 
temperature conditions and was degraded to complex reaction mixture within 2 hrs. 
Therefore we modified the synthetic scheme as shown in Figure 5-16. Incorporation of 
O-methyl protected intermediate 21a allowed us to use milder Lawesson’s reaction 
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Figure 5-16. Synthesis of 2nd generation 3-HPT based HDACi (a) NaN3, DMF, 75 
oC (b) 
methanesulfonyl chloride, Et3N, THF; (c) 3-methoxypyridin-2-one, K2CO3, THF/DMF, reflux (d) 
Phenylacetylene, CuI, DIPEA, THF/DMSO; (e) for 22a – BBr3, DCM; for 22b-f – H2, Pd/C, 
THF; (f) Lawesson’s reagent, toluene, reflux; (g) BBr3, DCM; (h) P4S10, 175 













5.9 In vitro HDAC Inhibition of 2
nd
 Generation 3-HPT based HDACi  
              Activities of 2nd generation compounds also were consistent for HDAC8 
selectivity over HDAC1 and thione compounds always outperformed their corresponding 
carbonyl compounds. For thione analogs, increase in methyelne spacer by 1-carbon to 
compound 17a shows significant loss of activity (comparing 17a and 24 in Table 5-2 and 
Table 5-3). Gradual increase in methylene spacer length from 3-carb 
on to 5-carbon shows improvement in activity with 5-carbon linker shows optimum 
activity (compound 25d, IC50 = 917 nM). However, one additional carbon linker again 
results in drop of activity with 7-fold difference (Table 5-3; comparing 25d and 25e). 
Interestingly, 7-carbon linker compound 25f showed superior activity than 25e however it 
still didn’t surpass the activity of 25d. 
This SAR study established that 5-carbon methylene chain is optimum linker in 
HDACi design containing 3-HPT as ZBG. In addition to five methylene spacer, one and 
seven methylene spacer showed comparable activities and should be viable leads as well.  
 
Table 5-3. In vitro HDAC Inhibition of 2
nd






12%  15% 
 
24 




Table 5-3 continued. 
 
22b 
8%  47% 
 
25b 
27%  63% 
 
22c 
15%  10% 
 
25c 













12%  5% 
 
25e 
23%  6791±910 
 
22f 
2%  42% 
 
25f 
35%  1377±205 
SAHA 38+/- 2  232±19 
SAHA is used for a positive control. 
NI – No significant Inhibition (below 20% Inhibition) 
% inhibitions of the compounds at 10 µM are given if the IC50 was above 10 µM. 
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5.10 Design of 3
rd
 Generation 3-HPT based HDACi 
 
            As demonstrated in section 5.9, we have established that 5-carbon methylene 
spacer traverses hydrophobic tunnel optimally to present 3-HPT in the vicinity of the 
active site zinc for tighter binding. We then undertook SAR study on surface recognition 
cap group with specific focus on the 5-carbon methylene spacer in the hope that such 
exercise will furnish more potent compounds. Based on our previous study on SAR 
studies on triazole based simple HDAC compounds42 and on 1st generation 3-HPT based 
HDACi, we proposed a distinct set of cap groups which could shed light on cap group 
orientation at the enzyme orientation (Figure 5-17).  
 
 
Figure 5-17. Design of 3rd Generation 3-HPT-based HDACi 
  
 
5.11 Synthesis of 3
rd
 Generation 3-HPT based HDACi 
 
            The synthetic route to the 3rd generation compounds is identical to that described 
for the 2nd generation compounds. The new surface cap recognition cap groups were 
coupled to ZBG modified linker using Cu(I)-catalyzed Huisgen cycloaddition51 to give 
intermediates in good to excellent yields. As described earlier, Lawessons’ chemistry49 
followed by deprotection with BBr3 resulted in desired compounds 29a-29g and 30a-30g. 
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Carbonyl derivatives were also synthesized using similar deprotection chemistry (Figure 
5-18).  
 
Figure 5-18. Synthesis of 3rd Generation HDACi i) 3-methoxypyridin-2-one, K2CO3, THF, 
reflux; ii) R-alkynes, CuI, DIPEA, DMSO:THF; iii) Lawesson’s reagent, Toluene, reflux; iv) 
BBr3, DCM. Compounds 26, 27a-27e synthesized by Quaovi Sojdi. Included here to show 
complete synthetic scheme. 
 
 
5.12 In Vitro HDAC inhibition of 3
rd
 Generation 3-HPT based HDACi  
 
 The 3rd generation compounds in 3-HPT series were tested against HDAC1 & 
HDAC8 using the label-free SAMDI mass spectrometry assay as previously described.46 
The trend in HDAC inhibition activity was very similar to that observed in the early 
generation compounds with the thione compounds showing superior activity compared to 
the carbonyl derivatives. In contrast to what was obtained for the 2nd generation 
compounds, the results from this study indicate that substitution on the phenyl ring as cap 
group is not helpful for anti-HDAC activity. Almost all of the cap groups other than 
simple phenyl ring failed to improve compound potency. In order to gain additional 
insight into binding interactions of 2nd and 3rd generation of compounds at the enzyme 
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active site, we performed docking analyses on the best compounds in this series against 
HDAC8.  
 




















































SAHA 38+/- 2  232±19 
                      
            SAHA is used for a positive control. 
NI – No significant Inhibition (below 20% Inhibition) 
% inhibitions of the compounds at 10 µM are given if the IC50 was above 10 µM. 




5.13 Molecular Docking Analysis of 3
rd
 Generation 3-HPT based 
HDACi 
 
              Compound 25d adopts a docked pose at HDAC8 active site which presents the 
phenyl cap group into a deep, non-solvent exposed hydrophobic pocket (Figure 5-19), 
while the 5-carbon methylene spacer optimally fills the connecting the hydrophobic 
pocket to the Zn2+ active site. The ideal spacer length of the 5-carbon methylene group 
facilitates a proper presentation off the 3-HPT ZBG to the active site Zn2+. The deep 
pocket where the phenyl ring orients consists of Tyr111, Ala112, Leu155, Tyr154 AA 
residues. Two tyrosine residues are within 3.5 Å of the phenyl cap group of compound 
25d and are ideally suited for pi-stacking interaction. Tyr154 is expected to have stronger 
 
pi-stacking interaction since plane of its ring is parallel to the phenyl cap group of 
compound 25d. However, Tyr
because the edge of its phenol ring is oriented toward the plane of the cap group 
Other AA resiudes such as Leu115 and Ala
overall hydrophobicity of the pocket into which the phenyl cap group of compound 
is bound (Figure4-19). This might lead to lower binding energy conformation and hence 
better IC50 value for this 2
nd generation compound. 
 
 
                               (a)            
Figure 5-19. (a) Docked structure of 
HDAC8 showing key AA residues forming deep pocket around phenyl cap group. 
 
 
                   Figure 5-20 shows
methylene linker compound 
almost the similar orientation, except for slight kinks, at the methylene groups. The major 
difference between the docked poses of 
slightly pushed outside of pi-
171 
111 will contribute less to the pi-stacking interaction 
112 are within 3.5 Å and contribute to the 
 
   
                                                                (b) 
25d against HDAC8 (b) Docked structure of 
 
 an overlay of the docked structures of 
25e. Both compounds bind to the same pocket and adopt 
25d and 25e is at their phenyl cap group which is 





25d and six 
25e and thus 
 
abolishing this important interaction. This could be the reason that there is almost 7
activity difference between 25d
                               (a)                                                                            (b)
Figure 5-20. (a) Overlay of docked structures of 
against HDAC8 showing key AA residues forming deep pocket around phenyl cap group. 
 
               Similarly, compound 
21). However para-cyano substitution on cap group 
pushed out of the binding pocket seen for compound 
tyrosine residues are not far away from
not optimum for pi-stacking interaction with the phenyl group of 
hydrophobic interactions with Ala112 and Leu
a compensatory pi-stacking interaction with Trp
for compound 30d relative to 
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 and 25e.  
    
 
25d and 25e; (b) Docked structure of 
30d binds to same pocket as discussed earlier
30d causes its phenyl ring to be 
25d (Figure 5-20). Though two 
 the phenyl cap group (~3.2 Å), their orie
30d
155 are completely lost. However, there is 











                               (a)                                                                            (b)
Figure 5-21. (a) Docked structure of 
showing key AA residues forming deep pocket around phenyl cap group. 
 
The preference for the
all of the compounds tested in this series. This is an important and interesting observation 
considering the fact that other aromatic ZBG such as benzamide showed HDAC1 
selectivity (250 fold).53 To obtain information on the structural basis of the observed
disparity in the HDAC isoform selectivity
docking analysis on lead compound 
                                 (a)                                                                         (b)
Figure 5-22. (a) Docked structure of 
HDAC8 
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30d; (b) Docked structure of 30d against HDAC8 
 
 HDAC8 isoform over HDAC1 was consistent for almost 
 for these compounds, we performed molecular 
12d as previously described on two HDAC isoforms 
   
 








tested. HDAC8 docking revealed that 12d orients optimally at the active site which tracks 
well with inhibition activity observed for 12d. However, HDAC1 docking of 12d reveal 
that there is no fruitful interaction of compound 12d at HDAC1 enzyme active site. 
Morever, ZBG of 12d is far away from Zn2+ ion and that could be the reason that no 
HDAC1 inhibition was noticed. Repeated docking confirmed that the ZBG of 12d was 
unable to deeply penetrate (~14 Å) the Zn2+ active site of HDAC1.  
 
5.14 Conclusion  
                 We have used fragment based and structure based drug design approaches to 
successfully incorporate a novel nonhydroxamate ZBG into HDACi design. We have 
disclosed for the first time that heterocyclic aromatic 3-HPT based ZBG are compatible 
with HDAC inhibition. Preliminary biological studies on these compounds reveal isoform 
selectivity for HDAC8 enzyme as relative to HDAC1. Molecular docking studies 
performed on this novel ZBG furnished interesting information about HDAC8 active site 
and how this information could be used to generate more potent and selective analogs. 
Ongoing biological study on more HDAC isoforms should lead to better understanding of 
these 3-HPT based HDACi. In addition to 3-HPT; 3-hydroxypyridin-4-ones, pyrones, 
thiopyrones represent other good choices of ZBG that can be incorporated for more 







5.15 General Procedures and Experimental 
                 Bromoalkanoic acid, benzyl bromide, 4-bromobenzylbromide, 4-
(bromomethyl)-1,1’-biphenyl, 3-methoxy-2(1H)-pyridone, propargyl bromide, 
phenylacetylene and representative boronic acids were purchased from either Sigma–
Aldrich or Alfa-Aesar. Anhydrous solvents and other reagents were purchased and used 
without further purification.  Analtech silica gel plates (60 F254) were used for analytical 
TLC, and Analtech preparative TLC plates (UV 254, 2000 µm) were used for 
purification.  UV light was used to examine the spots. Silica gel (200–400 Mesh) was 
used in column chromatography.  NMR spectra were recorded on a Varian-Gemini 400 
magnetic resonance spectrometer.  1H NMR spectra were recorded in parts per million 
(ppm) relative to the peak of CDCl3, (7.24 ppm), CD3OD (3.31 ppm), or DMSO-d6 (2.49 
ppm).  13C spectra were recorded relative to the central peak of the CDCl3 triplet (77.0 
ppm), CD3OD (49.0 ppm), or the DMSO-d6 septet (39.7 ppm), and were recorded with 
complete heterodecoupling.  Multiplicities are described using the abbreviation s, singlet; 
d, doublet, t, triplet; q, quartet; m, multiplet; and app, apparent. High-resolution mass 
spectra were recorded at the Georgia Institute of Technology mass spectrometry facility 
in Atlanta. Synthesis of 1a was adapted from literature protocol.54 Azidoalkanols (1a-1f) 
were prepared according to literature protocols55 and was used without further 
purification. Synthesis of phenyl azide and 4-azido-N,N-dimethylaniline were adapted 






Synthesis of 1-methyl-3-methoxypyridin-2-one (4a) 
To a stirring reaction mixture of 3-methoxypyridin-2-one (0.2 g, 1.6 mmol) and KOH 
(0.18 g, 3.2 mmol) in methanol was added MeI (0.68 g, 4.8 mmol) dropwise in condenser 
equipped round bottom flask. After overnight stirring at room temperature revealed 
quantitative formation of product. Reaction mixture was then diluted with water (35 mL) 
and CHCl3 (40 mL). Organic layer was washed with water (1X35 mL), brine (1X30 mL) 
and dried over Na2SO4 and solvent was evaporated off under vacuo to yield pure 4a (0.20 
g, 89%) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 6.66 (m, 1H), 6.35 (d, J = 7.4 
Hz, 1H), 5.83 (t, J = 7.1 Hz, 1H), 3.52 (s, 3H), 3.28 (s, 3H). 13C NMR (100 MHz, CDCl3) 
δ 158.01, 149.56, 128.81, 111.91, 104.31, 55.44, 37.10.  
 
1-Benzyl-3-methoxypyridin-2-one (4b) 
To a stirring reaction mixture of 3-methoxypyridin-2-one (0.2 g, 1.6 mmol) and K2CO3 
(0.66 g, 4.8 mmol) in DMF (8 mL) was added benzyl bromide (0.33 g, 1.92 mmol) 
dropwise in a condenser equipped round bottom flask. Reaction mixture was then heated 
to 100 oC. After overnight stirring, reaction mixture was cooled down and diluted with 
water (40 mL) and CHCl3 (50 mL). Organic layer was washed with water (3X40 mL), 
brine (1X30 mL) and dried over Na2SO4 and solvent was evaporated off under vacuo to 
yield pure 4b (0.26 g, 75%) as a colorless oil without any further purification needed.  1H 
NMR (400 MHz, CDCl3) δ 7.26 (m, 5H), 6.85 (dd, J = 6.9, 1.7 Hz, 1H), 6.54 (dd, J = 7.5, 
1.6 Hz, 1H), 6.03 (m, 1H), 5.13 (s, 2H), 3.76 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 





Reaction of 3-methoxypyridin-2-one (0.2 g, 1.6 mmol), K2CO3 (0.66 g, 4.8 mmol), (4-
bromomethyl)-1,1’-biphenyl (0.47 g, 1.92 mmol) in DMF (8 mL) according to method 
described for synthesis of 4b followed by column chromatography with CH2Cl2, acetone 
(0-15% gradient), MeOH (0-5% gradient) afforded pure 4c (0.35 g, 76%) as a colorless 
oil. 1H NMR (400 MHz, CDCl3) δ 7.48 (dd, J = 25.9, 20.6 Hz, 4H), 7.32 (m, 5H), 6.88 
(m, 1H), 6.54 (d, J = 7.2 Hz, 1H), 6.04 (t, J = 7.1 Hz, 1H), 5.16 (s, 2H), 3.76 (s, 3H). 13C 
NMR (100 MHz, CDCl3) δ 157.86, 149.97, 140.51, 140.24, 135.28, 128.51, 128.40, 
127.71, 127.16, 127.13, 126.74, 111.82, 104.80, 55.56, 51.36. 
 
1-Methyl-3-hydroxypyridin-2-one (5a) 
To a solution of 4a (0.1 g, 0.68 mmol) in dry CH2Cl2 (8 mL) was slowly added 1M BBr3 
(0.82 mL) at -30 oC under inert atmosphere. The reaction mixture was stirred for 48 h at 
room temperature. The mixture was again cooled to -30 oC & then MeOH (5 mL) was 
slowly added to the mixture. After evaporation of solvent, the residue was adjusted to pH 
7 with 1M NaOH and then extracted with CHCl3 (3 X 30mL). The combined organic 
layer dried over Na2SO4. After evaporation of solvent, the residue was purified by prep-
TLC with CH2Cl2:Acetone:MeOH (10:1:0.2) to give 61 mg (72%) of pure off white solid 
5a.  1H NMR (400 MHz, CDCl3) δ 7.92 (s, 1H), 6.78 (dd, J = 11.1, 7.1 Hz, 2H), 6.10 (t, J 
= 7.0 Hz, 1H), 3.57 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 158.82, 146.67, 127.63, 
114.36, 106.68, 37.28. HRMS (EI) calcd for C6H7NO2 [M]






Reaction of 4b (0.15 g, 0.55 mmol) with 1M BBr3 (0.66 mL) in dry CH2Cl2 (5 mL) 
within 48 h according to procedure 5a afforded pure 5b (0.13 g, 90%) as slightly 
brownish solid. 1H NMR (400 MHz, CDCl3) δ 7.31 (m, 5H), 6.83 (m, 3H), 6.14 (t, J = 
7.1 Hz, 1H), 5.19 (s, 2H). 13C NMR (100 MHz, CDCl3) δ 158.62, 146.78, 135.82, 128.74, 





Reaction of 4c (0.13 g, 0.43 mmol) with 1M BBr3 (0.51 mL) in dry CH2Cl2 (7 mL) 
within 48 h according to procedure 5a afforded pure 5c (0.1 g, 82%) as slightly brownish 
solid.  1H NMR (400 MHz, DMSO-d6) δ 9.06 (s, 1H), 7.61 (d, J = 7.5 Hz, 4H), 7.36 (m, 
6H), 6.70 (d, J = 6.5 Hz, 1H), 6.12 (t, J = 6.9 Hz, 1H), 5.16 (s, 2H).  13C NMR (100 MHz, 
DMSO-d6) δ 147.02, 139.77, 139.46, 136.58, 128.93, 128.35, 128.15, 127.49, 126.86, 
126.66, 114.75, 105.64, 51.07. HRMS (EI) calcd for C18H15NO2 [M]




A suspension of 4b (0.060 g, 0.28 mmol) and Lawesson’s reagent (0.067 g, 0.17 mmol) 
in toluene (10 mL) was heated to reflux overnight. Reaction mixture was then cooled to 
room temperature. Toluene was evaporated off under vacuo and resulting crude solid was 
directly loaded on prep-TLC. Elution with CH2Cl2: Acetone: MeOH (5:1:0.2) gave 6b 53 
mg (82%) of yellow solid. 1H NMR (400 MHz, CDCl3) δ 7.30 (m, 6H), 6.65 (d, J = 7.7 
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Hz, 1H), 6.54 (t, J = 7.0 Hz, 1H), 5.89 (s, 2H), 3.88 (s, 3H).  13C NMR (100 MHz, 
CDCl3) δ 173.18, 159.01, 135.18, 131.70, 128.72, 128.03, 127.98, 111.57, 109.63, 58.79, 
56.61. HRMS (EI) calcd for C13H13NOS [M]
+ 231.0718 found 231.0716. 
 
1-(1,1’-Biphenylmethyl)-3-methoxypyridin-2-thione (6c) 
Reaction of 4c (0.13 g, 0.44 mmol) and Lawesson’s reagent (0.11 g, 0.27 mmol) in 
toluene according to method described for synthesis of 6b afforded 122 mg of 6c (88%) 
of yellow solid. 1H NMR (400 MHz, CDCl3) δ 7.52 (m, 1H), 7.35 (m, 2H), 6.66 (dd, J = 
7.8, 1.3 Hz, 1H), 6.55 (dd, J = 7.8, 6.6 Hz, 1H), 5.93 (s, 1H), 3.89 (s, 1H). 13C NMR (100 
MHz, CDCl3) δ 173.08, 158.99, 140.81, 140.20, 134.14, 131.72, 128.61, 128.42, 127.35, 
127.28, 126.83, 111.62, 109.67, 104.80, 58.52, 56.58. HRMS (EI) calcd for C19H17NOS 




Reaction of 6b (0.050 g, 0.21 mmol) with 1M BBr3 (0.66 mL) in dry CH2Cl2 (5 mL) 
within 48 h according to procedure 5a afforded pure 7b (0.034 g, 72%) as olive green 
solid. 1H NMR (400 MHz, CD3OD) δ 7.34 (m, 3H), 6.84 (m, 1H), 5.83 (d, J = 49.5 Hz, 
1H). 13C NMR (100 MHz, CD3OD) δ 128.12, 127.61, 127.27, 126.94, 113.77. HRMS 
(EI) calcd for C12H11NOS [M]
+ 217.0561 found 217.0762. 
 
1-(1,1’-Biphenylmethyl)-3-hydroxypyridin-2-thione (7c) 
Reaction of 6c (0.10 g, 0.32 mmol) with 1M BBr3 (0.48 mL) in dry CH2Cl2 (5 mL) 
within 48 h according to procedure 5a afforded pure 7c (0.074 g, 90%) as olive green 
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solid. 1H NMR (400 MHz, CD3OD) δ 7.39 (m, 9H), 6.88 (m, 3H), 5.86 (s, 2H). 
13C NMR 
(100 MHz, CD3OD) δ 141.33, 140.21, 128.71, 128.52, 127.49, 127.45, 126.89. HRMS 
(EI) calcd for C18H15NOS [M]
+ 293.0874 found 293.0873. 
 
1-(4-Bromobenzyl)-3-methoxypyridin-2(1H)-one (8) 
To a stirring reaction mixture of 3-methoxypyridin-2-one (2.00 g, 16 mmol) and K2CO3 
(4.42 g, 32 mmol) in THF was added 4-bromobenzyl bromide (5.20 g, 20.8 mmol) 
slowly. Reaction mixture was the heated to reflux and stirring continued overnight. 
Reaction mixture was then cooled down and separated into organic and aqueous layer by 
adding CH2Cl2 (120 mL) and water (60 mL). Organic layer was separated and 
subsequently washed with water (2 X 60 mL), brine (1 X 40 mL). Organic layer was 
dried on Na2SO4 and solvent was evaporated in vacuo. Crude yellowish solid was 
triturated with hexanes to give pure white solid 8 (3.49 g, 74%) without further 
purification. 1H NMR (400 MHz, CDCl3) δ 7.25 (m, 2H), 7.04 (m, 2H), 6.78 (dd, J = 6.8, 
1.2 Hz, 1H), 6.45 (dd, J = 7.2, 1.6 Hz, 1H), 5.94 (t, J = 7.2 Hz, 1H), 4.95 (s, 2H), 3.64 (s, 
3H). 13C NMR (100 MHz, CDCl3) δ 157.71, 149.91, 135.29, 131.49, 129.59, 127.53, 




Representative procedure for Suzuki coupling reactions for synthesis of 9 – 
1-(4-Cyano-(1,1’-biphenylmethyl))-3-methoxyoxypyridin-2-one (9a) 
8 (0.26 g, 0.86 mmol), (4-cyanophenyl)boronic acid (0.14 g, 0.95 mmol), 2M aq. K2CO3 
(0.24 g, 1.73 mmol), toluene (8 mL), EtOH (4mL) and water (4mL) were added into 
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reaction flask equipped with magnetic stirrer and water condenser. The resulting 
suspension was degassed fir 10 min by sparging with argon gas. Pd(PPh3)4 (2.5 mol%) 
was added and the reaction mixture was heated to reflux overnight under argon 
atmosphere. After cooling to room temperature, CH2Cl2 was added (50 mL) & washed 
with water (1 X 40 mL), brine (1 X 20 mL) and dried on Na2SO4. Column 
chromatography using gradient CHCl3:Acetone:MeOH (with 5% - 20% of acetone and 
1% - 8% MeOH gradual increase)  gave pure off white solid 9a (0.42 g, 78%). 1H NMR 
(CDCl3, 400 MHz) δ 7.60 (m, 4H), 7.40 (m, 4H), 6.90 (dd, J = 6.8, 1.6 Hz, 1H), 6.55 (dd, 
J = 7.6, 1.6 Hz, 1H), 6.07 (t, J = 7.2 Hz, 1H), 5.16 (s, 2H), 3.75 (s, 3H). 13C NMR (100 
MHz, CDCl3) δ 158.08, 150.28, 144.96, 138.62, 137.13, 132.56, 131.96, 128.85, 128.55, 
128.43, 127.96, 127.60, 127.53, 118.88, 112.11, 110.88, 105.24, 56.20, 51.80. HRMS 
(EI) calcd for C20H6N2O2 [M]
+ 316.1212 found 316.1210. 
 
1-(3-Cyano-(1,1’-biphenylmethyl))-3-methoxyoxypyridin-2-one (9b) 
Reaction of 3 (0.25 g, 0.85 mmol), (3-cyanophenyl)boronic acid (0.14g, 0.93 mmol), 2M 
aq. K2CO3 (0.23 g, 1.69 mmol) and Pd(PPh3)4  (2.5 mol%) according to method described 
for synthesis of 9a within 18 h afforded 175 mg of 9b (66 %) of white solid. 1H NMR 
(400 MHz, CDCl3) δ 7.70 (m, 2H), 7.48 (m, 6H), 6.92 (dd, J = 6.9, 1.6 Hz, 1H), 6.57 (dd, 
J = 7.4, 1.4 Hz, 1H), 6.08 (t, J = 7.2 Hz, 1H), 5.16 (s, 2H), 3.76 (s, 3H). 13C NMR (100 
MHz, CDCl3) δ 158.09, 150.24, 141.70, 138.33, 136.81, 131.38, 130.76, 130.45, 129.66, 
128.87, 127.96, 127.36, 118.76, 112.82, 112.14, 105.26, 55.84, 51.66. HRMS (EI) calcd 
for C20H16N2O2 [M]





Reaction of 3 (0.15 g, 0.50 mmol), (2-cyanophenyl)boronic acid (0.09 g, 0.60 mmol), 2M 
aq. K2CO3 (0.14 g, 1.69 mmol) and Pd(PPh3)4 (2.5 mol%) according to method described 
for synthesis of 9a within 18 h afforded 118 mg of 9c (75 %) of white solid. 1H NMR 
(400 MHz, CDCl3) δ 7.72 (m, 1H), 7.60 (m, 1H), 7.45 (m, 2H), 6.94 (dd, J = 6.9, 1.7 Hz, 
1H), 6.60 (dd, J = 7.4, 1.6 Hz, 1H), 6.10 (t, J = 7.2 Hz, 1H), 5.21 (s, 1H), 3.80 (s, 1H). 
13C NMR (100 MHz, CDCl3) δ 158.01, 150.18, 144.70, 137.56, 136.94, 133.61, 132.78, 
129.91, 129.01, 128.31, 127.92, 127.55, 118.54, 112.01, 110.94, 105.13, 55.74, 51.60. 
HRMS (EI) calcd for C20H16N2O2 [M]
+ 316.1212 found 316.1201. 
 
1-(4-Methyl-(1,1’-biphenylmethyl))-3-methoxyoxypyridin-2-one (9d) 
Reaction of 8 (0.25g, 0.85 mmol), p-tolylboronic acid (0.14g, 1.02 mmol), 2M aq. K2CO3 
(0.23g, 1.69 mmol), Pd(PPh3)4  (2.5 mol%)  according to method described for synthesis 
of 9a within 18 h afforded 259 mg of 9d (quantitative) of white solid. 1H NMR (400 
MHz, CDCl3) δ 7.49 (d, J = 8.1 Hz, 2H), 7.42 (d, J = 8.1 Hz, 2H), 7.33 (d, J = 8.1 Hz, 
2H), 7.19 (d, J = 8.0 Hz, 2H), 6.88 (dd, J = 6.9, 1.6 Hz, 1H), 6.54 (dd, J = 7.4, 1.4 Hz, 
1H), 6.03 (t, J = 7.2 Hz, 1H), 5.15 (s, 2H), 3.76 (s, 3H), 2.34 (s, 3H). 13C NMR (100 
MHz, CDCl3) δ 157.81, 149.88, 140.39, 137.29, 136.87, 134.93, 129.21, 128.35, 127.66, 
126.91, 126.53, 111.75, 104.78, 55.51, 51.31, 20.80.  HRMS (EI) calcd for C20H19NO2 







Reaction of 3 (0.20 g, 0.68 mmol), m-tolylboronic acid (0.11 g, 0.82 mmol), 2M aq. 
K2CO3 (0.19 g, 1.36 mmol) and Pd(PPh3)4 (2.5 mol%) according to method described for 
synthesis of 9a within 18 h afforded 259 mg of 9e (quantitative) of white solid. 1H NMR 
(400 MHz, CDCl3) δ 7.49 (m, 1H), 7.29 (m, 2H), 7.11 (d, J = 7.2 Hz, 1H), 6.88 (dd, J = 
6.9, 1.7 Hz, 1H), 6.53 (dd, J = 7.4, 1.6 Hz, 1H), 6.03 (t, J = 7.2 Hz, 1H), 5.15 (s, 1H), 
3.75 (s, 1H), 2.35 (s, 1H). 13C NMR (100 MHz, CDCl3) δ 157.81, 149.86, 140.58, 
140.16, 137.99, 135.11, 128.37, 128.29, 127.83, 127.66, 127.46, 127.10, 123.80, 111.81, 
104.80, 55.48, 51.30, 21.19. HRMS (EI) calcd for C20H19NO2 [M]




Reaction of 3 (0.20 g, 0.68 mmol), O-tolylboronic acid (0.11 g, 0.82 mmol), 2M aq. 
K2CO3 (0.19 g, 1.36 mmol) and Pd(PPh3)4 (2.5 mol%) according to method described for 
synthesis of 9a within 18 h afforded 243 mg of 9f (98%) of white solid. 1H NMR (400 
MHz, CDCl3) δ 7.31 (d, J = 7.9 Hz, 1H), 7.17 (m, 2H), 6.93 (m, 1H), 6.56 (dd, J = 7.4, 
1.6 Hz, 1H), 6.06 (t, J = 7.2 Hz, 1H), 5.18 (s, 1H), 3.76 (s, 1H), 2.20 (s, 1H). 13C NMR 
(100 MHz, CDCl3) δ 158.13, 150.23, 141.51, 141.26, 135.23, 135.00, 130.33, 129.68, 
129.51, 128.13, 127.85, 127.34, 125.77, 112.13, 105.07, 55.82, 51.79, 20.45. HRMS (EI) 
calcd for C20H19NO2 [M]





Reaction of 8 (0.25g, 0.85 mmol), (4-(dimethylamino)phenyl)boronic acid (0.17g, 1.02 
mmol), 2M aq. K2CO3 (0.23g, 1.69 mmol), Pd(PPh3)4 (2.5 mol%) according to method 
described for synthesis of 9a within 18 h afforded 230 mg of 9g (81 %) as white solid. 1H 
NMR (400 MHz, CDCl3) δ 7.46 (m, 4H), 7.29 (m, 2H), 6.86 (dd, J = 7.2, 2.0 Hz, 1H), 
7.73 (m, 2H), 6.52 (dd, J = 7.2, 1.6 Hz, 1H), 6.01 (t, J = 7.2 Hz, 1H), 5.13 (s, 2H), 3.76 
(s, 3H), 2.93 (s, 6H). 13C NMR (100 MHz, CDCl3) δ 157.86, 149.90, 149.73, 140.55, 
133.81, 128.43, 128.04, 127.68, 127.28, 126.16, 112.40, 111.77, 104.69, 55.53, 51.31, 
40.18. HRMS (EI) calcd for C21H22N2O2 [M]
+ 334.1681 found 334.1684. 
 
1-(4-(6-(Dimethylamino)pyridin-3-yl)benzyl))-3-methoxyoxypyridin-2-one (9h) 
Reaction of 8 (0.43g, 1.44 mmol), (6-(dimethylamino)pyridine-3-yl)boronic acid (0.2 g, 
1.20 mmol), 2M aq. K2CO3 (0.33g, 2.41 mmol), Pd(PPh3)4  (2.5 mol%)  according to 
method described for synthesis of 9a within 18 h afforded 335 mg of 9h (83%) of white 
solid. 1H NMR (400 MHz, CDCl3) δ 8.28 (d, J = 2.3 Hz, 1H), 7.51 (dd, J = 8.8, 2.5 Hz, 
1H), 7.33 (d, J = 8.2 Hz, 2H), 7.22 (d, J = 8.2 Hz, 2H), 6.80 (dd, J = 6.9, 1.6 Hz, 1H), 
6.44 (m, 2H), 5.94 (t, J = 7.2 Hz, 1H), 5.04 (s, 2H), 3.66 (s, 3H), 2.97 (s, 6H). 13C NMR 
(100 MHz, CDCl3) δ 158.12, 157.61, 149.68, 145.49, 137.75, 135.14, 134.20, 128.35, 
127.54, 125.69, 123.15, 111.62, 105.23, 104.62, 55.36, 51.16, 37.66. HRMS (EI) calcd 
for C20H21N3O2 [M]
+ 335.1634 found 335.1635. 
 
1-(4-(Pyridin-4-yl)benzyl)-3-methoxy-pyridin-2-one (9i) 
Reaction of 8 (0.25g, 0.85 mmol), pyrdin-4-ylboronic acid (0.12g, 1.02 mmol), 2M aq. 
K2CO3 (0.23g, 1.69 mmol), Pd(PPh3)4 (2.5 mol%) according to method described for 
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synthesis of 9a within 18 h afforded 203 mg of 9i (82%) of white solid. 1H NMR (400 
MHz, CDCl3) δ 8.54 (dd, J = 4.5, 1.6 Hz, 2H), 7.48 (m, 2H), 7.36 (m, 4H), 6.87 (dd, J = 
6.9, 1.7 Hz, 1H), 6.53 (dd, J = 7.4, 1.6 Hz, 1H), 6.03 (t, J = 7.2 Hz, 1H), 5.13 (s, 2H), 
3.72 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 157.82, 150.32, 150.01, 149.90, 147.40, 
137.31, 137.28, 128.57, 127.68, 127.04, 121.22, 111.90, 104.98, 55.57, 51.42. HRMS 
(EI) calcd for C18H16N2O2 [M]
+ 292.1212 found 292.1205. 
 
Representative procedure for Thionation reactions for synthesis of 10 – 
 
1-(4-Cyano-(1,1’-biphenylmethyl))-3-methoxyoxypyridin-2-thione (10a) 
A suspension of 9a (0.13 g, 0.42 mmol) and Lawesson’s reagent (0.10 g, 0.25 mmol) in 
toluene (10 mL) was heated to reflux overnight. Reaction mixture was then cooled to 
room temperature. Toluene was evaporated off under vacuo and resulting crude solid was 
directly loaded on prep-TLC. Elution with CHCl3: Acetone: EtOH (12:1:0.2) gave 10a 
123 mg (88%) of yellow solid. 1H NMR (CDCl3, 400 MHz) δ 7.60 (m, 4H), 7.40 (m, 
4H), 6.90 (dd, J = 6.8, 1.6 Hz, 1H), 6.55 (dd, J = 7.6, 1.6 Hz, 1H), 6.07 (t, J = 7.2 Hz, 
1H), 5.16 (s, 2H), 3.75 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 158.08, 150.28, 144.96, 
138.62, 137.13, 132.56, 131.96, 128.85, 128.55, 128.43, 127.96, 127.60, 127.53, 118.88, 







Reaction of 9b (0.11 g, 0.36 mmol) and Lawesson’s reagent (0.09 g, 0.22 mmol) in 
toluene according to method described for synthesis of 10a afforded 113 mg of 10b 
(95%) of yellow solid. 1H NMR (400 MHz, DMSO-d6) δ 7.92 (m, 3H), 7.84 (m, 2H), 
7.71 (d, J = 8.4 Hz, 2H), 7.36 (d, J = 8.8 Hz, 2H), 7.00 (m, 1H), 6.80 (m, 1H), 5.95 (s, 
2H), 3.78 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 173.39, 159.26, 144.82, 138.81, 
135.79, 132.55, 131.81, 128.65, 127.58, 127.50, 118.77, 111.80, 110.98, 109.69, 58.63, 
56.74. HRMS (EI) calcd for C20H16N2OS [M]
+ 332.0983 found 332.0984. 
 
1-(2-Cyano-(1,1’-biphenylmethyl))-3-methoxyoxypyridin-2-thione (10c) 
Reaction of 9c (0.09 g, 0.28 mmol) and Lawesson’s reagent (0.07 g, 0.17 mmol) in 
toluene according to method described for synthesis of 10a afforded 72 mg of 10c (77%) 
of yellow solid. 1H NMR (400 MHz, CDCl3) δ 7.74 (m, 1H), 7.63 (td, J = 7.7, 1.4 Hz, 
1H), 7.45 (m, 2H), 6.71 (dd, J = 7.8, 1.3 Hz, 1H), 6.62 (dd, J = 7.8, 6.6 Hz, 1H), 6.00 (s, 
1H), 5.28 (s, 1H), 3.93 (s, 1H). 13C NMR (100 MHz, CDCl3) δ 173.38, 159.22, 144.68, 
137.79, 135.80, 133.67, 132.86, 131.95, 129.97, 129.17, 128.25, 127.66, 118.59, 111.84, 
111.01, 109.76, 58.63, 56.74. HRMS (EI) calcd for C20H16N2OS [M]




Reaction of 9d (0.12 g, 0.39 mmol) and Lawesson’s reagent (0.09 g, 0.23 mmol) in 
toluene according to method described for synthesis of 10a afforded 117 mg of 10d 
(94%) as yellow solid. 1H NMR (400 MHz, CDCl3) δ 7.51 (m, 2H), 7.42 (m, 2H), 7.34 
(m, 3H), 7.21 (dd, J = 8.4, 0.6 Hz, 2H), 6.66 (dd, J = 7.8, 1.2 Hz, 1H), 6.55 (dd, J = 7.8, 
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6.6 Hz, 1H), 5.92 (s, 2H), 3.89 (s, 3H), 2.36 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 
173.05, 158.97, 140.74, 137.30, 137.08, 133.81, 131.70, 129.33, 128.42, 127.12, 126.64, 






Reaction of 9e (0.12 g, 0.37 mmol) and Lawesson’s reagent (0.09 g, 0.23 mmol) in 
toluene according to method described for synthesis of 10a afforded 112 mg of 10e 
(93%) as yellow solid. 1H NMR (400 MHz, CDCl3) δ 7.53 (m, 1H), 7.33 (m, 2H), 7.14 
(dd, J = 7.1, 0.6 Hz, 1H), 6.67 (dd, J = 7.8, 1.2 Hz, 1H), 6.56 (m, 1H), 5.94 (s, 1H), 3.91 
(s, 1H), 2.39 (s, 1H). 13C NMR (100 MHz, CDCl3) δ 173.21, 159.07, 141.06, 140.28, 
138.24, 134.07, 131.72, 128.57, 128.48, 128.09, 127.69, 127.44, 124.01, 111.62, 109.66, 
58.60, 56.63, 21.39. HRMS (EI) calcd for C20H19NOS [M]
+ 305.1187 found 321.1188. 
 
1-(2-Methyl-(1,1’-biphenylmethyl))-3-methoxyoxypyridin-2-thione (10f) 
Reaction of 9f (0.14 g, 0.45 mmol) and Lawesson’s reagent (0.11 g, 0.27 mmol) in 
toluene according to method described for synthesis of 10a afforded 118 mg of 10f (86%) 
as yellow solid. 1H NMR (400 MHz, CDCl3) δ 7.42 (dd, J = 6.6, 1.0 Hz, 1H), 7.22 (m, 
3H), 6.68 (d, J = 7.3 Hz, 1H), 6.59 (m, 1H), 5.96 (s, 1H), 3.90 (s, 1H), 2.22 (s, 1H). 13C 
NMR (100 MHz, CDCl3) δ 158.97, 141.54, 140.93, 135.02, 133.59, 131.79, 130.13, 
129.46, 129.42, 127.65, 127.18, 125.57, 111.62, 109.67, 58.56, 56.57, 20.25. HRMS (EI) 
calcd for C20H19NOS [M]




Reaction of 9g (0.22 g, 0.67 mmol) and Lawesson’s reagent (0.16 g, 0.40 mmol) in 
toluene according to method described for synthesis of 10a afforded 172 mg of 10g 
(73%) as yellow solid. 1H NMR (400 MHz, CDCl3) δ 7.39 (m, 5H), 7.22 (m, 2H), 6.69 
(m, 3H), 6.65 (m, 1H), 5.82 (s, 2H), 3.82 (s, 3H), 2.88 (s, 6H). 13C NMR (100 MHz, 
CDCl3) δ 172.36, 158.73, 149.92, 140.89, 132.48, 131.84, 128.44, 128.20, 127.29, 
126.32, 112.69, 112.02, 110.17, 58.68, 56.31, 40.24. HRMS (EI) calcd for C21H22N2OS 
[M]+ 350.1453 found 350.1451. 
 
1-(4-(6-(Dimethylamino)pyridin-3-yl)benzyl))-3-methoxyoxypyridin-2-thione (10h) 
Reaction of 9h (0.14 g, 0.42 mmol) and Lawesson’s reagent (0.10 g, 0.25 mmol) in 
toluene according to method described for synthesis of 10a afforded 130 mg of 10h 
(88%) of yellow solid. 1H NMR (400 MHz, CDCl3) δ 8.32 (d, J = 2.3 Hz, 1H), 7.56 (dd, 
J = 8.6, 2.1 Hz, 1H), 7.36 (dd, J = 19.8, 7.3 Hz, 3H), 7.26 (d, J = 8.0 Hz, 2H), 6.61 (d, J = 
7.8 Hz, 1H), 6.50 (m, 2H), 5.85 (s, 2H), 3.83 (s, 3H), 3.03 (s, 6H).  13C NMR (100 MHz, 
CDCl3) δ 172.74, 158.80, 158.31, 145.65, 138.13, 135.32, 133.08, 131.66, 128.46, 
125.95, 123.21, 111.57, 109.64, 105.42, 58.42, 56.47, 37.86. HRMS (EI) calcd for 
C20H21N3OS [M]
+ 351.1405 found 351.1405. 
 
1-(4-(Pyridin-4-yl)benzyl)-3-methoxypyridin-2-thione (10i) 
Reaction of 9i (0.13 g, 0.45 mmol) and Lawesson’s reagent (0.11 g, 0.27 mmol) in 
toluene according to method described for synthesis of 10a afforded 104 mg of 10i (76%) 
as yellow solid with greenish tinge. 1H NMR (400 MHz, CDCl3) δ 8.59 (d, J = 5.9 Hz, 
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2H), 7.55 (d, J = 8.3 Hz, 2H), 7.39 (m, 5H), 6.67 (dd, J = 7.8, 1.1 Hz, 1H), 6.58 (dd, J = 
7.7, 6.7 Hz, 1H), 5.95 (s, 2H), 3.89 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 173.29, 
159.15, 150.11, 147.43, 137.67, 136.17, 131.78, 128.58, 127.28, 121.35, 111.72, 109.67, 
58.54, 56.66. HRMS (EI) calcd for C18H16N2OS [M]
+ 308.0983 found 308.0975. 
 
Representative procedure for deprotection of O-methyl group for synthesis of 11 – 
1-(4-Cyano-(1,1’-biphenylmethyl))-3-hydroxyoxypyridin-2-one (11a) 
To a solution of 9a (0.1 g, 0.32 mmol) in dry CH2Cl2 (8 mL) was slowly added 1M BBr3 
(0.35 mL) at -30 oC under argon atmosphere. The reaction mixture was stirred for 32 h at 
room temperature. The mixture was again cooled to -30 oC & then MeOH (5 mL) was 
slowly added to the mixture. After evaporation of solvent, the residue was adjusted to pH 
7 with 1M NaOH and then extracted with CHCl3 (3 X 30mL). The combined organic 
layer dried over Na2SO4. After evaporation of solvent, the residue was purified by prep-
TLC with CHCl3: Acetone: EtOH (10:1:0.2) to give 89 mg of 11a (94%) as pure slightly 
brownish solid. 1H NMR (400 MHz, DMSO) δ 9.08 (s, 1H), 7.87 (dd, J = 24.8, 7.9 Hz, 
4H), 7.71 (d, J = 7.6 Hz, 2H), 7.40 (d, J = 7.7 Hz, 2H), 7.29 (d, J = 6.7 Hz, 1H), 6.70 (d, 
J = 6.7 Hz, 1H), 6.13 (t, J = 6.8 Hz, 1H), 5.18 (s, 2H). 13C NMR (100 MHz, CDCl3) δ 
147.11, 145.13, 139.24, 136.77, 132.87, 128.95, 127.97, 127.89, 127.06, 119.08, 114.15, 







Reaction of 9b (0.05g, 0.15 mmol) with 1M BBr3 (0.26 mL) in dry CH2Cl2 within 48 h 
according to procedure 11a afforded pure 11b (44 mg, quantitative) as slightly brownish 
solid.  1H NMR (400 MHz, DMSO-d6) δ 9.08 (s, 1H), 8.11 (s, 1H), 7.98 (d, J = 7.8 Hz, 
1H), 7.70 (m, 4H), 7.40 (d, J = 7.7 Hz, 2H), 7.28 (d, J = 6.2 Hz, 1H), 6.70 (d, J = 6.8 Hz, 
1H), 6.13 (t, J = 6.7 Hz, 1H), 5.17 (s, 2H). 13C NMR (100 MHz, CDCl3) δ 146.78, 
141.62, 138.62, 136.13, 131.31, 130.82, 130.51, 129.62, 128.71, 127.49, 126.66, 118.66, 





Reaction of 9c (0.072g, 0.15 mmol) with 1M BBr3 (0.34 mL) in dry CH2Cl2 within 48 h 
according to procedure 11a afforded pure 11c (61 mg, 90%) as slightly brownish solid. 
1H NMR (400 MHz, CDCl3) δ 7.75 (d, J = 7.6 Hz, 1H), 7.63 (t, J = 7.7 Hz, 1H), 7.53 (d, 
J = 7.3 Hz, 1H), 7.43 (m, 2H), 7.12 (m, 1H), 6.86 (dd, J = 28.2, 6.6 Hz, 1H), 6.19 (t, J = 
6.1 Hz, 1H), 5.25 (s, 1H). 13C NMR (100 MHz, CDCl3) δ 144.67, 137.88, 136.42, 
133.71, 132.85, 129.95, 129.23, 128.20, 127.69, 118.56, 111.08, 107.17, 52.13. HRMS 
(EI) calcd for C19H14N2O2 [M+H]
+ 302.1055 found 302.1053. 
 
1-(4-Methyl-(1,1’-biphenylmethyl))-3-hydroxyoxypyridin-2-one (11d) 
Reaction of 9d (0.06 g, 0.20 mmol) with 1M BBr3 (0.30 mL) in dry CH2Cl2 (5 mL) 
within 48 h according to procedure 11a afforded pure 11d (57 mg, quantitative) as 
slightly brownish solid.1H NMR (400 MHz, DMSO-d6) δ 9.07 (s, 1H), 7.57 (m, 2H), 7.50 
(d, J = 8.1 Hz, 2H), 7.34 (d, J = 6.8 Hz, 2H), 7.25 (dd, J = 14.8, 7.1 Hz, 3H), 6.69 (d, J = 
191 
 
7.4 Hz, 1H), 6.11 (t, J = 7.1 Hz, 1H), 5.14 (s, 2H), 2.30 (s, 3H). 13C NMR (100 MHz, 
DMSO-d6) δ 139.81, 137.29, 137.22, 136.68, 129.94, 128.77, 127.00, 126.89, 51.69, 
21.10.  Even after repeated cycles, quaternary carbons couldn’t be visualized. (No 
improvement with relaxation delay of 2 sec). HRMS (EI) calcd for C19H17NO2 [M]
+ 
291.1259 found 291.1250. 
 
1-(3-Methyl-(1,1’-biphenylmethyl))-3-hydroxyoxypyridin-2-one (11e) 
Reaction of 9e (0.064 g, 0.20 mmol) with 1M BBr3 (0.30 mL) in dry CH2Cl2 (5 mL) 
within 48 h according to procedure 11a afforded pure 11e (60 mg, quantitative) as 
slightly brownish solid. 1H NMR (400 MHz, CDCl3) δ 7.56 (d, J = 7.5 Hz, 1H), 7.33 (m, 
2H), 7.17 (d, J = 7.2 Hz, 1H), 6.85 (dd, J = 22.2, 6.4 Hz, 1H), 6.16 (t, J = 6.5 Hz, 1H), 
5.23 (s, 1H), 2.42 (s, 1H). 13C NMR (100 MHz, CDCl3) δ 146.71, 141.19, 140.38, 
138.32, 134.70, 128.63, 128.41, 128.16, 127.79, 127.56, 126.60, 124.11, 113.66, 106.98, 
52.10, 21.45. HRMS (EI) calcd for C19H17NO2 [M]
+ 291.1259 found 291.1263. 
 
1-(2-Methyl-(1,1’-biphenylmethyl))-3-hydroxyoxypyridin-2-one (11f) 
Reaction of 9f (0.077 g, 0.25 mmol) with 1M BBr3 (0.38 mL) in dry CH2Cl2 (5 mL) 
within 48 h according to procedure 11a afforded pure 11f (65 mg, 90%) as slightly 
brownish solid. 1H NMR (400 MHz, CDCl3) δ 7.28 (m, 3H), 6.87 (dd, J = 31.4, 6.8 Hz, 
1H), 6.18 (t, J = 6.9 Hz, 1H), 5.27 (d, J = 16.7 Hz, 1H), 2.26 (s, 1H). 13C NMR (100 
MHz, CDCl3) δ 146.73, 141.81, 141.14, 135.24, 134.30, 130.31, 129.66, 127.68, 127.37, 
126.73, 125.75, 113.59, 106.99, 52.21, 20.40. HRMS (EI) calcd for C19H17NO2 [M]
+ 





Reaction of 9g (0.10 g, 0.30 mmol) with 1M BBr3 (0.45 mL) in dry CH2Cl2 (8 mL)within 
48 h according to procedure 11a afforded pure 11g (84 mg, 87%) as slightly brownish 
solid. 1H NMR (400 MHz, DMSO-d6) δ 9.06 (s, 1H), 7.52 (d, J = 8.0 Hz, 3H), 7.28 (m, 
4H), 6.76 (m, 2H), 6.10 (t, J = 5.8 Hz, 1H), 5.12 (s, 2H), 2.90 (s, 6H). 13C NMR (100 
MHz, CDCl3) δ 158.71, 149.98, 146.62, 141.07, 135.81, 133.29, 128.83, 128.47, 128.21, 
128.07, 127.98, 127.55, 126.57, 113.48, 112.60, 106.89, 52.11, 40.44. HRMS (EI) calcd 
for C20H20N2O2 [M]
+ 320.1524 found 320.1512. 
 
1-(4-(6-(Dimethylamino)pyridin-3-yl)benzyl))-3-hydroxyoxypyridin-2-one (11h) 
Reaction of 9h (0.10 g, 0.29 mmol) with 1M BBr3 (0.45 mL) in dry CH2Cl2 (7 mL) 
within 48 h according to procedure 11a afforded pure 11h (67 mg, 83%) as slightly 
brownish solid. 1H NMR (400 MHz, CDCl3) δ 8.40 (s, 1H), 7.66 (d, J = 8.0 Hz, 1H), 7.49 
(d, J = 7.7 Hz, 2H), 7.33 (d, J = 7.7 Hz, 2H), 6.84 (dd, J = 27.3, 6.8 Hz, 3H), 6.57 (d, J = 
8.7 Hz, 1H), 6.15 (t, J = 7.0 Hz, 1H), 5.20 (s, 2H), 3.12 (s, 6H). 13C NMR (100 MHz, 
CDCl3) δ 158.47, 146.67, 145.66, 138.31, 135.79, 133.89, 131.95, 128.49, 126.79, 
126.28, 123.61, 114.16, 107.19, 105.94, 52.13, 38.15. HRMS (EI) calcd for C19H19N3O2 
[M]+ 321.1477 found 321.1479. 
 
1-(4-(Pyridin-4-yl)benzyl)-3-hydroxypyridin-2-one (11i) 
Reaction of 9i (0.10 g, 0.34 mmol) with 1M BBr3 (0.51 mL) in dry CH2Cl2 within 48 h 
according to procedure 11a afforded pure 11i (79 mg, 83%) as slightly brownish solid. 1H 
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NMR (400 MHz, CDCl3) δ 8.65 (s, 2H), 7.46 (s, 2H), 7.39 (d, J = 7.9 Hz, 2H), 6.83 (dd, 
J = 22.5, 7.0 Hz, 2H), 6.16 (t, J = 7.0 Hz, 1H), 5.22 (s, 2H). 13C NMR (100 MHz, CDCl3) 
δ 150.23, 147.62, 146.76, 137.98, 136.87, 128.66, 127.51, 126.64, 121.58, 113.66, 
107.13, 52.19. HRMS (FAB) calcd for C17H15N2O2 [M+H]





Reaction of 10a (0.10 g, 0.30 mmol) with 1M BBr3 (0.33 mL) in dry CH2Cl2 (8 mL) 
within 48 h according to procedure 11a afforded pure 12a (84 mg, 88%) as olive green 
color solid. 1H NMR (400 MHz, DMSO-d6) δ 7.87 (m, 5H), 7.74 (d, J = 8.1 Hz, 2H), 
7.37 (d, J = 8.1 Hz, 2H), 7.04 (m, 1H), 6.90 (d, J = 8.1 Hz, 1H), 5.87 (s, 2H). 13C NMR 
(100 MHz, CDCl3) δ 164.47, 144.66, 139.24, 134.64, 132.60, 128.56, 127.74, 127.62, 
118.75, 111.15, 61.79, 29.64.HRMS (EI) calcd for C19H15N2OS [M]




Reaction of 10b (0.07 g, 0.21 mmol) with 1M BBr3 (0.32 mL) in dry CH2Cl2 (5 mL) 
within 48 h according to procedure 11a afforded pure 12b (53 mg, 79%) as olive green 
color solid. 1H NMR (400 MHz, CD3OD) δ 7.89 (m, 2H), 7.65 (m, 5H), 7.44 (d, J = 8.2 
Hz, 2H), 7.02 (d, J = 7.7 Hz, 2H), 6.77 (m, 1H), 5.90 (s, 2H). 13C NMR (100 MHz, 
CD3OD) δ 142.99, 140.04, 132.82, 132.18, 131.69, 131.12, 130.03, 129.97, 129.89, 
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128.69, 128.59, 119.83, 113.94, 106.40, 54.78. HRMS (EI) calcd for C19H14N2O2 
[M+H]+ 318.0827 found 318.0827 
 
1-(2-Cyano-(1,1’-biphenylmethyl))-3-hydroxyoxypyridin-2-thione (12c) 
Reaction of 10c (0.042 g, 0.21 mmol) with 1M BBr3 (0.19 mL) in dry CH2Cl2 (5 mL) 
within 48 h according to procedure 11a afforded pure 12c (31 mg, 78%) as olive green 
color solid. 1H NMR (400 MHz, CD3OD) δ 7.77 (dd, J = 7.7, 0.9 Hz, 1H), 7.67 (m, 2H), 
7.48 (m, 4H), 7.01 (d, J = 13.1 Hz, 1H), 6.70 (m, 1H), 5.90 (s, 1H). 13C NMR (100 MHz, 
CD3OD) δ 145.34, 138.90, 134.40, 133.88, 130.75, 129.88, 128.90, 128.62, 119.17, 
115.12, 111.38. HRMS (EI) calcd for C19H14N2O2 [M+H]
+ 318.0821 found 318.0827 
 
1-(4-Methyl-(1,1’-biphenylmethyl))-3-hydroxyoxypyridin-2-thione (12d) 
Reaction of 10d (0.06 g, 0.20 mmol) with 1M BBr3 (0.30 mL) in dry CH2Cl2 (5 mL) 
within 48 h according to procedure 11a afforded pure 12d (45 mg, 73%) as olive green 
color solid. 1H NMR (400 MHz, CD3OD) δ 7.70 (d, J = 1.1 Hz, 1H), 7.63 (d, J = 6.3 Hz, 
1H), 7.55 (d, J = 8.2 Hz, 2H), 7.40 (m, 3H), 7.21 (d, J = 8.1 Hz, 2H), 7.03 (dd, J = 14.9, 
7.8 Hz, 2H), 6.75 (t, J = 7.0 Hz, 1H), 5.87 (s, 2H), 2.35 (s, 3H). Even after repeated 
cycles, quaternary carbons couldn’t be visualized. (No improvement with relaxation 
delay of 2 sec). HRMS (EI) calcd for C19H17NOS [M]
+ 307.1031 found 307.1022. 
 
1-(3-Methyl-(1,1’-biphenylmethyl))-3-hydroxyoxypyridin-2-thione (12e) 
Reaction of 10e (0.08 g, 0.20 mmol) with 1M BBr3 (0.36 mL) in dry CH2Cl2 (5 mL) 
within 48 h according to procedure 11a afforded pure 12e (51 mg, 70%) as olive green 
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color solid. 1H NMR (400 MHz, CD3OD) δ 7.53 (m, 1H), 7.30 (m, 2H), 7.12 (d, J = 7.2 
Hz, 1H), 6.97 (m, 1H), 6.68 (m, 1H), 5.81 (s, 1H), 2.36 (s, 1H). 13C NMR (100 MHz, 
CD3OD) δ 141.53, 140.21, 138.34, 128.62, 128.48, 128.21, 127.69, 127.54, 124.03, 
21.19. HRMS (EI) calcd for C19H17NOS [M]
+ 307.1031 found 307.1031. 
 
1-(2-Methyl-(1,1’-biphenylmethyl))-3-hydroxyoxypyridin-2-thione (12f) 
Reaction of 10f (0.08 g, 0.20 mmol) with 1M BBr3 (0.36 mL) in dry CH2Cl2 (5 mL) 
within 48 h according to procedure 11a afforded pure 12f (49 mg, 67%) as olive green 
color solid. 1H NMR (400 MHz, CD3OD) δ 7.54 (m, 1H), 7.19 (m, 3H), 6.98 (m, 1H), 
6.70 (m, 1H), 5.83 (s, 1H), 2.19 (s, 1H). 13C NMR (100 MHz, CD3OD) δ 142.14, 140.99, 
135.05, 130.21, 129.58, 129.48, 127.76, 127.33, 125.66, 20.02. HRMS (EI) calcd for 
C19H17NOS [M]
+ 307.1031 found 307.1034. 
 
1-(4-Dimethylamino-(1,1’-biphenylmethyl))-3-hydroxyoxypyridin-2-thione (12g) 
Reaction of 10g (0.11 g, 0.33 mmol) with 1M BBr3 (0.39 mL) in dry CH2Cl2 (5 mL) 
within 48 h according to procedure 11a afforded pure 12g (68 mg, 62%) as olive green 
color solid. 1H NMR (400 MHz, CDCl3) δ 8.57 (d, J = 8.5 Hz, 1H), 7.53 (d, J = 8.2 Hz, 
2H), 7.46 (m, 2H), 7.33 (d, J = 8.0 Hz, 3H), 6.97 (d, J = 6.8 Hz, 1H), 6.77 (d, J = 8.8 Hz, 
2H), 6.62 (m, 1H), 5.79 (s, 2H), 2.98 (s, 6H). 13C NMR (100 MHz, CDCl3) δ 169.71, 
155.14, 150.08, 141.51, 131.92, 130.80, 129.00, 128.83, 127.99, 127.58, 126.68, 113.58, 
112.62, 111.90, 60.11, 40.45. HRMS (EI) calcd for C20H20N2OS [M]






Reaction of 10h (0.064 g, 0.18 mmol) with 1M BBr3 (0.27 mL) in dry CH2Cl2 (5 mL) 
within 48 h according to procedure 11a afforded pure 12h (48 mg, 79%) as olive green 
color solid. 1H NMR (400 MHz, CDCl3) δ 8.30 (s, 1H), 7.70 (d, J = 8.9 Hz, 1H), 7.46 (s, 
2H), 7.31 (t, J = 7.6 Hz, 3H), 6.98 (d, J = 7.8 Hz, 1H), 6.67 (m, 2H), 5.75 (s, 2H), 3.11 (s, 
8H). 13C NMR (100 MHz, CDCl3) δ 157.02, 143.45, 142.18, 137.74, 136.98, 132.81, 
128.75, 127.56, 126.37, 123.70, 114.43, 107.03, 38.48, 29.54. HRMS (EI) calcd for 
C19H19N3OS [M]
+ 337.1249 found 337.1251. 
 
1-(4-(Pyridin-4-yl)benzyl)-3-hydroxypyridin-2-thione (12i) 
Reaction of 10i (0.08 g, 0.25 mmol) with 1M BBr3 (0.38 mL) in dry CH2Cl2 (5 mL) 
within 48 h according to procedure 11a afforded pure 12i (65 mg, 88%) as olive green 
color solid. 1H NMR (400 MHz, CDCl3) δ 8.65 (d, J = 5.3 Hz, 2H), 8.55 (s, 1H), 7.62 (d, 
J = 8.0 Hz, 2H), 7.42 (m, 5H), 6.99 (d, J = 7.5 Hz, 1H), 6.67 (t, J = 7.0 Hz, 1H), 5.85 (s, 
2H). 13C NMR (100 MHz, CDCl3) δ 170.05, 155.32, 150.25, 147.44, 138.22, 135.48, 
130.91, 128.80, 127.55, 121.48, 113.73, 111.94, 59.91. HRMS (EI) calcd for 
C17H14N2OS [M]
+ 294.0827 found 294.0823. 
 
1-Propargyl-3-methoxypyridin-2-one (13)  
To a stirring solution of 3-methoxy-2-pyridinone (1.00 g, 8.00 mmol) in DMF (25 mL), 
was added propargyl bromide (80 wt% solution in toluene, 1.5 equiv) and K2CO3 (3.313 
g, 24 mmol). Reaction mixture was heated to 100 oC. After overnight reaction, reaction 
mixture was partitioned between EtOAc  (120 mL)and water (100 mL). Organic layer 
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was separated and washed repeatedly with water (7 X 100 mL) and brine (1 X 60 mL). 
Organic layer was dried on Na2SO4 and evaporated under vacuo to yield dark brown 
crude product. Column chromatography using gradient CH2Cl2:Acetone (max 20%) gave 
pure 13 (0.79 g, 60%) as a slightly brownish solid. 1H NMR (CDCl3, 400 MHz) δ 2.36 
(1H, t, J = 2.8), 3.67 (3H, m), 4.66 (1H, d, J = 2.8), 6.05 (1H, t, J = 7.2), 6.50 (1H, dd, J = 
1.6, 7.2), 7.11 (1H, dd, J = 1.6, 6.8); 13C NMR (CDCl3, 100 MHz) δ 37.2, 55.5, 74.6, 




1-Phenyltriazolylmethyl-3-methoxypyridin-2-one (14a)  
13 (0.32 g, 1.951 mmol) and phenylazide (0.348 g, 2.926 mmol) were dissolved in 
anhydrous THF (10 mL) and stirred under argon at room temperature.  Copper (I) iodide 
(0.011 g, 0.07 mmol) and Hunig’s base (0.1 mL) were then added to the reaction mixture, 
and stirring continued for 4 h.  The reaction mixture was diluted with CH2Cl2 (40 mL) 
and washed with 1:4 NH4OH/saturated NH4Cl (3 x 30 mL) and saturated NH4Cl (30 mL).  
The organic layer was dried over Na2SO4 and concentrated in vacuo.  The crude product 
was triturated with hexanes to give 510 mg (92%) of white solid 14a.1H NMR (CDCl3, 
400 MHz) δ 3.58 (3H, s), 5.11 (2H, s), 5.93 (1H, t, J = 7.6), 6.42 (1H, d, J = 7.2), 7.07 
(1H, d, J = 6.4), 7.16-7.20 (1H, m), 7.26 (2H, t, J = 7.6), 7.49 (2H, d, J = 8.0); 13C NMR 
(CDCl3, 100 MHz) δ 44.2, 55.2, 104.7, 112.0, 119.7, 121.8, 127.9, 128.1, 129.0, 136.2, 
142.8, 149.3, 157.2. HRMS (EI) calcd for C15H14N4O2 [M]
+ 282.1117 found 282.1115. 
 
1-(4-Dimethylamino)phenylltriazolylmethyl-3-methoxypyridin-2-one (14b)  
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Reaction of 4-azido-N,N-dimethylaniline (0.09 g, 0.61 mmol) and 13 (0.10 g, 0.61 mmol) 
within 4 h as described for synthesis of 14a gave compound 14b (0.13 g, 68 %) as a 
white solid. 1H NMR (400 MHz, CDCl3) δ 8.04 (s, 1H), 7.41 (m, 2H), 7.15 (dd, J = 6.9, 
1.7 Hz, 1H), 6.62 (m, 2H), 6.51 (dd, J = 7.5, 1.6 Hz, 1H), 6.03 (m, 1H), 5.19 (s, 2H), 3.70 
(s, 3H), 2.89 (s, 6H). 13C NMR (100 MHz, CDCl3) δ 157.54, 150.18, 149.65, 142.60, 
128.17, 126.18, 121.90, 121.43, 112.20, 111.84, 104.93, 55.55, 44.54, 40.08. HRMS (EI) 
calcd for C17H19N5O2 [M]
+ 325.1539 found 325.1544. 
 
1-Phenyltriazolylmethyl-3-hydroxypyridin-2-one (15a)  
Reaction of 14a (0.212 g, 0.75 mmol) and 1M BBr3 in CH2Cl2 (1.5 equiv) withing 48 h 
as described for the synthesis of 11a gave compound 15a (0.123 g, 61%) as light brown 
solid. 1H NMR (DMSO-d6, 400 MHz) δ 5.27 (2H, s), 6.13 (1H, t, J = 6.4), 6.67 (1H, d, J 
= 7.2), 7.30 (1H, d, J = 5.6), 7.45-7.49 (1H, m), 7.57 (2H, t, J = 7.6), 7.87 (2H, d, J = 
8.0), 8.73 (1H, s), 9.08 (1H, s); 13C NMR (100 MHz, CDCl3) δ 136.59, 129.60, 128.94, 
122.29, 120.62, 107.99, 29.29. (quaternary cabons were not seen). HRMS (EI) calcd for 
C14H12N4O2 [M]
+ 268.0960 found 268.0967. 
 
1-(4-Dimethylamino)phenylltriazolylmethyl-3-hydroxypyridin-2-one (15b)  
Reaction of 14b (0.045 g, 0.14 mmol) and 1M BBr3 in CH2Cl2 (0.22 mL, 1.5 equiv) 
withing 48 h as described for the synthesis of 11a gave compound 15b (0.033 g, 77%) as 
light brown solid. 1H NMR (400 MHz, CDCl3) δ 8.08 (s, 1H), 7.48 (dd, J = 19.9, 8.4 Hz, 
2H), 7.18 (d, J = 6.7 Hz, 1H), 6.69 (ddd, J = 25.8, 24.8, 7.5 Hz, 4H), 6.16 (t, J = 6.9 Hz, 
1H), 5.31 (s, 2H), 2.98 (m, 6H). 13C NMR (100 MHz, CDCl3) δ 158.35, 150.52, 146.68, 
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142.48, 127.10, 126.44, 122.06, 121.88, 121.76, 112.12, 107.14, 44.66, 40.33. HRMS 
(EI) calcd for C16H17N5O2 [M]
+ 311.1382 found 311.1386. 
 
1-Phenyltriazolylmethyl-3-methoxypyridin-2-thione (16a)  
Reaction of 14a (0.295 g, 1.04 mmol) and Lawesson’s reagent (0.252 g, 0.624 mmol) in 
toluene (15 mL) within 12 h as described for the synthesis of 10a gave compound 16a 
(0.291 g, 94%) as yellow solid. 1H NMR (CDCl3, 400 MHz) δ 3.90 (3H, s), 6.04 (2H, s), 
6.62-6.68 (2H, m), 7.38-7.42 (1H, m), 7.48 (2H, t, J = 7.2), 7.68 (2H, d, J = 8.0), 7.82 
(1H, d, J = 4.8), 8.53 (1H, s); 13C NMR (CDCl3, 100 MHz) δ 50.9, 56.4, 110.0, 112.0, 
120.2, 122.4, 128.5, 129.3, 132.2, 136.4, 141.9, 158.7, 171.5 HRMS (EI) calcd for 
C15H14N4O2 [M]
+ 282.1117 found 282.1115. HRMS (EI) calcd for C15H14N4OS [M]
+ 
298.0888 found 298.0888. 
 
1-(4-Dimethylamino)phenylltriazolylmethyl-3-methoxypyridin-2-thione (16b)  
Reaction of 14b (0.078 g, 0.248 mmol) and Lawesson’s reagent (0.06 g, 0.15 mmol) in 
toluene (8 mL) within 12 h as described for the synthesis of 10a gave compound 16b 
(0.07 g, 84%) as yellow solid. 1H NMR (400 MHz, CDCl3) δ 8.36 (s, 1H), 7.81 (dd, J = 
6.4, 1.5 Hz, 1H), 7.46 (m, 2H), 6.66 (m, 4H), 6.01 (s, 2H), 3.87 (s, 3H), 2.97 (s, 6H). 13C 
NMR (100 MHz, CDCl3) δ 171.82, 158.93, 150.44, 141.54, 132.44, 126.29, 122.49, 
121.77, 112.10, 112.03, 110.14, 56.65, 51.20, 40.29. HRMS (EI) calcd for C17H19N5OS 
[M]+ 314.1310 found 314.1304. 
 
1-Phenyltriazolylmethyl-3-hydroxypyridin-2-thione (17a)  
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Reaction of 16a (0.28 g, 0.93 mmol) and 1M BBr3 in CH2Cl2 (1.5 equiv) within 48 h as 
described for the synthesis of 11a gave compound 17a (0.178 g, 67%) as olive green 
solid. 1H NMR (400 MHz, CDCl3) δ 8.43 (d, J = 16.6 Hz, 1H), 8.39 (s, 1H), 7.79 (dd, J = 
6.6, 1.3 Hz, 1H), 7.69 (m, 2H), 7.46 (m, 3H), 6.97 (dd, J = 7.7, 1.2 Hz, 1H), 6.69 (dd, J = 
7.6, 6.8 Hz, 1H), 5.94 (s, 2H). 13C NMR (100 MHz, CDC3) δ 168.59, 155.12, 141.60, 
136.66, 131.65, 129.69, 128.99, 122.57, 120.60, 114.04, 112.47, 77.30, 76.99, 76.67, 
52.08. HRMS (EI) calcd for C14H12N4OS [M]
+ 284.0730 found 284.0732. 
 
1-(4-Dimethylamino)phenylltriazolylmethyl-3-hydroxypyridin-2-thione (17b)  
Reaction of 16b (0.07 g, 0.212 mmol) and 1M BBr3 in CH2Cl2 (0.64 mL, 1.5 equiv) 
within 48 h as described for the synthesis of 11a gave compound 17b (0.032 g, 48%) as 
olive green solid. 1H NMR (400 MHz, CDCl3) δ 8.42 (s, 1H), 8.29 (d, J = 11.5 Hz, 1H), 
7.79 (d, J = 6.4 Hz, 1H), 7.50 (m, 2H), 6.98 (dd, J = 36.5, 28.9 Hz, 2H), 6.72 (m, 3H), 
5.94 (s, 2H), 3.01 (d, J = 2.7 Hz, 6H). 13C NMR (100 MHz, CDCl3) δ 155.09, 150.66, 
141.13, 131.72, 127.68, 126.27, 122.45, 121.97, 114.04, 112.52, 112.16, 52.21, 40.41. 
HRMS (EI) calcd for C16H17N5OS [M]
+ 327.1154 found 327.1154. 
 
Representative Procedure for Conversion of Azidoalkanol to azidoalkyl 
methanesulfonate 19 – 
 2-Azidoethyl methanesulfonate (19a) – 
To a solution of compound 2-azidoethanol (1.00 g, 11.49 mmol) in THF (25 mL) and 
triethylamine (Et3N) (2.418 mL, 17.24 mmol) was added mesyl chloride (1.328 mL, 
17.24 mmol) at 0 °C, and the mixture was allowed to warm to room temperature. Stirring 
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continued for 3 h, during which TLC revealed a quantitative conversion into a higher Rf 
product. CH2Cl2 (70 mL) and saturated sodium bicarbonate (50 mL) were added, and the 
two layers were separated. The organic layer was washed with sodium bicarbonate (2 × 
50 mL), saturated brine (45 mL) and dried over Na2SO4. Solvent was evaporated off to 
give crude compound 19a (1.70 g) as a colorless oil, which was used for next step 
without further purification. 
 
2-Azidopropyl methanesulfonate (19b) – 
Reaction of 3-azidopropanol  (1.00 g, 9.90 mmol) and mesyl chloride (1.14 mL, 14.85 
mmol) within 3 h as described for synthesis of 19a gave compound 19b (1.18 g) as a 
crude colorless oil.  
 
2-Azidobutyl methanesulfonate (19c) – 
Reaction of 4-azidobutanol  (0.80 g, 6.95 mmol) and mesyl chloride (1.48 mL, 10.43 
mmol) within 3 h as described for synthesis of 19a gave compound 19b (1.33 g) as a 
crude colorless oil. 
 
2-Azidopentyl methanesulfonate (19d) – 
Reaction of 5-azidopentanol  (1.1 g, 8.53 mmol) and mesyl chloride (0.98 mL, 12.79 
mmol) within 3 h as described for synthesis of 19a gave compound 19d (1.54 g) as a 





2-Azidohexyl methanesulfonate (19e) – 
Reaction of 6-azidohexanol  (0.74 g, 5.22 mmol) and mesyl chloride (0.61 mL, 7.83 
mmol) within 3 h as described for synthesis of 19a gave compound 19e (0.87 g) as a 
crude colorless oil. 
2-Azidoheptyl  methanesulfonate (19f) – 
Reaction of 7-azidoheptanol  (0.55 g, 3.49 mmol) and mesyl chloride (0.41 mL, 5.30 
mmol) within 3 h as described for synthesis of 19a gave compound 19f (0.79 g) as a 
crude colorless oil. 
 
Representative procedure for synthesis of 1-(2-azidoalkyl)-3-methoxypyridin-2-ones  
1-(2-Azidoethyl)-3-methoxypyridin-2-one (20a)  
3-methoxypyridin-2-one (0.40 g, 3.20 mmol), 19a (0.79 g, 4.80 mmol),  and K2CO3 (1.32 
g, 9.60 mmol) stirred overnight in THF at reflux temperature. Reaction mixture was 
cooled down to room temperature. Reaction mixture was partitioned between CH2Cl2 (60 
mL) and water (50 mL). Organic layer washed with water (2 x 35 mL), brine (1 x 30 
mL). Organic layer dried on Na2SO4 and evaporated in vacuo. Crude product was 
purified by flash chromatography with stepwise gradient of CH2Cl2 and acetone (max 
15%) to give 0.34 mg of 20a (55%) as colorless oil. 1H NMR (400 MHz, CDCl3) δ 6.77 
(dd, J = 6.9, 1.6 Hz, 1H), 6.48 (dd, J = 7.5, 1.6 Hz, 1H), 5.96 (m, 1H), 3.91 (m, 2H), 3.62 
(s, 3H), 3.52 (m, 2H). 13C NMR (100 MHz, CDCl3) δ 157.39, 149.41, 128.61, 112.16, 
104.37, 55.36, 49.00, 48.91. HRMS (EI) calcd for C8H10N4O2 [M]





1-(3-Azidopropyl)-3-benzyloxypyridin-2-one (20b)  
Reaction of 3-benzyloxypyridin-2-one (0.40 g, 1.99 mmol) and 19b (0.53 g, 2.98 mmol) 
within 16 h as described for synthesis of 20a gave compound 20b (0.30 g, 53%) as a 
colorless oil.   1H NMR (300 MHz, CDCl3) δ 7.28 (m, 5H), 6.84 (dd, J = 6.9, 1.6 Hz, 
1H), 6.60 (dd, J = 7.4, 1.5 Hz, 1H), 5.98 (t, J = 7.1 Hz, 1H), 3.97 (t, J = 6.8 Hz, 2H), 3.28 
(t, J = 6.5 Hz, 2H), 1.98 (p, J = 6.7 Hz, 2H). 13C NMR (75 MHz, CDCl3) δ 157.78, 
148.65, 135.93, 128.85, 128.24, 127.69, 127.03, 115.16, 104.53, 70.39, 48.14, 47.06, 
27.66. HRMS (EI) calcd for C15H16N4O2 [M]
+ 284.1273 found 284.1271. 
 
1-(4-Azidobutyl)-3-benzyloxypyridin-2-one (20c)  
Reaction of 3-benzyloxypyridin-2-one (0.40 g, 1.99 mmol) and 19c (0.58 g, 2.98 mmol) 
within 16 h as described for synthesis of 20a gave compound 20c (0.36 g, 62%) as a 
colorless oil.   1H NMR (400 MHz, CDCl3) δ 7.22 (m, 5H), 6.78 (dd, J = 6.9, 1.7 Hz, 
1H), 6.54 (dd, J = 7.4, 1.7 Hz, 1H), 5.91 (m, 1H), 4.96 (s, 2H), 3.85 (t, J = 7.2 Hz, 2H), 
3.17 (t, J = 6.8 Hz, 2H), 1.71 (m, 2H), 1.48 (m, 2H). 13C NMR (100 MHz, CDCl3) δ 
157.52, 148.27, 135.78, 128.37, 127.98, 127.42, 126.82, 114.92, 104.32, 70.09, 50.43, 
48.46, 25.83, 25.42. HRMS (EI) calcd for C16H18N4O2 [M]
+ 298.1430 found 298.1446. 
 
1-(5-Azidopentyl)-3-benzyloxypyridin-2-one (20d)  
Reaction of 3-benzyloxypyridin-2-one (0.50 g, 2.49 mmol) and 19d (0.62 g, 2.98 mmol) 
within 16 h as described for synthesis of 20a gave compound 20d (0.49 g, 63%) as a 
colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.35 (d, J = 8.0 Hz, 2H), 7.23 (m, 3H), 6.81 
(m, 1H), 6.56 (m, 1H), 5.94 (m, 1H), 5.01 (s, 2H), 3.85 (m, 2H), 3.18 (m, 2H), 1.71 (m, 
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2H), 1.54 (m, 2H), 1.32 (m, 2H). 13C NMR (100 MHz, CDCl3) δ 157.68, 148.47, 135.98, 
128.60, 128.12, 127.53, 126.93, 115.09, 104.32, 70.27, 50.77, 49.21, 28.19, 28.06, 23.37. 
HRMS (EI) calcd for C17H20N4O2 [M]
+ 312.1586 found 312.1589. 
 
1-(6-Azidohexyl)-3-benzyloxypyridin-2-one (20e)  
Reaction of 3-benzyloxypyridin-2-one (0.50 g, 2.49 mmol) and 19d (0.66 g, 2.98 mmol) 
within 16 h as described for synthesis of 20a gave compound 20e (0.48 g, 60%) as a 
colorless oil.   1H NMR (400 MHz, CDCl3) δ 7.15 (m, 5H), 6.65 (dd, J = 7.4, 1.8 Hz, 
1H), 6.45 (dd, J = 7.4, 1.8 Hz, 1H), 5.81 (t, J = 7.1 Hz, 1H), 4.92 (s, 2H), 3.76 (t, J = 6.8 
Hz, 2H), 3..05 (t, J = 6.8 Hz, 2H), 1.58 (m, 2H), 1.40 (m, 2H), 1.90 (m, 4H). 13C NMR 
(100 MHz, CDCl3) δ 157.55, 148.25, 135.95, 128.60, 128.10, 126.95, 126.50, 115.05, 
104.90, 70.50, 51.05, 49.20, 28.65, 28.50, 26.20, 25.80. HRMS (FAB) calcd for 
C18H23N4O2 [M+H]
+ 327.1821 found 327.1848. 
 
1-(7-Azidoheptyl)-3-benzyloxypyridin-2-one (20f)  
Reaction of 3-benzyloxypyridin-2-one (0.79 g, 3.38 mmol) and 19f (0.81 g, 4.05 mmol) 
within 16 h as described for synthesis of 20a gave compound 20f (0.55 g, 48%) as a 
colorless oil.  1H NMR (400 MHz, CDCl3) δ 7.42 (dd, J = 7.8, 1.0 Hz, 2H), 7.31 (m, 3H), 
6.85 (dd, J = 6.9, 1.7 Hz, 1H), 6.61 (dd, J = 7.4, 1.7 Hz, 1H), 5.99 (m, 1H), 5.09 (s, 2H), 
3.93 (m, 2H), 3.23 (t, J = 6.9 Hz, 2H), 1.74 (m, 2H), 1.55 (m, 2H), 1.34 (m, 6H).  13C 
NMR (100 MHz, CDCl3) δ 158.32, 149.19, 136.63, 129.15, 128.74, 128.13, 127.52, 




Representative procedure for synthesis of 21 
1-Phenyltriazolylethyl-3-methoxypyridin-2-one (21a)  
 
Phenylacetylene (0.167 g, 1.63 mmol) and 20a (0.265 g, 1.36 mmol) were dissolved in 
anhydrous THF (10 mL) and stirred under argon at room temperature.  Copper (I) iodide 
(0.011 g, 0.07 mmol) and Hunig’s base (0.1 mL) were then added to the reaction mixture, 
and stirring continued for 4 h.  The reaction mixture was diluted with CH2Cl2 (40 mL) 
and washed with 1:4 NH4OH/saturated NH4Cl (3 x 30 mL) and saturated NH4Cl (30 mL).  
The organic layer was dried over Na2SO4 and concentrated in vacuo.  The crude product 
was triturated with hexanes to give 366 mg (91%) of white solid 21a. 1H NMR (400 
MHz, CDCl3) δ 7.68 (s, 1H), 7.47 (d, J = 7.5 Hz, 2H), 7.11 (m, 3H), 6.43 (d, J = 7.4 Hz, 
1H), 6.35 (dd, J = 6.8, 0.9 Hz, 1H), 5.78 (t, J = 7.2 Hz, 1H), 4.57 (t, J = 5.7 Hz, 2H), 4.25 
(t, J = 5.6 Hz, 2H), 3.53 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 157.70, 149.08, 147.21, 
129.40, 128.30, 128.08, 127.80, 125.00, 120.91, 113.02, 105.44, 55.15, 49.72, 47.44. 
HRMS (EI) calcd for C16H16N4O2 [M]
+ 296.1273 found 296.1268. 
 
1-Phenyltriazolylpropyl-3-benzyloxypyridin-2-one (21b)  
Reaction of phenylacetylene (0.127 g, 1.25 mmol) and 20b (0.295 g, 1.04 mmol) within 4 
h as described for synthesis of 21a gave compound 21b (0.31 g, 77%) as a white solid.   
1H NMR (400 MHz, CDCl3) δ 8.00 (s, 1H), 7.77 (d, J = 7.3 Hz, 2H), 7.27 (m, 8H), 6.88 
(d, J = 5.7 Hz, 1H), 6.57 (d, J = 6.4 Hz, 1H), 5.95 (t, J = 7.1 Hz, 1H), 4.99 (s, 2H), 4.34 
(t, J = 6.4 Hz, 2H), 3.94 (t, J = 6.4 Hz, 2H), 2.32 (m, 2H). 13C NMR (100 MHz, CDCl3) δ 
157.92, 148.47, 147.30, 135.73, 130.26, 128.81, 128.49, 128.22, 127.76, 127.71, 127.01, 
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125.33, 120.16, 114.95, 104.83, 70.33, 47.00, 46.48, 29.30. HRMS (EI) calcd for 
C23H22N4O2 [M]
+ 386.1743 found 386.1734.  
 
1-Phenyltriazolylbutyl-3-benzyloxypyridin-2-one (21c)  
Reaction of phenylacetylene (0.124 g, 1.21 mmol) and 20c (0.30 g, 1.01 mmol) within 4 
h as described for synthesis of 21a gave compound 21c (0.31 g, 77%) as a white solid. 1H 
NMR (400 MHz, CDCl3) δ 7.83 (s, 1H), 7.76 (m, 2H), 7.26 (m, 8H), 6.76 (dd, J = 6.9, 
1.5 Hz, 1H), 6.56 (dd, J = 7.4, 1.5 Hz, 1H), 5.91 (t, J = 7.1 Hz, 1H), 4.99 (s, 2H), 4.31 
(m, 2H), 3.89 (t, J = 7.1 Hz, 2H), 1.85 (m, 2H), 1.67 (m, 2H). 13C NMR (100 MHz, 
CDCl3) δ 157.71, 148.38, 147.20, 135.83, 130.29, 128.45, 128.41, 128.16, 127.68, 
127.63, 126.96, 125.25, 119.87, 114.99, 104.60, 70.26, 49.11, 48.02, 26.78, 25.65. 
HRMS (EI) calcd for C24H24N4O2 [M]
+ 400.1899 found 400.1888. 
 
1-Phenyltriazolylpentyl-3-benzyloxypyridin-2-one (21d)  
Reaction of phenylacetylene (0.04 g, 0.32 mmol) and 20d (0.10 g, 0.32 mmol) within 4 h 
as described for synthesis of 21a gave compound 21d (0.092 g, 72%) as a white solid.   
1H NMR (400 MHz, CDCl3) δ 7.78 (m, 3H), 7.30 (m, 8H), 6.79 (d, J = 6.8 Hz, 1H), 6.57 
(d, J = 7.3 Hz, 1H), 5.94 (t, J = 7.1 Hz, 1H), 5.02 (s, 2H), 4.31 (t, J = 7.0 Hz, 2H), 3.87 (t, 
J = 7.2 Hz, 2H), 1.91 (m, 2H), 1.74 (m, 2H), 1.30 (m, 2H). 13C NMR (100 MHz, CDCl3) 
δ 157.80, 148.57, 147.39, 136.02, 130.44, 128.64, 128.56, 128.27, 127.81, 127.71, 
127.05, 125.40, 119.57, 115.12, 104.49, 70.40, 49.71, 49.06, 29.42, 28.03, 23.05.  
 
1-Phenyltriazolylhexyl-3-benzyloxypyridin-2-one (21e)  
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Reaction of phenylacetylene (0.80 g, 0.78 mmol) and 20e (0.21 g, 0.65 mmol) within 4 h 
as described for synthesis of 21a gave compound 21e (0.16 g, 56%) as a white solid.   
NMR (400 MHz, CDCl3) δ 7.66 (m, 3H), 7.20 (m, 8H), 6.68 (dd, J = 6.9, 1.5 Hz, 1H), 
6.46 (dd, J = 7.4, 1.5 Hz, 1H), 5.82 (t, J = 7.1 Hz, 1H), 4.92 (s, 2H), 4.18 (t, J = 6.8 Hz, 
2H), 3.75 (t, J = 6.8 Hz, 2H), 1.76 (m, 2H), 1.56 (m, 2H), 1.19 (m, 4H). 13C NMR (100 
MHz, CDCl3) δ 157.64, 148.46, 147.27, 135.95, 130.36, 128.57, 128.48, 128.19, 127.72, 
127.60, 126.96, 125.32, 119.37, 115.02, 104.37 70.45, 50.03, 49.35, 29.90, 28.66, 25.87, 
25.78. HRMS (FAB) calcd for C26H29N4O2 [M+H]
+ 429.2290 found 429.2291. 
 
1-Phenyltriazolylheptyl-3-benzyloxypyridin-2-one (21f)  
Reaction of phenylacetylene (0.90 g, 0.88 mmol) and 20f (0.25 g, 0.735 mmol) within 4 h 
as described for synthesis of 21a gave compound 21f (0.23 g, 63%) as a white solid.   1H 
NMR (400 MHz, CDCl3) δ 7.79 (m, 3H), 7.31 (m, 8H), 6.83 (dd, J = 6.9, 1.7 Hz, 1H), 
6.60 (dd, J = 7.4, 1.7 Hz, 1H), 5.97 (t, J = 7.1 Hz, 1H), 5.07 (s, 2H), 4.35 (t, J = 7.1 Hz, 
2H), 3.91 (m, 2H), 1.88 (m, 2H), 1.71 (m, 2H), 1.32 (d, J = 10.0 Hz, 6H). 13C NMR (100 
MHz, CDCl3) δ 158.31, 149.13, 147.92, 136.57, 130.93, 129.15, 129.04, 128.74, 128.28, 
128.15, 127.51, 125.90, 125.86, 119.75, 115.60, 104.79, 70.92, 50.52, 49.90, 30.42, 
29.13, 28.72, 26.53, 26.46. HRMS (FAB) calcd for C27H31N4O2 [M+H]
+ 443.2447 found 
443.2494. 
 
1-Phenyltriazolylethyl-3-hydroxypyridin-2-one (22a)  
To a solution of 21a (0.10 g, 0.338 mmol) in dry CH2Cl2 (8 mL) was slowly added 1M 
BBr3 (1.2 equiv) at -30 
oC under argon atmosphere. The reaction mixture was stirred for 
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48 h at room temperature. The mixture was again cooled to -30 oC and the MeOH (5 mL) 
was slowly added to the mixture. After evaporation of solvent, the residue was adjusted 
to pH 7 with 1M NaOH and then extracted with CHCl3 (30 mL X 3). The combined 
organic layer dried over Na2SO4 to give 79 mg (83%)of 22a as slightly brownish solid 
without any further purification required.  1H NMR (400 MHz, DMSO) δ 9.11 (s, 1H), 
8.51 (s, 1H), 7.78 (d, J = 7.3 Hz, 2H), 7.43 (t, J = 7.6 Hz, 2H), 7.31 (t, J = 7.3 Hz, 1H), 
6.75 (d, J = 5.9 Hz, 1H), 6.64 (d, J = 6.0 Hz, 1H), 5.95 (t, J = 7.0 Hz, 1H), 4.76 (t, J = 5.5 
Hz, 2H), 4.42 (t, J = 5.6 Hz, 2H). 13C NMR (100 MHz, DMSO) δ 158.25, 147.17, 
146.77, 131.11, 129.34, 128.41, 128.31, 125.54, 122.23, 115.38, 105.76, 49.42, 48.33. 
HRMS (EI) calcd for C15H14N4O2 [M]
+ 282.1117 found 282.1120. 
 
1-Phenyltriazolylpropyl-3-hydroxypyridin-2-one (22b)  
To a solution of 21b (0.29 g, 1.01 mmol) in CH2Cl2:EtOAc:MeOH (2:2:1, 10 mL) was 
added 10% Pd on carbon (15 mg). Reaction was stirred under ballon hydrogen pressure 
for 5 h. Reaction mixture was filtered and solvent was evaporated. Column 
chromatography using gradient CH2Cl2:Acetone (max 20%) gave pure 22b (0.19 g, 64%) 
as a slightly brownish solid. 1H NMR (400 MHz, DMSO) δ 9.03 (s, 1H), 8.62 (s, 1H), 
7.82 (d, J = 7.6 Hz, 2H), 7.38 (m, 3H), 7.15 (d, J = 6.6 Hz, 1H), 6.68 (d, J = 6.4 Hz, 1H), 
6.11 (t, J = 6.7 Hz, 1H), 4.43 (t, J = 6.4 Hz, 2H), 3.99 (m, 2H), 2.27 (m, 2H). 13C NMR 
(100 MHz, CDCl3) δ 147.49, 129.71, 128.52, 127.99, 125.29, 120.42, 107.98, 66.61, 
47.10, 29.27. (expected aromatic carbons = 11; quaternary carbons can’t be seen even 
after repeated cycles) HRMS (EI) calcd for C16H16N4O2 [M]




1-Phenyltriazolylbutyl-3-hydroxypyridin-2-one (22c)  
Reaction of 21c (0.25 g, 0.62 mmol) in anhydrous THF as described for synthesis of 22b 
gave 22c ( 0.12 g, 63%) of pure product. 1H NMR (400 MHz, CDCl3) δ 7.79 (m, 3H), 
7.41 (t, J = 7.6 Hz, 2H), 7.32 (t, J = 7.4 Hz, 1H), 6.76 (m, 3H), 6.13 (t, J = 7.2 Hz, 1H), 
4.45 (t, J = 6.8 Hz, 2H), 4.02 (t, J = 7.1 Hz, 2H), 1.99 (m, 2H), 1.82 (m, 2H). 13C NMR 
(100 MHz, CDCl3) δ 158.47, 147.63, 146.62, 130.41, 128.69, 127.99, 126.60, 125.53, 
119.80, 114.15, 107.10, 49.38, 48.57, 27.02, 26.01. HRMS (EI) calcd for C17H18N4O2 
[M]+ 310.1430 found 310.1425. 
 
1-Phenyltriazolylpentyl-3-hydroxypyridin-2-one (22d)  
Reaction of 21d (0.085 g, 0.20 mmol) in anhydrous THF as described for synthesis of 
22b gave 22d (0.045 g, 68%) of pure product. 1H NMR (400 MHz, DMSO) δ 8.56 (s, 
1H), 7.82 (d, J = 8.1 Hz, 2H), 7.43 (t, J = 7.7 Hz, 2H), 7.32 (t, J = 7.4 Hz, 1H), 7.10 (dd, 
J = 6.8, 1.6 Hz, 1H), 6.65 (dd, J = 7.2, 1.5 Hz, 1H), 6.05 (t, J = 7.0 Hz, 1H), 4.38 (t, J = 
7.0 Hz, 2H), 3.89 (t, J = 7.2 Hz, 2H), 1.89 (m, 2H), 1.67 (m, 2H), 1.25 (m, 2H). 13C NMR 
(100 MHz, CDCl3) δ 158.44, 147.67, 146.61, 130.51, 128.72, 128.01, 126.71, 125.57, 
119.54, 113.81, 106.86, 49.86, 49.38, 29.58, 28.31, 23.19. HRMS (FAB) calcd for 
C18H21N4O2 [M+H]
+ 325.1664 found 325.1683. 
 
1-Phenyltriazolylhexyl-3-hydroxypyridin-2-one (22e)  
Reaction of 21e (0.15 g, 0.35 mmol) in anhydrous THF as described for synthesis of 22b 
gave 22e ( 0.081 g, 69%) of pure product. 1H NMR (400 MHz, CDCl3) δ 7.81 (m, 3H), 
7.42 (m, 2H), 7.32 (m, 1H), 6.77 (m, 2H), 6.12 (t, J = 7.1 Hz, 1H), 4.38 (t, J = 7.1 Hz, 
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2H), 3.95 (m, 2H), 1.95 (m, 2H), 1.76 (d, J = 7.0 Hz, 2H), 1.39 (m, 4H). 13C NMR (100 
MHz, CDCl3) δ 158.20, 147.25, 146.40, 130.30, 128.60, 127.85, 126.65, 125.40, 119.65, 
113.90, 106.80, 50.20, 49.60, 30.05, 28.95, 26.00, 25.90. HRMS (FAB) calcd for 
C19H23N4O2 [M+H]
+ 339.1821 found 339.1814. 
 
1-Phenyltriazolylheptyl-3-hydroxypyridin-2-one (22f)  
Reaction of 21f (0.22 g, 0.50 mmol) in anhydrous THF as described for synthesis of 22b 
gave 22f (0.13 g, 74%) of pure product. 1H NMR (400 MHz, DMSO) δ 8.91 (s, 1H), 8.57 
(s, 1H), 7.82 (d, J = 7.4 Hz, 2H), 7.42 (t, J = 7.6 Hz, 2H), 7.31 (t, J = 7.3 Hz, 1H), 7.09 
(d, J = 6.6 Hz, 1H), 6.64 (d, J = 7.0 Hz, 1H), 6.04 (t, J = 6.9 Hz, 1H), 4.36 (t, J = 7.0 Hz, 
2H), 3.86 (t, J = 7.2 Hz, 2H), 1.83 (m, 2H), 1.61 (m, 2H), 1.26 (m, 6H). 13C NMR (100 
MHz, CDCl3) δ 158.80, 147.89, 147.00, 130.88, 129.05, 128.30, 127.12, 125.87, 119.83, 
114.13, 107.10, 50.48, 50.05, 30.37, 29.20, 28.67, 26.46, 26.42. HRMS (FAB) calcd for 
C20H25N4O2 [M+H]
+ 353.1977 found 353.1992. 
 
1-Phenyltriazolylethyl-3-methoxypyridin-2-thione (23)  
To a stirring solution of Lawesson’s reagent (0.075 g, 0.185 mmol) in toluene (10 mL), 
was added starting material 21a (0.10g, 0.33 mmol). Reaction mixture was heated to 
reflux temperature. After overnight reaction, solvent was evaporated under reduced 
pressure. Crude product was dissolved in small amount of CH2Cl2 to load onto 
preparative-TLC and eluted with CHCl3:Acetone:EtOH (10:1:0.2) to give pure yellow 
solid 23 (0.07 g, 68%). 1H NMR (400 MHz, CDCl3) δ 7.69 (d, J = 7.4 Hz, 2H), 7.56 (s, 
1H), 7.35 (t, J = 7.5 Hz, 2H), 7.28 (m, 1H), 6.97 (d, J = 6.6 Hz, 1H), 6.62 (d, J = 7.8 Hz, 
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1H), 6.37 (m, 1H), 5.13 (t, J = 5.6 Hz, 2H), 5.03 (t, J = 5.6 Hz, 2H), 3.86 (s, 3H). 13C 
NMR (100 MHz, CDCl3) δ 171.92, 158.94, 147.52, 132.68, 129.92, 128.69, 128.14, 
125.43, 120.96, 111.72, 110.22, 56.72, 56.63, 46.38. HRMS (EI) calcd for C16H16N4OS 
[M]+ 312.1045 found 312.1039. 
 
1-Phenyltriazolylethyl-3-hydroxypyridin-2-thione (24)  
Reaction of 23 (0.062 g, 0.198 mmol) and 1M BBr3 in CH2Cl2 (0.218 mmol) within 48 h 
as described for synthesis of 11a gave compound 24 (0.055 g, 93%) as a dark violet solid.  
1H NMR (400 MHz, CDCl3) δ 8.40 (s, 1H), 7.73 (d, J = 7.3 Hz, 2H), 7.51 (s, 1H), 7.40 (t, 
J = 7.5 Hz, 2H), 7.33 (t, J = 7.3 Hz, 1H), 6.95 (dd, J = 9.2, 7.2 Hz, 2H), 6.46 (m, 1H), 
5.08 (m, 4H). 13C NMR (100 MHz, CDCl3) δ 168.47, 155.10, 147.75, 132.00, 129.82, 
128.77, 128.30, 125.53, 120.90, 113.66, 112.61, 57.45, 46.41. HRMS (EI) calcd for 
C15H14N4OS [M]
+ 298.0888 found 298.0888. 
 
1-Phenyltriazolylpropyl-3-hydroxypyridin-2-thione (25b) 
22b (0.062 g, 0.21 mmol) was ground together with P4S10 (0.047g, 0.105 mmol) in 
mortar and pestle to form grey powder. The powder was stirred under argon in a flask 
fitted with condenser and heated to 175 oC for 2 h. The reaction flask was covered with 
aluminium foil during reaction. After 2h of reaction, flask was cooled down to room 
temperature. 25 mL of CH2Cl2:MeOH (10%) mixtures was added and stirred for 15 min. 
This reaction mixture then washed with water (2 X 30 mL). Organic layer dried with 
Na2SO4 and evaporated to yield crude product which was purified by prep-TLC (Eluent 
- CH2Cl2:MeOH (8%)  to give 25b (0.04 g, 60%) as olive green solid. 
1H NMR (400 
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MHz, CDCl3) δ 8.47 (s, 1H), 7.82 (m, 3H), 7.50 (d, J = 6.5 Hz, 1H), 7.43 (t, J = 7.5 Hz, 
2H), 7.34 (t, J = 7.4 Hz, 1H), 6.97 (m, 1H), 6.66 (m, 1H), 4.62 (t, J = 6.9 Hz, 2H), 4.48 
(m, 2H). 13C NMR (100 MHz, CDCl3) δ 168.59, 155.22, 148.03, 131.85, 130.17, 128.84, 
128.29, 125.61, 119.84, 113.87, 112.28, 54.99, 46.95, 28.02. HRMS (EI) calcd for 
C16H16N4OS [M]
+ 312.1045 found 312.1060. 
 
1-Phenyltriazolylbutyl-3-hydroxypyridin-2-thione (25c) 
Reaction of 22c (0.055 g, 0.18 mmol) and P4S10 (0.051 g, 0.115 mmol) under neat 
conditions as described for synthesis of 25b gave compound 25c (0.032 g, 55%) as a 
olive green solid. δ 8.50 (s, 1H), 7.81 (m, 3H), 7.36 (m, 4H), 6.94 (d, J = 7.6 Hz, 1H), 
6.62 (t, J = 6.8 Hz, 1H), 4.54 (t, J = 7.6 Hz, 2H), 4.46 (t, J = 6.4 Hz, 2H), 2.03  (m, 4H). 
13C NMR (100 MHz, CDCl3) δ 168.51, 155.08, 147.73, 131.02, 130.36, 128.79, 128.13, 
125.58, 119.91, 113.87, 112.10, 56.96, 49.41, 27.02, 25.08. HRMS (EI) calcd for 
C17H18N4OS [M]
+ 326.1201 found 326.1200. 
 
1-Phenyltriazolylpentyl-3-hydroxypyridin-2-thione (25d) 
Reaction of 22d (0.025 g, 0.077 mmol) and P4S10 (0.020 g, 0.046 mmol) under neat 
conditions as described for synthesis of 25b gave compound 25d (0.019 g, 73%) as a 
olive green solid. 1H NMR (400 MHz, DMSO) δ 8.55 (d, J = 2.9 Hz, 2H), 7.83 (t, J = 7.8 
Hz, 3H), 7.43 (q, J = 7.4 Hz, 2H), 7.32 (t, J = 6.6 Hz, 1H), 7.08 (m, 1H), 6.92 (dd, J = 
31.0, 6.8 Hz, 1H), 6.81 (m, 1H), 4.51 (m, 2H), 4.41 (t, J = 7.0 Hz, 2H), 1.89 (m, 4H), 
1.32 (m, 2H). 13C NMR (100 MHz, CDCl3) δ 168.37, 155.10, 147.66, 131.04, 130.46, 
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128.75, 128.05, 125.57, 119.68, 113.69, 111.96, 57.73, 49.73, 29.47, 27.12, 23.04. 
HRMS (EI) calcd for C18H20N4OS [M]
+ 340.1358 found 326.1364. 
 
1-Phenyltriazolylhexyl-3-hydroxypyridin-2-thione (25e) 
Reaction of 22e (0.18 g, 0.532 mmol) and P4S10 (0.118 g, 0.266 mmol) under neat 
conditions as described for synthesis of 25b gave compound 25e (0.080 g, 42%) as a 
olive green semi-solid.  1H NMR (400 MHz, CDCl3) δ 8.57 (s, 1H), 7.83 (d, J = 7.5 Hz, 
2H), 7.76 (s, 1H), 7.41 (t, J = 7.5 Hz, 2H), 7.32 (m, 2H), 6.94 (m, 1H), 6.72 (m, 1H), 4.49 
(m, 2H), 4.40 (t, J = 6.9 Hz, 2H), 1.97 (m, 4H), 1.36 (m, 4H). 13C NMR (100 MHz, 
CDCl3) δ 164.38, 162.90, 147.70, 130.54, 128.76, 128.03, 126.64, 125.61, 119.51, 
118.75, 118.29, 59.74, 50.10, 29.91, 27.99, 25.82, 25.65. HRMS (ESI) calcd for 
C19H23N4OS [M+H]
+ 355.1587 found 355.1632. 
 
1-Phenyltriazolylheptyl-3-hydroxypyridin-2-thione (25f) 
Reaction of 22f (0.12 g, 0.532 mmol) and P4S10 (0.076 g, 0.17 mmol) under neat 
conditions as described for synthesis of 25b gave compound 25f (0.054 g, 43%) as a 
olive green semi-solid. 1H NMR (400 MHz, DMSO) δ 8.55 (m, 1H), 7.81 (d, J = 8.2 Hz, 
2H), 7.65 (d, J = 6.2 Hz, 1H), 7.42 (m, 2H), 7.30 (m, 1H), 7.02 (m, 1H), 6.85 (m, 1H), 
4.50 (m, 2H), 4.36 (t, J = 7.1 Hz, 2H), 1.85 (d, J = 7.0 Hz, 4H), 1.33 (s, 6H). 13C NMR 
(100 MHz, CDCl3) δ 147.76, 130.66, 128.76, 130.39, 128.98, 128.80, 128.06, 125.97, 
125.67, 119.46, 60.10, 50.25, 30.11, 29.67, 28.33, 26.13, 26.10. 
 HRMS (FAB) calcd for C20H25N4OS [M+H]





Reaction of 27a (0.235 g, 0.667 mmol) and Lawesson’s reagent (0.162 g, 0.40 mmol) in 
toluene (12 mL) within 12h as described for the synthesis of 10a gave compound 28a 
(0.232 g, 95%) as yellow solid. 1H NMR (400 MHz, CDCl3) δ 7.77 (s, 1H), 7.73 (d, J = 
8.2 Hz, 2H), 7.33 (m, 1H), 7.25 (dd, J = 11.4, 5.2 Hz, 2H), 6.66 (d, J = 7.8 Hz, 1H), 6.59 
(dd, J = 7.8, 6.5 Hz, 1H), 4.60 (m, 2H), 4.43 (t, J = 6.9 Hz, 2H), 3.91 (s, 3H), 2.38 (s, 
3H), 2.01 (m, 4H), 1.43 (m, 2H); 13C NMR (75 MHz, CDCl3) δ 171.03, 158.50, 147.11, 
137.37, 131.77, 129.02, 127.33, 125.03, 119.32, 111.60, 109.78, 56.27, 49.28, 30.48, 
29.05, 26.51, 22.57, 20.82. HRMS (EI) calcd for C20H24N4OS [M]




Reaction of 27b (0.137 g, 0.389 mmol) and Lawesson’s reagent (0.094 g, 0.223 mmol) in 
toluene (10 mL) within 12 h as described for the synthesis of 10a gave compound 28b 
(0.104 g, 73%) as yellow solid. 1H NMR (400 MHz, CDCl3) δ 7.78 (s, 1H), 7.62 (s, 1H), 
7.54 (d, J = 7.7 Hz, 1H), 7.26 (m, 2H), 7.07 (d, J = 7.6 Hz, 1H), 6.59 (m, 1H), 6.52 (dd, J 
= 7.8, 6.5 Hz, 1H), 4.50 (m, 2H), 4.34 (t, J = 7.0 Hz, 2H), 3.81 (s, 3H), 2.32 (s, 3H), 1.90 
(m, 4H), 1.33 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 171.47, 158.81, 147.45, 138.19, 
131.83, 130.21, 128.58, 128.46, 126.03, 122.48, 119.68, 111.72, 109.80, 56.55, 56.47, 







Reaction of 27c (0.124 g, 0.351 mmol) and Lawesson’s reagent (0.085 g, 0.21 mmol) in 
toluene (10 mL) within 12 h as described for the synthesis of 10a gave compound 28c 
(0.093 g, 72%) as yellow solid.  1H NMR (400 MHz, CDCl3) δ 7.72 (m, 1H), 7.27 (m, 
2H), 6.60 (m, 1H), 4.57 (m, 1H), 4.42 (t, J = 7.0 Hz, 1H), 3.86 (s, 1H), 2.44 (s, 1H), 1.99 
(m, 2H), 1.41 (dt, J = 15.2, 7.6 Hz, 1H). 13C NMR (100 MHz, CDCl3) δ 171.81, 159.04, 
146.84, 135.33, 131.86, 130.74, 129.81, 128.68, 127.94, 125.93, 121.86, 111.78, 109.79, 
104.88, 56.75, 56.61, 49.60, 29.45, 26.85, 22.97, 21.36. HRMS (EI) calcd for 
C20H24N4OS [M]
+ 368.1671 found 368.1662. 
 
1-(4-Benzonitrile)triazolylpentyl-3-methoxypyridin-2-thione (28d) 
Reaction of 27d (0.210 g, 0.551 mmol) and Lawesson’s reagent (0.133 g, 0.330 mmol) in 
toluene (12 mL) within 12 h as described for the synthesis of 10a gave compound 28d 
(0.146 g, 67%) as yellow solid. 1H NMR (400 MHz, CDCl3) δ 7.64 (m, 3H), 7.28 (m, 
1H), 6.73 (d, J = 8.3 Hz, 2H), 6.61 (d, J = 7.6 Hz, 1H), 6.52 (t, J = 7.1 Hz, 1H), 4.50 (m, 
2H), 4.31 (t, J = 6.7 Hz, 2H), 3.81 (s, 3H), 2.92 (s, 6H), 1.89 (m, 4H), 1.32 (m, 2H); 13C 
NMR (100 MHz, CDCl3) δ 171.44, 158.81, 149.78, 147.77, 131.91, 126.37, 119.05, 
118.34, 112.52, 111.73, 109.84, 56.60, 56.49, 49.44, 40.45, 29.29, 26.74, 22.81. HRMS 
(EI) calcd for C21H27N5OS [M]
+ 397.1936 found 397.1928. 
 
1-(3-Benzonitrile)triazolylpentyl-3-methoxypyridin-2-thione (28e) 
Reaction of 27e (0.190 g, 0.523 mmol) and Lawesson’s reagent (0.130 g, 0.314 mmol) in 
toluene (10 mL) within 12 h as described for the synthesis of 10a gave compound 28e 
(0.133 g, 67%) as yellow solid. 1H NMR (400 MHz, CDCl3) δ 7.98 (s, 1H), 7.84 (d, J = 
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8.4 Hz, 2H), 7.56 (d, J = 8.4 Hz, 2H), 7.30 (d, J = 6.5 Hz, 1H), 6.60 (d, J = 7.0 Hz, 1H), 
6.52 (dd, J = 7.7, 6.6 Hz, 1H), 4.48 (m, 2H), 4.34 (t, J = 6.9 Hz, 2H), 3.76 (s, 3H), 1.88 
(m, 4H), 1.31 (m, 2H). 13C NMR (100 MHz, CDCl3) δ 171.23, 158.70, 145.36, 134.76, 
132.30, 131.78, 125.68, 121.20, 118.49, 111.83, 110.73, 109.92, 56.43, 49.50, 29.01, 
26.56, 22.56. HRMS (EI) calcd for C20H21N5OS [M]
+ 379.1467 found 379.1466. 
 
1-(4-(N,N-dimethylaniline))triazolylpentyl-3-methoxypyridin-2-thione (28f) 
Reaction of 27f (0.145 g, 0.40 mmol) and Lawesson’s reagent (0.098 g, 0.241 mmol) in 
toluene (10 mL) within 12 h as described for the synthesis of 10a gave compound 28f 
(0.149 g, 98%) as yellow solid. 1H NMR (400 MHz, CDCl3) δ 8.12 (t, J = 1.4 Hz, 1H), 
8.06 (m, 1H), 7.90 (s, 1H), 7.59 (dt, J = 7.7, 1.4 Hz, 1H), 7.52 (t, J = 7.8 Hz, 1H), 7.33 
(dd, J = 6.5, 1.4 Hz, 1H), 6.67 (dd, J = 7.9, 1.3 Hz, 1H), 6.60 (dd, J = 7.8, 6.5 Hz, 1H), 
4.59 (m, 2H), 4.46 (t, J = 6.9 Hz, 2H), 3.89 (s, 3H), 2.02 (m, 4H), 1.43 (m, 2H); 13C 
NMR (100 MHz, CDCl3) δ 171.30, 158.73, 145.13, 131.82, 131.71, 130.97, 129.52, 
129.44, 128.64, 120.61, 118.28, 112.49, 111.81, 109.91, 56.44, 49.62, 29.11, 26.64, 
22.68. HRMS (EI) calcd for C20H21N5OS [M]
+ 379.1467 found 379.1469. 
 
1-(4-(3-Trifluomethyl)-benzonitrile)triazolylpentyl-3-methoxypyridin-2-thione (28g) 
Reaction of 27g (0.090 g, 0.2088 mmol) and Lawesson’s reagent (0.051 g, 0.1252 mmol) 
in toluene (10 mL) within 12 h as described for the synthesis of 10a gave compound 28g 
(0.075 g, 81%) as yellow solid. 1H NMR (400 MHz, CDCl3) δ 8.28 (s, 1H), 8.12 (d, J = 
6.7 Hz, 2H), 7.86 (d, J = 8.1 Hz, 1H), 7.36 (d, J = 6.5 Hz, 1H), 6.68 (d, J = 7.8 Hz, 1H), 
6.61 (t, J = 7.2 Hz, 1H), 4.59 (m, 2H), 4.47 (m, 2H), 3.88 (s, 3H), 2.02 (m, 4H), 1.43 (m, 
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2H); 13C NMR (100 MHz, CDCl3) δ 171.84, 159.14, 144.54, 135.55, 135.22, 133.51, 
133.18, 131.81, 128.59, 121.86, 120.86, 115.46, 112.00, 109.97, 108.47, 77.31, 76.99, 
76.67, 56.69, 49.87, 29.19, 26.77, 22.77. HRMS (EI) calcd for C21H20N5OSF3 [M]
+ 
447.1341 found 447.1341. 
 
1-(4-Tolyl)triazolylpentyl-3-hydroxypyridin-2-one (29a) 
Reaction of 27a (0.10 g, 0.284 mmol) and 1M BBr3 (0.34 mL) in CH2Cl2 (8 mL) within 
48 h as described for the synthesis of 11a gave compound 29a (0.049 g, 52%) as light 
brown solid. 1H NMR (400 MHz, CDCl3) δ 7.71 (m, 3H), 7.24 (m, 2H), 6.76 (t, J = 6.4 
Hz, 2H), 6.12 (t, J = 7.0 Hz, 1H), 4.40 (t, J = 6.9 Hz, 2H), 3.96 (t, J = 7.1 Hz, 2H), 2.38 
(s, 3H), 2.00 (m, 2H), 1.82 (m, 2H), 1.39 (m, 2H); 13C NMR (100 MHz, DMSO) δ 
171.80, 146.31, 137.02, 129.40, 128.08, 125.02, 120.79, 114.36, 105.20, 49.27, 48.22, 
29.17, 28.01, 22.85, 20.82. HRMS (EI) calcd for C19H22N4O2 [M]




Reaction of 27b (0.073 g, 0.207 mmol) and 1M BBr3 (0.24 mL) in CH2Cl2 (8 mL) within 
48 h as described for the synthesis of 11a gave compound 29b (52 mg, 74%) as light 
brown solid. 1H NMR (400 MHz, CDCl3) δ 7.74 (s, 1H), 7.67 (s, 1H), 7.59 (d, J = 7.7 
Hz, 1H), 7.30 (t, J = 7.6 Hz, 1H), 7.14 (d, J = 7.4 Hz, 1H), 6.76 (t, J = 6.2 Hz, 2H), 6.12 
(t, J = 7.1 Hz, 1H), 4.39 (t, J = 6.9 Hz, 2H), 3.96 (t, J = 7.2 Hz, 2H), 2.39 (s, 3H), 1.99 
(m, 2H), 1.80 (m, 2H), 1.38 (m, 2H).  13C NMR (100 MHz, CDCl3) δ 158.58, 147.87, 
146.52, 138.46, 130.38, 128.86, 128.67, 126.75, 126.31, 122.72, 119.48, 113.61, 106.85, 
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49.91, 49.45, 29.65, 28.38, 23.27, 21.38.  HRMS (EI) calcd for C19H22N4O2 [M]
+ 
338.1743 found 338.1741. 
1-(2-Tolyl)triazolylpentyl-3-hydroxypyridin-2-one (29c) 
Reaction of 27c (0.065 g, 0.18 mmol) and 1M BBr3 (0.27 mL) in CH2Cl2 (8 mL) within 
48 h as described for the synthesis of 11a gave compound 29c (54 mg, 87%) as light 
brown solid. 1H NMR (400 MHz, dmso) δ 8.92 (s, 1H), 8.36 (s, 1H), 7.71 (m, 1H), 7.25 
(m, 1H), 7.09 (d, J = 6.8 Hz, 1H), 6.64 (d, J = 6.9 Hz, 1H), 6.04 (t, J = 7.0 Hz, 1H), 4.39 
(t, J = 6.9 Hz, 1H), 3.88 (t, J = 7.0 Hz, 1H), 2.41 (s, 1H), 1.90 (m, 1H), 1.67 (m, 1H), 
1.25 (m, 1H). 13C NMR (100 MHz, CD3OD) δ 146.28, 135.00, 130.15, 128.96, 128.21, 
127.72, 125.38, 122.09, 106.72, 49.43, 48.98, 29.05, 27.78, 22.69, 20.09. HRMS (EI) 
calcd for C19H22N4O2 [M]
+ 338.1743 found 338.1741. 
 
1-(4-Benzonitrile)triazolylpentyl-3-hydroxypyridin-2-one (29d) 
Reaction of 27d (0.075 g, 0.197 mmol) and 1M BBr3 (0.24 mL) in CH2Cl2 (8 mL) within 
48 h as described for the synthesis of 11a gave compound 29d (43 mg, 60%) as light 
brown solid. 1H NMR (400 MHz, CDCl3) δ 7.69 (d, J = 8.8 Hz, 2H), 7.61 (s, 1H), 6.77 
(m, 4H), 6.11 (t, J = 7.1 Hz, 1H), 4.37 (t, J = 6.9 Hz, 2H), 3.96 (t, J = 7.2 Hz, 2H), 2.99 
(s, 6H), 1.99 (m, 2H), 1.81 (m, 2H), 1.39 (m, 2H). 13C NMR (100 MHz, CDCl3) δ 158.57, 
150.35, 148.26, 146.61, 126.84, 126.61, 118.87, 118.11, 113.72, 112.49, 106.86, 49.83, 
49.52, 40.46, 29.70, 28.41, 23.34. HRMS (EI) calcd for C20H25N5O2 [M]






Reaction of 27e (0.09 g, 0.25 mmol) and 1M BBr3 (0.30 mL) in CH2Cl2 (8 mL) within 48 
h as described for the synthesis of 11a gave compound 29e (62 mg, 72%) as light brown 
solid. 1H NMR (400 MHz, DMSO) δ 8.93 (s, 1H), 8.76 (s, 1H), 8.01 (d, J = 7.7 Hz, 2H), 
7.90 (d, J = 8.0 Hz, 2H), 7.09 (d, J = 6.4 Hz, 1H), 6.64 (d, J = 7.1 Hz, 1H), 6.04 (t, J = 
7.0 Hz, 1H), 4.41 (t, J = 6.5 Hz, 2H), 3.88 (t, J = 6.9 Hz, 2H), 1.89 (m, 2H), 1.67 (m, 2H), 
1.24 (m, 2H). 13C NMR (100 MHz, CDCl3) δ 146.62, 145.80, 134.92, 132.57, 126.69, 
125.93, 120.88, 118.70, 114.06, 111.19, 107.06, 50.00, 49.29, 29.43, 28.28, 23.08. 
HRMS (EI) calcd for C19H19N5O2 [M]
+ 349.1539 found 349.1544. 
 
1-(4-(N,N-dimethylaniline))triazolylpentyl-3-hydroxypyridin-2-one (29f) 
Reaction of 27f (0.078 g, 0.22 mmol) and 1M BBr3 (0.26 mL) in CH2Cl2 (6 mL) within 
48 h as described for the synthesis of 11a gave compound 29f (48 mg, 64%) as light 
brown solid. 1H NMR (400 MHz, CD3OD) δ 8.39 (s, 1H), 8.16 (s, 1H), 8.12 (d, J = 7.5 
Hz, 1H), 7.68 (d, J = 7.5 Hz, 1H), 7.61 (t, J = 7.6 Hz, 1H), 7.04 (m, 1H), 6.76 (m, 1H), 
6.21 (m, 1H), 4.45 (m, 2H), 3.99 (m, 2H), 2.01 (m, 2H), 1.78 (m, 2H), 1.33 (m, 2H). 13C 
NMR (100 MHz, CDCl3) δ 145.61, 131.97, 131.31, 129.74, 129.65, 129.10, 120.30, 
118.49, 112.99, 104.90, 50.07, 49.40, 29.52, 28.37, 23.17. HRMS (EI) calcd for 
C19H19N5O2 [M]
+ 349.1539 found 349.1539. 
 
1-(4-(3-Trifluomethyl)-benzonitrile)triazolylpentyl-3-hydroxypyridin-2-one (29g) 
Reaction of 27g (0.042 g, 0.097 mmol) and 1M BBr3 (0.17 mL) in CH2Cl2 (6 mL) within 
48 h as described for the synthesis of 11a gave compound 29g (35 mg, 85%) as light 
brown solid. 1H NMR (400 MHz, CDCl3) δ 8.24 (s, 1H), 8.12 (d, J = 7.9 Hz, 1H), 8.00 
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(s, 1H), 7.86 (d, J = 7.9 Hz, 1H), 6.75 (t, J = 5.8 Hz, 2H), 6.12 (t, J = 7.0 Hz, 1H), 4.44 (t, 
J = 6.9 Hz, 2H), 3.96 (t, J = 7.1 Hz, 2H), 2.02 (m, 2H), 1.81 (m, 2H), 1.37 (m, 2H). 13C 
NMR (100 MHz, CDCl3) δ 158.58, 146.54, 144.71, 135.49, 135.26, 128.57, 126.70, 
123.59, 123.54, 121.46, 115.47, 113.82, 108.63, 107.02, 50.19, 49.31, 29.45, 28.30, 
23.12.  HRMS (EI) calcd for C20H18N5O2F3 [M]
+ 417.1413 found 417.1425. HRMS (EI) 
calcd for C20H18N5O2F3 [M]
+ 417.1413 found 417.1425.  
 
1-(4-Tolyl)triazolylpentyl-3-hydroxypyridin-2-thione (30a) 
Reaction of 28a (0.075 g, 0.203 mmol) and 1M BBr3 (0.24 mL) in CH2Cl2 (8 mL) within 
48 h as described for the synthesis of 11a gave compound 30a (0.042 g, 62%) as olive 
green solid. 1H NMR (400 MHz, CD3OD) δ 8.18 (s, 1H), 7.66 (d, J = 8.0 Hz, 2H), 7.55 
(d, J = 5.7 Hz, 1H), 7.20 (d, J = 7.7 Hz, 2H), 6.97 (d, J = 6.7 Hz, 1H), 4.55 (m, 2H), 4.43 
(t, J = 6.7 Hz, 2H), 2.34 (s, 3H), 2.01 (m, 4H), 1.39 (t, J = 22.5 Hz, 2H). 13C NMR (100 
MHz, CD3OD) δ 149.25, 139.68, 130.93, 129.13, 127.01, 122.27, 51.41, 30.95, 24.51, 
21.83. HRMS (EI) calcd for C19H22N4OS [M]
+ 354.1514 found 354.1512.  
 
1-(3-Tolyl)triazolylpentyl-3-hydroxypyridin-2-thione (30b) 
Reaction of 28b (0.10 g, 0.271 mmol) and 1M BBr3 (0.33 mL) in CH2Cl2 (8 mL) within 
48 h as described for the synthesis of 11a gave compound 30b (0.053 g, 56%) as olive 
green solid. 1H NMR (400 MHz, CD3OD) δ 8.20 (s, 1H), 7.61 (s, 1H), 7.55 (m, 2H), 7.26 
(t, J = 7.6 Hz, 1H), 7.12 (d, J = 7.5 Hz, 1H), 6.92 (m, 2H), 4.55 (m, 2H), 4.44 (t, J = 6.7 
Hz, 2H), 2.36 (s, 3H), 2.01 (m, 4H), 1.41 (m, 2H). 13C NMR (100 MHz, CD3OD) δ 
149.29, 140.05, 131.87, 131.78, 130.38, 130.20, 127.90, 127.63, 124.13, 122.51, 51.40, 
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31.07, 30.93, 28.97, 24.49, 22.02. HRMS (EI) calcd for C19H22N4OS [M]
+ 354.1514 
found 354.1523.  
1-(2-Tolyl)triazolylpentyl-3-hydroxypyridin-2-thione (30c) 
Reaction of 28c (0.072 g, 0.195 mmol) and 1M BBr3 (0.30 mL) in CH2Cl2 (8 mL) within 
48 h as described for the synthesis of 11a gave compound 30c (0.046 g, 67%) as olive 
green solid. 1H NMR (400 MHz, CD3OD) δ 7.94 (s, 1H), 7.61 (m, 1H), 7.47 (s, 1H), 7.21 
(m, 1H), 6.97 (m, 1H), 6.76 (m, 1H), 4.52 (m, 1H), 4.45 (t, J = 6.8 Hz, 1H), 2.38 (s, 1H), 
2.01 (m, 2H), 1.43 (m, 1H). 13C NMR (100 MHz, CD3OD) δ 146.74, 135.53, 130.65, 
129.46, 128.69, 128.21, 125.88, 122.79, 53.41, 49.83, 29.42, 27.32, 22.98, 20.55. HRMS 
(EI) calcd for C19H22N4OS [M]
+ 354.1514 found 354.1509.  
 
1-(4-Benzonitrile)triazolylpentyl-3-hydroxypyridin-2-thione (30d) 
Reaction of 28d (0.10 g, 0.271 mmol) and 1M BBr3 (0.33 mL) in CH2Cl2 (8 mL) within 
48 h as described for the synthesis of 11a gave compound 30d (0.053 g, 56%) as olive 
green solid. 1H NMR (400 MHz, DMSO-d6) δ 8.53 (s, 1H), 8.27 (s, 1H), 7.82 (d, J = 7.1 
Hz, 1H), 7.62 (d, J = 8.8 Hz, 2H), 7.06 (d, J = 7.5 Hz, 1H), 6.93 (m, 1H), 6.77 (m, 2H), 
4.52 (d, J = 6.9 Hz, 2H), 4.36 (t, J = 7.0 Hz, 2H), 3.21 (s, 6H), 1.88 (m, 4H), 1.34 (m, 
2H). HRMS (EI) calcd for C20H25N5OS [M]
+ 383.1780 found 383.1776.  
 
1-(3-Benzonitrile)triazolylpentyl-3-hydroxypyridin-2-thione (30e) 
Reaction of 28e (0.095 g, 0.25 mmol) and 1M BBr3 (0.30 mL) in CH2Cl2 (8 mL) within 
48 h as described for the synthesis of 11a gave compound 30e (0.055 g, 60%) as olive 
green solid. 1H NMR (400 MHz, DMSO) δ 8.76 (s, 1H), 8.01 (d, J = 8.1 Hz, 2H), 7.87 
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(m, 2H), 7.65 (d, J = 6.4 Hz, 1H), 7.00 (m, 1H), 6.87 (d, J = 8.2 Hz, 1H), 6.70 (m, 1H), 
4.44 (m, 4H), 1.89 (m, 4H), 1.31 (m, 2H). 13C NMR (100 MHz, CDCl3) δ 168.23, 155.01, 
145.75, 134.86, 132.56, 131.00, 125.91, 121.05, 118.68, 113.76, 112.04, 111.17, 57.64, 
49.81, 29.31, 27.06, 22.91. HRMS (EI) calcd for C19H19N5OS [M]




Reaction of 28f (0.105 g, 0.25 mmol) and 1M BBr3 (0.33 mL) in CH2Cl2 (8 mL) within 
48 h as described for the synthesis of 11a gave compound 30f (0.072 g, 66%) as olive 
green solid. 1H NMR (400 MHz, CD3OD) δ 8.38 (s, 1H), 8.15 (s, 1H), 8.10 (d, J = 7.9 
Hz, 1H), 7.63 (m, 3H), 6.95 (d, J = 7.5 Hz, 1H), 6.67 (m, 1H), 4.57 (m, 2H), 4.48 (t, J = 
7.0 Hz, 2H), 2.03 (m, 4H), 1.43 (m, 2H). 13C NMR (100 MHz, CD3OD) δ 145.34, 
132.04, 131.14, 129.72, 129.58, 128.63, 121.75, 112.74, 104.99, 49.79, 29.08, 27.04, 
22.73. HRMS (EI) calcd for C19H19N5OS [M]
+ 365.1310 found 365.1310. 
 
1-(4-(3-Trifluomethyl)-benzonitrile)triazolylpentyl-3-hydroxypyridin-2-thione (30g) 
Reaction of 28g (0.105 g, 0.25 mmol) and 1M BBr3 (0.33 mL) in CH2Cl2 (8 mL) within 
48 h as described for the synthesis of 11a gave compound 30g (0.072 g, 66%) as olive 
green solid. 1H NMR (400 MHz, CD3OD) δ 8.59 (s, 1H), 8.35 (s, 1H), 8.21 (d, J = 7.8 
Hz, 1H), 8.00 (t, J = 9.5 Hz, 1H), 7.58 (d, J = 6.2 Hz, 1H), 6.96 (d, J = 7.5 Hz, 1H), 6.72 
(m, 1H), 4.57 (m, 4H), 2.04 (m, 4H), 1.42 (m, 2H). 13C NMR (100 MHz, CD3OD) δ 
146.09, 137.48, 137.24, 134.79, 130.46, 125.55, 124.87, 123.60, 122.77, 116.84, 109.75, 
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55.10, 51.63, 30.84, 28.90, 24.47. HRMS (EI) calcd for C19H19N5OS [M]
+ 365.1310 
found 365.1310. HRMS (EI) calcd for C20H18N5OS [M]
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LEISHMANOLYSIS (GP63) AS AN ANTI-LEISHMANIAL 
TARGET  
 
6.1 Leishmaniasis  
 
Leishmaniasis is a tropical/sub-tropical parasitic disease caused by protozoan 
parasites of the genus Leishmania.1 It is transmitted to humans by more than 20 
leishmanial species and is transmitted by the bite of ~ 30 different phlebotomine sand fly 
species.1,5 The parasite exists in two different forms, promastigotes, the motile flagilated 
form found in the gut of the sandfly vector and amastigotes, the non-flagellated, non-
motile form found in the mammalian host.2 The leishmania parasites live in the 
macrophages as amastigotes. The macrophages are ingested by the fly during the blood- 
meal and the amastigotes are relesed into the stomach of insect. Almost immediately the 
amastigotes transform into the flagellate promastigote form. The promastigotes multiply 
by the binary fission and transfers to sandfly’s proboscis. When the sandfly next feeds on 
a mammalian host, the leishmania promastigotes are transferred to the host. Once in the 
host the promastigotes are taken up by the macrophages where they rapidly revert back to 
the amastigote form. The released amastigotes are taken up by additional macrophages 





Leishmaniasis consists of four main clinical forms: visceral leishmaniasis (VL; 
also known as kala azar), cutaneous leishmaniasis (CL), mucocutaneous leishmaniasis 
(MCL; also known as espundia),
Among all of these, visceral leishmaniasis (VL) which is caused by parasite 
donovani is fatal if left untreated. 
           Leishmaniasis is contributing to significant morbidity and mo
has an estimated incidence of 500,000 new cases 
toll that is highest among all the parasitic diseases except malaria.
is distributed worldwide, but mainly concentrated in tropics and sub
229 
Figure 6-1. Leishmania life cycle3 
 
 
 and post-kala-azaar dermal leishmaniasis (PKDL)
4 
rtality worldwide. 
and 60,000 deaths each year, a death 
5 Human leishmaniasis 







of death toll occurs in developing countries such as Bangladesh, Brazil, Ethiopia, India, 
Nepal and Sudan sharing large percentage of death tolls.6 
 
 
                                         Red shades – visceral leishmaniasis affected area. 
  
Figure 6-2. Leishmania worldwide endemics.6 
 
Due to lack of effective vaccines and vector control measures, chemotherapy is 
used as front line defense against the disease. Leishmaniasis is an emerging serious threat 
to public health due to the increasing occurrence of opportunistic infection in human 
immunodeficiency virus-infected patients and the emergence of multi-drug resistant 
strains.7 Also, many drugs are too expensive to treat in developing countries where most 
of the infection occurs.  The limited chemotherapeutic approach for the treatment of 
leishmanial infections is based on amphotericin B, miltefosine, paromomycin, and 
antimony agents like sodium stibogluconate and meglumine antimoniate.6,8 These are 
unsatisfactory agents because their toxicity causes serious side effects that often result in 
patients deserting the treatment. Moreover, these anti-leishmanial agents are high-priced 
and their modes of activity are poorly understood. According to the World Health 
Organization (WHO) report, infections caused by Leismania are among the most 
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hazardous infectious diseases.4a Therefore, there is an urgent need for affordable 
alternative agents to curtail leishmaniasis. To thrive in human hosts, Leishmania digest 
key host proteins, primarily to obtain nutrients and also to evade the host’s immune 
system. It is well established that gp63, a zinc metalloprotease, is essential for the 
degradation of host proteins and it is an attractive target for the development of new 
chemotherapeutics against this deadly parasitic disease.9  
 
6.2 Leishmanolysin (gp63)  
 
 




The major surface glycoprotein gp63 (leishmanolysin; promastigote surface 
protease) is a zinc-metalloenzyme which is expressed in high density on the surface of 
the promastigote form of Leishmania, where it is enzymatically active against 
polypeptide surface.9 It has been established that gp63 is a virulence factor implicated in 
infection of leishmaniasis.10 With the aid of other major cell surface components such as 
the lipophosphoglycans (LPGs) and glycoinositolphospholipid (GIPL), gp63 enables 
 
promastigotes to reach and infect sufficient macrophages to establish an infection. 
Despite the attractiveness of gp63 as
efficient, non-toxic inhibitors of gp63.
6.3 Comparison of HDAC8 
  In previous chapter, 
HPT based HDACi (chapter 5, section 5.14). 
of HDAC8 active site is conducive for 
the 3-HPT analogs were not able to penetrate 
by the selectivity of these 3
metalloenzyme which share structural attributes to HDAC8. 
metalloenzymes revealed that gp63 (discussed in chapter 5)
site with calatytic zinc located at
(Figure 6-4) We hypothesized that 
also be potential hits for gp63.
instigated our efforts for developing inhib
 
                                (a)                                                               (b)
Figure 6-4. (a) Enzyme active site of HDAC8 (b) Enzyme active site of gp63
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 anti-leishmanial target, there are currently no 
9 
and gp63 enzyme active site 
I discussed the structural basis for HDAC8 selectivity 
One of the finding is that the shallow nature 
3-HPT chelation to the catalytic Zn2+
the deep active site of HDAC1. Intrigued 
-HPT based compounds, we decided to explore other zinc 
A literature survey on zinc 
 has also very shallow active 
 the surface and near the entrance of deep subpocket.
the 3-HPT based HDAC8 selective inhibitors could 
 The lack of effective, non-toxic inhibitor of gp63 further 
itors of gp63.  








6.4 Design of 1
st
 Generation GP63 Inhibitors by Molecular Docking 
Analysis 
 
               The crystal structure of gp63 from 
domain (PDB code: 1LMLa) (Figure 6
active site structural motif found in other zinc proteases
inferred that gp63 active site could be amenable to the design of specific inhibitors in 
similar manner to other zinc pro
molecular docking and the tools of Organic Chemistry to exemplify gp63 active site as a 
target for small molecules with 
molecular insights on the functionalities at the active site of gp63 that could facilitate 
specific small molecule binding interactions. This development will guide 
structural optimization studies on lead inhibit
 
Figure 6-5. GP63 crystal structure
purpose. Pocket 1 & pocket 2 indicate possible binding sites for inhibitor design)
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Leishmania major is available in the public 
-5).11 The structure revealed that gp63 contained an 
 such as HDAC enzymes
teases. Our first specific goal in this study









 is to use 




We used molecular dock program (AutoDock) to probe the binding interactions 
between our proposed compounds and gp63 as described in chapter 5.12 We began our 
studies by docking fragment 3-hydroxy-2-pyridinone against gp63. From a population of 
100, the docked complexes for each inhibitor were selected according to the criteria of 
interaction energy in combination with geometrical matching quality.12 In preliminary 
docking studies we observed that 3-hydroxypyridin-2(1H)-one 1a bound within the 
vicinity of the active site Zn2+ ion (Fig. 3b), albeit with low binding energy. A close 
analysis of the docked structure revealed that the N-1 group of compound 1a is pointing 
into a deep pocket, designated pocket-2, which constitutes one of the two binding pockets 
in gp63 active site. 
             Based on this observation, we designed compound 22e and 22f that linked the 
crucial 3-hydroxypyridin-2-ones moiety of 1a to a triazolyl-phenyl ring through 6-C and 
7-C methylene groups respectively. The 6-C and 7-C methylene groups were estimated to 
be ideal spacer for connecting the two groups based on the distance between the active 
site Zn2+ ion and the center of pocket-1. We anticipated that these compounds will 
present their 3-hydroxypyridin-2-one moiety closer to the Zn2+ ion, thereby result in 
stronger interaction. As anticipated, compounds 22e and 22f adopted docked orientations 
whereby the 3-hydroxypyridin-2-one moiety is much closer to the active site Zn2+ ion 
(Figure 6-6a). However, 22e and 22f each adopt two different docked orientations at two 
gp63 binding pockets (Figure 6-6b, 6-6c). Either docked conformation has stronger 
affinity relative to that of 1a. Pocket 2 conformations of compounds 22e and 22f exhibit 
















Figure 6-6. (a) Structures of first generation molecules based on 3
skeleton. (b) Docked structures of 3




             The methylene linker of compound 
hydrophobic contact in pocket
twisted kinks in spacer region. We hypothesized that having rigid system, such as in 
biphenyl compound 5c, could solve this problem. Unfortunately, docked structure 
made no productive interaction with enzyme active site. However, para
compound 11a bind exclusively to pocket
pocket-1 Thr 229 and hydrophobic
dimethylamino substituted compound 
conformations in pocket 1 and 2 with p












    
-hydroxypyridin
-hydroxypyridin-2(1H)-one 1a and triazole
22f at the active site of gp63. 
22e and 22f, though make favorable 
-1, adopts energetically costly conformations with sharply 
-cyano substituted 
-1, with specific H-bonding interactio
 interaction with Pro347. Surprisingly, p
11g has two nearly energetically equivalent 
-dimethylamino moiety making close contact with 


















(a)                                                            (b) 
 
Figure 6-7. (a) Representative structures of gp63-binding small molecules used in molecular 
docking analysis. Docked structures of (b) p-dimethylamino substituted biphenyl compound 11g  
 
 
             This led us to postulate that having p-pyridinyl ring as in compound 11i instead 
of p-dimethylaminophenyl ring of compound 11g should further enhance affinity for 
pocket-2. And to our delight, it indeed resulted in exclusively pocket-2 binding 
compound 11i with very low binding energy. It makes near optimal interactions with key 






    
(a)                                                            (b) 
Figure 6-8. Docked structure of p-pyridinylbenzyl compound 11i a) space filling model b) 
Cartoon model with compound 11i making key interactions at active site. 
 
 
                To experimentally validate these in silico results, these compounds were 
synthesized as depicted in chapter 5 (Figure 5-13, 5-15, 5-16, 5-18). To obtain any 
evidence for the beneficial effect (or lack thereof) of incorporation of sulfur group14 into 
the ZBG of the 3-hydroxypyridin-2-one compounds described herein, we synthesized 
thione analogs as well and tested them for promastigote and the amastigote forms of the 
L. donovani.  
 
6.5 Whole Cell Activities of 1
st
 Generation Antileishmanials 
 
                Due to lack of standard in vitro assay for determining activity against gp63 
enzyme, in collaboration with Dr. Tekwani’s lab at University of Mississippi, we 
investigated the in vitro  whole cell anti-leishmanial activity of 1st generation compounds 
against the promastigote and amastigote stage of Leishmania donovani. Interestingly, 






(exclusive pocket 2 binder) was found to be inactive. (Table 6-1) Therefore we surmised 
that pocket 1 is only drugalbe site at the active site of gp63.   
              Many of these compounds inhibit the viability of either stage of L. donovani 
with IC50 values that tracked reasonably well with our molecular docking outputs (Figure 
6-6, 6-7). The triazole-linked 3-hydroxypyridin-2-ones compounds 22e and 22f have 
modest anti-leishmanial activity. (Table 6-1) This is not unexpected as the presumably 
energetically costly conformations adopted by these compounds may prevent them from 
efficiently binding to gp63 active site (Figure 6-5).  Conformationally rigid compounds 
11a and 11g have IC50 values that are about 3-4.5 fold more potent than the flexible 
compounds 22e and 22f. This result indicates that a rigid system is better suited to bind to 
the enzyme active. Interestingly for most of these compounds, incorporation of sulfur into 
the ZBG of the 3-hydroxypyridin-2-one compounds generally showed five to seven-fold 
better IC50 relative to the corresponding non-thiolated compounds. An exiciting exception 
is 12g which shows almost 34-fold enhancement in anti-leishmanial activity relative to 
the corresponding carbonyl compound 11g (Table 6-1).  
             To obtain evidence for compound selective toxicity, we investigated their effect 
on non-transformed vero cells. None of these compounds is cytotoxic to Vero cells at 
maximum tested conc. 5 µg/ml. Finally, cytotoxicity activity of some of these compounds 
against tumor derived macrophage cell line RAW 264.7 indicate ability of these 
compounds to obliterate transformed cells, possibly through HDAC8 inhibition. 
The clear trend in activity exhibited by these 1st generation antileishmanial 
tracked well with their HDAC8 inhibition activities. Most of the compounds which 
showed good inhibition of HDAC8 were also active against Leishmania parasite. This 
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further supported our initial submission that the structural attributes of HDAC8 enzyme 
active site are shared by gp63 metalloenzyme as well. In light of this observation, we 
further pursued SAR study by subjecting additional HDAC8 selective compounds which 
we reported in previous chapter to screening against L. donovani.  
 


















IC50 (ng/ml) IC50 (µg/ml) 
 
1a 
NA NA 18 35 NC <1.6 
 
1b 
6 27 NT NT NC NT 
 
22e 
21 > 40 6 30 NC 3.1 
 
25e 
3.7 40 <1.6 5 NC 15 
 
22f 
20.5 40 6.2 28 NC 3.2 
 
25f 
3.6 12 <1.6 <1.6 NC 2.8 
 
11a 
4.6 40 5 22 NC 1.8 
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Table 6-1 continued. 
 
12a 
0.7 1.5 NT NT NC NT 
 
11g 
7.5 > 40 4 7.5 NC 23 
 
12g 
0.22 1 NT NT NC NT 
 
11i 
NA NA 21 >40 NC 13 
 
12i 
NT NT NT NT NT NT 
Pentamidine 1.0 2.0 NT NT NT NT 
Amphotericine B 0.2 0.4 NT NT NT NT 
Miltefosine 5.1b NT NT NT NT NT 
 
NC = Not cytotoxicity; NT = Not tested; ND = Not determined; NA = Inactive 
aWhole cell activities data were generated by Tekwani lab at University of Mississippi. 
bData from Saugar J. M. et al. J. Med. Chem. 2007, 50, 5994-6003 (converted from µM to µg/ml)  


















6.6 Structure-Activity Relationship (SAR) of antileishmanial activity of   
      HDAC8 Selective HDACi (2
nd
 Generation Antileishmanials) 
 
             In order to pursue SAR studies of these antileishmanials, we screened additional 
HDAC8 selective compounds reported in earlier chapter (chapter 5, Table 5-1, 5-2, 5-3, 
5-5). Activities of representative HDAC8 selective inhibitors are reported in Table 6-2. 
Agaist promastigote form, rigid systems such as compounds 11 and 12 fared much better 
than flexible systems such as more than 2-C methylene linker (Table 6-2). As expected, 
thione analogs showed several fold superior activity than carbonyl analogs. Changing 
position of cyano group from para- position (compound 12a) to meta- position 
(compound 12b) only slightly altered the activity in favor of meta-cyano substitution. 
Replacement of N,N-dimethylamino group of compound 12g to other electron donating 
group such as methyl group (compound 12d) was found to be tolerable. Among all 
triazole based linker compounds, compound 17a with single methylene spacer showed 
best activity. There was steady decrease in potency as number of methylene spacer kept 
on increasing. However, for five methylene spacer there was increase in potency. 
Additional SAR on five methyelene linker compounds did not improve IC50 significantly 
with all of the activities ranged from 3 to 6 µg/ml (Table 6-2). However, six and seven-
methylene compounds (25e and 25f) again showed improvement in activity (Table 6-2). 
However they still couldn’t surpass the IC50 values of one-methylene linker compounds 
(compound 17a). Activities for amastigote form were not available for all of the 
compounds by the time I write this report, however they seem to track well with their 





Table 6-2. Whole cell activity against the promastigote and amastigote form of L. donovania 
 

















IC50 (ng/ml) IC50 (µg/ml) 
 
11b 
9 >40 NT NT NC NT 
 
12b 
0.4 1.3 NT NT NC NT 
 
11d 
6 33 NT NT NC NT 
 
12d 
0.3 1.2 NT NT NC NT 
 
15a 
NA NA 18 >40 NC 2.5 
 
17a 
1.6 7.5 <1.6 <1.6 NC 2.8 
 
22a 
NA NA 19 >40 NC 10 
 
24 
3.9 18 18 40 NC 2.3 
 
22b 
NA NA 20 >40 NC 14 
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Table 6-2 continued. 
 
25b 





































NT NT NC NT 
30f 
3 >40 NT NT NC NT 
 
29d 
39 >40 NT NT NC NT 
 
30d 
3.9 40 NT NT NC NT 
 
29a 




Table 6-2 continued. 
 
30a 
2.9 7.9 NT NT NC NT 
 
29b 
24 >40 NT NT NC NT 
 
30b 
3.6 40 NT NT NC NT 
 
29e 
NA NA NT NT NC NT 
 
30e 
4 8 NT NT NC NT 
 
29g 
21 >40 NT NT NC NT 
30g 
4.7 20 NT NT NC NT 
Pentamidine 1.0 2.0 NT NT NT NT 
Amphotericine B 0.2 0.4 NT NT NT NT 
Miltefosine 5.1b NT NT NT NT NT 
 
NC = Not cytotoxicity; NT = Not tested; ND = Not determined; NA = Inactive 
aWhole cell activities data were generated by Tekwani lab at University of Mississippi. 











               The lack of affordable effective agents for the treatment and management of 
Leishmaniasis is emerging as a serious threat to public health. Multidrug resistance has 
exacerbated the available treatment modalities for this parasitic infection. Using a 
combination of molecular docking and whole cell assays, we have identified as subset of 
lead compounds that inhibit the viability of the promastigote stage of Leishmania 
donovani with IC50 comparable to Miltefosine, the only clinically approved oral drug 
against visceral leishmaniasis. Several compounds show high potency with limited 
cytotoxicity to normal mammalian cells. Future efforts will be directed to establish 
molecular mechanism of these compounds. Even though molecular dockings performed 
on gp63 enzyme helped us to corroborate our whole cell activities, there is possibility that 
these compounds might be hitting a putative HDAC8 homolog in L. donovani parasite. 
Nonetheless, this study introduces novel synthetic skeleton that can pave way for future 
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1H NMR of 65b: 
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1H and 13C NMR characterization for Dual Acting HDAC – Topoisomerase (Topo) 
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HPLC characterization of compounds 7 and 12a-d 
Solvent A = 0.1% formic acid in water 
Solvent B = 0.1 % formic acid in acetonitrile 
Compound 7 – 
Retention time – 6.46 min; Solvent – Gradient 5% - 60% solvent B over 20 min 
 
Compound 12a – 
Retention time – 15.06 min 











































































































































































































































































































































































































































































































































































































































































































































































Compound 12b – 
Retention time – 15.20 min 
Solvent – Gradient 0% - 100% solvent B over 30 min 
 
Compound 12c – 
Retention time – 16.98 min 
















































































































































































































































































































































































































































































































































































Compound 12d – 
Retention time – 16.93 min 
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